{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Welcome to the Second Lab - Week 1, Day 3\n",
    "\n",
    "Today we will work with lots of models! This is a way to get comfortable with APIs."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<table style=\"margin: 0; text-align: left; width:100%\">\n",
    "    <tr>\n",
    "        <td style=\"width: 150px; height: 150px; vertical-align: middle;\">\n",
    "            <img src=\"../assets/stop.png\" width=\"150\" height=\"150\" style=\"display: block;\" />\n",
    "        </td>\n",
    "        <td>\n",
    "            <h2 style=\"color:#ff7800;\">Important point - please read</h2>\n",
    "            <span style=\"color:#ff7800;\">The way I collaborate with you may be different to other courses you've taken. I prefer not to type code while you watch. Rather, I execute Jupyter Labs, like this, and give you an intuition for what's going on. My suggestion is that you carefully execute this yourself, <b>after</b> watching the lecture. Add print statements to understand what's going on, and then come up with your own variations.<br/><br/>If you have time, I'd love it if you submit a PR for changes in the community_contributions folder - instructions in the resources. Also, if you have a Github account, use this to showcase your variations. Not only is this essential practice, but it demonstrates your skills to others, including perhaps future clients or employers...\n",
    "            </span>\n",
    "        </td>\n",
    "    </tr>\n",
    "</table>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Start with imports - ask ChatGPT to explain any package that you don't know\n",
    "\n",
    "import os\n",
    "import json\n",
    "from dotenv import load_dotenv\n",
    "from openai import OpenAI\n",
    "from anthropic import Anthropic\n",
    "from IPython.display import Markdown, display"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Always remember to do this!\n",
    "load_dotenv(override=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "OpenAI API Key exists and begins sk-proj-\n",
      "Anthropic API Key exists and begins sk-ant-\n",
      "Google API Key exists and begins AI\n",
      "DeepSeek API Key exists and begins sk-\n",
      "Groq API Key exists and begins gsk_\n"
     ]
    }
   ],
   "source": [
    "# Print the key prefixes to help with any debugging\n",
    "\n",
    "openai_api_key = os.getenv('OPENAI_API_KEY')\n",
    "anthropic_api_key = os.getenv('ANTHROPIC_API_KEY')\n",
    "google_api_key = os.getenv('GOOGLE_API_KEY')\n",
    "deepseek_api_key = os.getenv('DEEPSEEK_API_KEY')\n",
    "groq_api_key = os.getenv('GROQ_API_KEY')\n",
    "\n",
    "if openai_api_key:\n",
    "    print(f\"OpenAI API Key exists and begins {openai_api_key[:8]}\")\n",
    "else:\n",
    "    print(\"OpenAI API Key not set\")\n",
    "    \n",
    "if anthropic_api_key:\n",
    "    print(f\"Anthropic API Key exists and begins {anthropic_api_key[:7]}\")\n",
    "else:\n",
    "    print(\"Anthropic API Key not set (and this is optional)\")\n",
    "\n",
    "if google_api_key:\n",
    "    print(f\"Google API Key exists and begins {google_api_key[:2]}\")\n",
    "else:\n",
    "    print(\"Google API Key not set (and this is optional)\")\n",
    "\n",
    "if deepseek_api_key:\n",
    "    print(f\"DeepSeek API Key exists and begins {deepseek_api_key[:3]}\")\n",
    "else:\n",
    "    print(\"DeepSeek API Key not set (and this is optional)\")\n",
    "\n",
    "if groq_api_key:\n",
    "    print(f\"Groq API Key exists and begins {groq_api_key[:4]}\")\n",
    "else:\n",
    "    print(\"Groq API Key not set (and this is optional)\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "request = \"Please come up with a challenging, nuanced question that I can ask a number of LLMs to evaluate their intelligence. \"\n",
    "request += \"Answer only with the question, no explanation.\"\n",
    "messages = [{\"role\": \"user\", \"content\": request}]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'role': 'user',\n",
       "  'content': 'Please come up with a challenging, nuanced question that I can ask a number of LLMs to evaluate their intelligence. Answer only with the question, no explanation.'}]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "messages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Imagine you are advising the mayor of an island city of 1,000,000 people facing an outbreak of a novel respiratory virus. You have 150,000 doses of a partially effective vaccine (60% efficacy at preventing symptomatic disease, 50% efficacy at preventing infection), antiviral treatment sufficient for 10,000 people (reduces progression to severe disease by 60% if given within 5 days of symptom onset), and the ability to implement one citywide non‑pharmaceutical intervention (choose either a 6‑week strict lockdown that reduces contacts by 70% or a 3‑month moderate social‑distancing campaign that reduces contacts by 35% with 80% compliance). Current epidemiological estimates: R0 between 1.8 and 3.2 (uncertain), mean incubation 5 days, mean infectious period 7 days, 5% of infections require hospital care, and hospital capacity is 2,500 beds. The population includes 100,000 people aged 65+, 200,000 essential workers with roughly double the contact rate of average residents, and 50,000 healthcare workers.\n",
      "\n",
      "Your goals (in order of priority) are: 1) minimize deaths, 2) prevent health‑system overload (hospitalizations > capacity), and 3) minimize economic disruption.\n",
      "\n",
      "Produce a single, final advisory plan that includes the following (do not reveal chain‑of‑thought; present only the final plan, numbers, and reasoning):\n",
      "\n",
      "1) A concrete allocation and prioritization plan: who receives the vaccine first and why, how to allocate antivirals (including criteria for treatment), and which NPI you choose and why. Specify timing and rollout assumptions.\n",
      "\n",
      "2) Quantitative justification: under clearly stated assumptions (including a best‑estimate R0 and one alternative R0), estimate approximate cumulative infections, hospitalizations, and deaths over the next 6 months under your plan, and compare those outcomes to two clearly defined alternative plausible strategies (each alternative should differ meaningfully in vaccine prioritization and/or choice of NPI). Give numbers or ranges and state key model simplifications or formulas used (no internal chain‑of‑thought; only final assumptions and calculations).\n",
      "\n",
      "3) Key uncertainties: list the critical unknowns that could change your decision, and for each, specify how you would update policy if new data reduced uncertainty (e.g., new estimate of vaccine effectiveness, faster spread, waning immunity).\n",
      "\n",
      "4) Three main risks or failure modes of your plan and specific mitigations for each.\n",
      "\n",
      "5) A one‑paragraph summary (2–4 sentences) of the plan written for the general public that explains what you will do, why, and what the community should expect and do.\n",
      "\n",
      "Be explicit about assumptions and tradeoffs; use approximate numerical estimates where asked.\n"
     ]
    }
   ],
   "source": [
    "openai = OpenAI()\n",
    "response = openai.chat.completions.create(\n",
    "    model=\"gpt-5-mini\",\n",
    "    messages=messages,\n",
    ")\n",
    "question = response.choices[0].message.content\n",
    "print(question)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "competitors = []\n",
    "answers = []\n",
    "messages = [{\"role\": \"user\", \"content\": question}]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Note - update since the videos\n",
    "\n",
    "I've updated the model names to use the latest models below, like GPT 5 and Claude Sonnet 4.5. It's worth noting that these models can be quite slow - like 1-2 minutes - but they do a great job! Feel free to switch them for faster models if you'd prefer, like the ones I use in the video."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "Below is a concise, action‑oriented advisory plan designed to minimize deaths, prevent hospital overload, and limit economic disruption. All numbers are approximate and based on a deliberately simple, transparent set of assumptions described inline.\n",
       "\n",
       "1) Concrete allocation and prioritization plan (vaccines, antivirals, NPIs)\n",
       "\n",
       "Assumptions used for this plan (consistently applied in all sections):\n",
       "- Population: 1,000,000. Hospital capacity: 2,500 beds.\n",
       "- Case severity: 5% of infections require hospitalization. Vaccination reduces infection risk by 50% and symptomatic disease by 60% in vaccinated people (i.e., 50% protection against infection; among breakthrough infections, a further 60% reduction in risk of developing symptomatic disease).\n",
       "- Incubation: mean 5 days; infectious period: ~7 days; generation time ~5 days.\n",
       "- Antivirals: up to 10,000 treatment courses total. They reduce progression to severe disease by 60% if given within 5 days of symptom onset; effect applies to those who would otherwise progress to severe disease.\n",
       "- Non-pharmaceutical intervention (NPI) options (choose one):\n",
       "  A) 6-week strict lockdown: 70% reduction in social contacts; assumed high compliance (consistent with the 70% contact reduction stated).\n",
       "  B) 3-month moderate social distancing: 35% reduction in contacts with ~80% compliance (less effective per person, longer duration).\n",
       "- Vaccine supply: 150,000 doses. For planning, assume one dose per person (single-dose deployment) with the stated efficacy values (50% infection protection; 60% protection against symptomatic disease). Priority is given to high-risk groups first.\n",
       "- Time horizon: 6 months.\n",
       "\n",
       "Selected plan (priority: deaths > health system capacity > economy)\n",
       "- Vaccination priority and rollout:\n",
       "  - Phase 1 (Weeks 0–2): Vaccinate all people aged 65+ (100,000 individuals) and all healthcare workers (50,000). This uses all 150,000 doses in a front-loaded rollout, with the intent of protecting the most vulnerable for death and preserving hospital capacity.\n",
       "  - Rationale: 65+ have the highest risk of death; healthcare workers are critical to maintaining hospital functionality and to reduce nosocomial transmission.\n",
       "  - Rollout cadence: Target ~50,000 vaccinations per week for Weeks 0–3, achieving full Phase 1 coverage by end of Week 3.\n",
       "  - Phase 2 (Weeks 3–24): If further vaccine stock arrives, continue vaccinating high‑risk adults (e.g., people with major comorbidities) and essential workers to blunt transmission and protect capacity; assume an additional ~50,000 doses through Weeks 4–6 if available.\n",
       "- Antiviral allocation (up to 10,000 courses):\n",
       "  - Criteria: Treat symptomatic adults who are 65+, or adults with high-risk comorbidities (e.g., cardiovascular disease, diabetes, chronic lung disease), and/or healthcare workers with symptomatic infection who present within 5 days of symptom onset.\n",
       "  - Rollout cadence: Begin immediately; prioritize seniors and known high‑risk patients, then expand to other high‑risk groups as supply allows (roughly 2,000–3,000 courses per week over Weeks 0–6 if demand is steady).\n",
       "  - Expected impact: Reduces progression to severe disease among treated individuals by 60%, which lowers hospitalization demand by up to roughly 0.03 per treated infected person (see quantitative justification). In practice this will shave a few thousand hospitalizations across the 6-month horizon, concentrated among high-risk cases.\n",
       "- Non-pharmaceutical intervention (NP I):\n",
       "  - Choice: 6-week strict lockdown (70% contact reduction).\n",
       "  - Rationale: This maximally reduces transmission quickly, dramatically lowers peak demand on hospitals, and buys time for the vaccine to protect the most vulnerable. This option best aligns with the priority to minimize deaths and avoid health-system overload.\n",
       "  - Timing: Start immediately (Day 0) and continue for 42 days. After 6 weeks, transition out of lockdown with maintenance of minimum necessary controls and the vaccination program continuing to scale up.\n",
       "  - Compliance assumption: 70% contact reduction is achieved; if real-world compliance falls significantly, reassess with targeted containment or micro‑lockdowns in high-transmission locales.\n",
       "\n",
       "Assumptions about timing and rollout:\n",
       "- Immediate deployment: Lockdown starts now; vaccine rollout begins Day 0 with Phase 1 completion by Day 21–Day 21 (end of Week 3).\n",
       "- Masking, testing, and contact tracing remain in place at baseline; the pivotal change is the 70% contact reduction from the lockdown.\n",
       "- Antivirals are deployed as soon as possible after symptom onset to eligible individuals throughout Weeks 0–6.\n",
       "- After Week 6, lockdown constraints are relaxed in a staged fashion (subject to hospital occupancy and local transmission) while vaccines and antivirals continue to operate.\n",
       "\n",
       "2) Quantitative justification (best‑estimate R0 and one alternative R0)\n",
       "\n",
       "Key assumed constants used for the numbers below:\n",
       "- Best-estimate R0: 2.6 (range 1.8–3.2 uncertainty; we use 2.6 as central).\n",
       "- Alternative R0 for sensitivity: 3.0.\n",
       "- Generation time: ~5 days.\n",
       "- NPI effectiveness: lockdown reduces effective reproduction number to Rt = R0 × (1 − 0.70) = 0.78 during Weeks 0–6.\n",
       "- Vaccine impact (on the population level): 7.5% effective reduction in susceptible population during the period (150,000 vaccinated × 50% efficacy against infection = 7.5% of population effectively protected against infection). This reduces the effective attack rate and the absolute number of infections accordingly.\n",
       "- Antivirals: 10,000 courses reduce hospitalizations among treated infected people by 60% (i.e., if 10,000 treated would have progressed to hospitalization at 5%, their hospitalization rate among treated steps down to 2%).\n",
       "\n",
       "Derived rough quantities (6-month horizon, i.e., ~26 weeks):\n",
       "- Without any interventions (for comparison): Under R0 ≈ 2.6, a substantial portion of the population would become infected with a sizable hospitalization burden. We do not rely on that as our baseline; instead, we compare interventions to expectations with the selected plan.\n",
       "- With Plan (6-week lockdown + vaccination of 65+ and healthcare workers + antivirals):\n",
       "  - Best estimate cumulative infections over 6 months: ~130,000 to ~170,000 (about 13–17% of the population).\n",
       "  - Best estimate cumulative hospitalizations: 6,500 to 8,500.\n",
       "    - Antiviral effect reduces hospitalizations by roughly 300–500 across the entire horizon (given 10,000 treated; 5% baseline hospitalization rate for infections; 60% reduction in progression to severe disease among treated), so adjust to ~6,200–8,200.\n",
       "  - Deaths (illustrative range with broad IFR assumptions, acknowledging vaccination protects the elderly): ~500–900 deaths (most fatalities concentrated among unvaccinated strata before full vaccine protection and in high-risk patients who still become infected).\n",
       "- Alternative Strategy A (Essential workers first vaccine priority, same lockdown):\n",
       "  - Cumulative infections: ~140,000 to ~210,000.\n",
       "  - Hospitalizations: ~7,000 to ~10,500 (antivirals yield modest reductions; total reductions similar in scale to the plan, but distribution shifts away from seniors; more hospitalizations in the non‑elderly group due to delayed vaccination).\n",
       "  - Deaths: ~900–1,700 (higher than Plan due to more infections among non‑elderly, with fewer elderly protected early).\n",
       "- Alternative Strategy B (Plan uses lockdown; but 3-month moderate distancing instead of lockdown; vaccine priority as in Plan):\n",
       "  - Cumulative infections: ~180,000 to ~260,000 (moderate, longer duration distancing but lower per-day effectiveness leads to higher total infections than a short, strict lockdown).\n",
       "  - Hospitalizations: ~9,000 to ~13,000.\n",
       "  - Deaths: ~1,200–2,200.\n",
       "\n",
       "Key simplifications and formulas used (for transparency):\n",
       "- Rt during lockdown: Rt_lockdown = R0 × (1 − 0.70) = 0.78 (best estimate; reduces growth phase to decay).\n",
       "- Population-level infection protection from vaccination: overall susceptible reduction ≈ 150,000 vaccinated × 50% efficacy against infection = 75,000 people effectively less susceptible; relative population effect ≈ 75,000 / 1,000,000 = 7.5% fewer infections in the epidemic wave, applied to rough final size.\n",
       "- Hospitalizations: H = 0.05 × I, where I is cumulative infections. Antiviral effect reduces hospitalizations among treated by 60%: for 10,000 treated, hospitalizations prevented ≈ 0.05 × 10,000 × 0.60 = 300 hospitalizations (as a rough cap, distributed across the horizon).\n",
       "- IFR and age distribution are not modeled in detail here; the death estimates are intended to be proportional to infections with heavier weight on vaccines preventing infection in the elderly and reducing severe disease.\n",
       "\n",
       "3) Key uncertainties (critical unknowns and adaptive updates)\n",
       "\n",
       "- Vaccine effectiveness against infection (VE_inf) in the real population: If VE_inf is lower than 50% or wanes quickly, infection reductions will be smaller; if VE_inf is higher or longer-lasting, infections and hospitalizations drop further.\n",
       "  - Update policy: If VE_inf proves higher, accelerate broader vaccination to more age/occupation groups earlier; if VE_inf is lower, rely more on NPIs and antivirals, and consider extending lockdown duration if hospital strain rises.\n",
       "- R0 value and real-world contact patterns: The true R0 and the effectiveness of the 70% contact reduction are uncertain (especially with essential workers and healthcare settings).\n",
       "  - Update policy: If R0 is closer to 3.0 or higher or if transmission among essential workers remains high, consider tighter or targeted lockdown segments, expand vaccination to essential workers sooner, or reimpose stricter NPIs in hotspots.\n",
       "- Antiviral uptake and real-world effectiveness: Availability, speed of deployment, adherence within 5 days, and real efficacy may differ.\n",
       "  - Update policy: If antivirals are less available or less effective than assumed, increase vaccination speed or consider shortening lockdown duration with increased testing and targeted quarantines; otherwise, expand antiviral allocation to household contacts of confirmed cases to widen indirect protection.\n",
       "- Hospital capacity dynamics and surge risk: If hospital demand accelerates beyond 2,500 beds, you may need to reintroduce stricter NPIs or temporary surge capacity measures.\n",
       "  - Update policy: Predefine trigger points (e.g., occupancy >2,000 beds for 7 consecutive days) to reimpose partial lockdown or to allocate more resources (temporary field hospitals, discharge planning to free beds).\n",
       "- Compliance and inequality: 80% compliance assumption for the moderate strategy may not hold; 70% contact reduction may vary by district and by essential worker settings.\n",
       "  - Update policy: Use data dashboards to identify and address pockets of noncompliance with targeted communications and localized restrictions if needed.\n",
       "\n",
       "4) Three main risks or failure modes and mitigations\n",
       "\n",
       "- Risk 1: Health-system overload if lockdown is delayed or vaccine impact is weaker than anticipated.\n",
       "  Mitigation: Implement the 6-week lockdown immediately and strictly, with clear metrics for hospital occupancy and ICU utilization. Pre-plan surge capacity (temporary beds, staffing) and ensure antivirals are prioritized for high-risk patients to maximize the protective effect on hospitalizations.\n",
       "- Risk 2: Inequitable access to vaccination and antivirals, leading to higher mortality in vulnerable subpopulations.\n",
       "  Mitigation: Proactively map and target vaccination outreach to 65+ in all neighborhoods, with mobile clinics in high‑risk blocks; ensure antivirals are available through primary care networks and hospital systems; monitor coverage by age, race/ethnicity, and ZIP code and adjust outreach accordingly.\n",
       "- Risk 3: Waning immunity or reduced VE, undermining the protection from vaccination over 6 months.\n",
       "  Mitigation: Plan for booster or second-dose requirements if supply allows; maintain high vaccination coverage for high-risk groups; keep NPIs ready to scale if case trajectories re-emerge; maintain robust testing and tracing as a backstop.\n",
       "\n",
       "5) Public-facing summary (2–4 sentences)\n",
       "\n",
       "We will implement a six-week citywide strict lockdown to quickly curb transmission, protect hospital capacity, and save lives, while rapidly vaccinating all residents aged 65+ and healthcare workers (150,000 doses). We will allocate antivirals to high-risk individuals who develop symptoms promptly to prevent hospitalizations. After the lockdown, vaccination will continue to expand to high-risk and essential workers, and we will monitor trends closely, ready to adjust NPIs if hospital usage or transmission rises. Use the expected decreases in risk from vaccination and antivirals to inform personal precautions (masking in crowded indoor spaces, hand hygiene, staying home when ill) and support community compliance.\n",
       "\n",
       "Notes for all readers:\n",
       "- This plan prioritizes minimizing deaths and avoiding hospital overload as the first objectives, recognizing that some economic disruption is unavoidable. Personal actions (masking in high-risk settings, testing when symptomatic, staying away from work if ill) remain essential even after vaccination, as breakthrough infections and transmission can still occur in partially protected populations."
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# The API we know well\n",
    "# I've updated this with the latest model, but it can take some time because it likes to think!\n",
    "# Replace the model with gpt-4.1-mini if you'd prefer not to wait 1-2 mins\n",
    "\n",
    "model_name = \"gpt-5-nano\"\n",
    "\n",
    "response = openai.chat.completions.create(model=model_name, messages=messages)\n",
    "answer = response.choices[0].message.content\n",
    "\n",
    "display(Markdown(answer))\n",
    "competitors.append(model_name)\n",
    "answers.append(answer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Anthropic has a slightly different API, and Max Tokens is required\n",
    "\n",
    "model_name = \"claude-sonnet-4-5\"\n",
    "\n",
    "claude = Anthropic()\n",
    "response = claude.messages.create(model=model_name, messages=messages, max_tokens=1000)\n",
    "answer = response.content[0].text\n",
    "\n",
    "display(Markdown(answer))\n",
    "competitors.append(model_name)\n",
    "answers.append(answer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "**Advisory Plan for the Island City Outbreak**\n",
       "\n",
       "This plan prioritizes minimizing deaths and preventing health system overload, recognizing that significant economic disruption is an unavoidable consequence of effective epidemic control. Our strategy leverages available resources (vaccines, antivirals) and decisive non-pharmaceutical interventions (NPIs) to flatten the curve and protect the most vulnerable.\n",
       "\n",
       "---\n",
       "\n",
       "**1) Allocation and Prioritization Plan**\n",
       "\n",
       "*   **Non-Pharmaceutical Intervention (NPI):**\n",
       "    *   **Choice:** Implement a **6-week strict lockdown** immediately (reducing contacts by 70%). This will be followed by a robust, continuous public health campaign promoting voluntary, sustained social distancing behaviors, aiming for an average of 40% contact reduction for the subsequent 4.5 months.\n",
       "    *   **Why:** The initial strict lockdown is crucial to rapidly reduce the effective reproduction number (R_eff) below 1, thereby suppressing the initial surge of infections. This buys invaluable time for vaccine rollout and allows the healthcare system to prepare. Given the high R0 uncertainty, a less stringent NPI like moderate social distancing alone would almost certainly lead to immediate and overwhelming health system overload. The subsequent sustained campaign aims to keep R_eff manageable and prevent a rapid rebound, balancing public health needs with economic feasibility.\n",
       "    *   **Timing:** Strict lockdown begins immediately upon plan announcement. Public health campaign promoting sustained distancing will launch concurrently with the end of the strict lockdown and continue for the remainder of the 6-month period.\n",
       "\n",
       "*   **Vaccine Prioritization (150,000 doses total; 50% efficacy preventing infection, 60% preventing symptomatic disease):**\n",
       "    *   **Phase 1 (First 2-3 weeks, 50,000 doses): Healthcare Workers (50,000 people).**\n",
       "        *   **Why:** Protecting healthcare workers is paramount to maintaining the functional capacity of our hospitals and clinics. Vaccinating them reduces their risk of infection and symptomatic illness, thereby minimizing absenteeism and preventing in-hospital transmission to vulnerable patients. This directly supports the goal of preventing health system overload.\n",
       "    *   **Phase 2 (Next 2-3 weeks, 100,000 doses): Individuals Aged 65+ (100,000 people).**\n",
       "        *   **Why:** This demographic faces the highest risk of severe disease and death from respiratory viruses. Vaccinating all individuals in this group directly targets the primary goal of minimizing deaths.\n",
       "    *   **Rollout Assumption:** We assume vaccine doses are distributed and administered rapidly within the first 4-6 weeks of the outbreak response. Protection is assumed to begin approximately 2 weeks post-vaccination.\n",
       "\n",
       "*   **Antiviral Allocation (10,000 treatments; reduces progression to severe disease by 60% if given within 5 days of symptom onset):**\n",
       "    *   **Criteria:** Antiviral treatments will be reserved exclusively for individuals with confirmed infection who present with symptoms within 5 days of onset.\n",
       "    *   **Prioritization:**\n",
       "        1.  **Individuals Aged 65+:** This group is at highest risk of severe outcomes. All available antivirals will be directed here first.\n",
       "        2.  **Individuals with significant comorbidities:** (e.g., chronic lung disease, heart disease, diabetes, immunosuppression). This priority group will be defined more specifically through clinical guidelines, to be treated if doses remain after the 65+ allocation is exhausted.\n",
       "        *   **Why:** With limited supply, antivirals must be allocated to those most likely to benefit from reduced progression to severe disease, directly aiming to minimize deaths and hospitalizations. The 65+ population aligns with this goal.\n",
       "\n",
       "---\n",
       "\n",
       "**2) Quantitative Justification**\n",
       "\n",
       "Our epidemiological estimates are based on a simplified compartmental model (SIR-like) with key parameters: mean incubation 5 days, mean infectious period 7 days, 5% of infections require hospital care, and an Infection Fatality Rate (IFR) of 0.5% for individuals under 65 and 5% for individuals 65+. We assume an average hospital stay of 10 days. Hospital overload is estimated to double the IFR for those requiring hospitalization.\n",
       "\n",
       "**Key Assumptions for Modeling:**\n",
       "*   **Best-estimate R0:** 2.5\n",
       "*   **Alternative R0:** 3.2\n",
       "*   **Vaccine Impact:** Reduces susceptibility by 50% (infection prevention). For those vaccinated 65+ who still get infected, the IFR is reduced by 60% from baseline (from 5% to 2%).\n",
       "*   **Antiviral Impact:** Averts 60% of deaths for the 10,000 highest-risk treated individuals (primarily 65+).\n",
       "*   **NPI Phases:** 6-week strict lockdown (70% contact reduction) followed by 4.5 months of 40% contact reduction due to sustained voluntary measures.\n",
       "*   **Hospital Capacity:** 2,500 beds (equivalent to 250 new admissions per day for a 10-day average stay).\n",
       "\n",
       "**Estimated Outcomes Over 6 Months:**\n",
       "\n",
       "| Metric             | My Plan (R0=2.5)      | My Plan (R0=3.2)      | Alternative 1 (EW + Moderate NPI) (R0=2.5) | Alternative 2 (No NPI + General Pop Vaccine) (R0=2.5) |\n",
       "| :----------------- | :-------------------- | :-------------------- | :------------------------------------------- | :---------------------------------------------------- |\n",
       "| **Cumulative Infections** | **327,000**           | **511,000**           | **740,000**                                  | **601,250**                                           |\n",
       "| **Hospitalizations**   | **16,350**            | **25,550**            | **37,000**                                   | **30,062**                                            |\n",
       "| **Peak Beds Needed**   | **~3,000** (tight)    | **~3,900** (overload) | **~6,000+** (massive overload)               | **~5,000+** (massive overload)                        |\n",
       "| **Deaths**             | **1,785**             | **5,000**             | **10,095**                                   | **8,446**                                             |\n",
       "\n",
       "**Reasoning for My Plan's Superiority:**\n",
       "*   **My Plan (R0=2.5):** The strict lockdown effectively suppresses the initial spread (limiting infections to ~5,000 in 6 weeks). The subsequent 40% contact reduction leads to an effective R (R_eff) of 1.5. Over the next 4.5 months, this results in approximately 322,000 new infections. Peak hospitalizations are estimated at around 3,000 beds, meaning the system operates at very tight capacity, but potentially avoids collapse. Deaths are minimized by prioritizing vaccination for the elderly and healthcare workers, and antiviral treatment for high-risk individuals.\n",
       "*   **My Plan (R0=3.2):** Even with the same NPIs, a higher R0 of 3.2 makes control significantly harder. The R_eff post-lockdown becomes 1.92, leading to more infections (~506,000 in 4.5 months) and significantly increased hospital demand (~3,900 peak beds). This scenario leads to substantial hospital overload, which is factored into the higher death toll. While challenging, this still represents a substantial improvement over alternative strategies.\n",
       "\n",
       "**Comparison with Alternative Strategies (Modeled at R0=2.5):**\n",
       "*   **Alternative 1 (Essential Workers + Moderate NPI):** Vaccinating essential workers may reduce some transmission, but the 3-month moderate NPI (effective 28% contact reduction, R_eff=1.8) and subsequent removal of NPIs leads to a massive wave of infections, overwhelming hospitals early on. Vaccinating essential workers does not directly protect the most vulnerable from death to the same extent as vaccinating the elderly. Deaths and hospitalizations are significantly higher.\n",
       "*   **Alternative 2 (No NPI + General Pop Vaccine):** Without any NPIs, R_eff remains at R0 (2.5). Even with 15% of the population vaccinated (randomly), the epidemic explodes, leading to widespread infection and catastrophic hospital overload. Deaths are extremely high due to uncontrolled spread and lack of care.\n",
       "\n",
       "---\n",
       "\n",
       "**3) Key Uncertainties and Policy Updates**\n",
       "\n",
       "1.  **True R0 Value:** The range 1.8-3.2 is wide.\n",
       "    *   **Policy Update:** If R0 is confirmed lower (e.g., closer to 1.8), we could potentially shorten the strict lockdown or implement a less stringent post-lockdown contact reduction (e.g., 30% instead of 40%) to reduce economic impact, provided hospital capacity is still maintained. If R0 is confirmed higher (e.g., closer to 3.2 or above), we would need to consider extending the strict lockdown or implementing stricter, longer-term NPIs (e.g., mandatory masking, stricter capacity limits) to prevent catastrophic hospital overload.\n",
       "2.  **Vaccine Efficacy against Severe Disease/Death:** The current efficacy figures are for preventing infection (50%) and symptomatic disease (60%).\n",
       "    *   **Policy Update:** If new data shows higher efficacy against severe disease/death, we could potentially ease NPIs slightly or prioritize further doses to other high-risk groups (e.g., those with comorbidities). If efficacy is lower, we would need to reinforce NPIs and potentially acquire more targeted antivirals.\n",
       "3.  **Compliance with NPIs:** Our model assumes high compliance during lockdown and sustained 40% reduction post-lockdown.\n",
       "    *   **Policy Update:** If compliance is lower than anticipated, real-time epidemiological data (e.g., rising case numbers, test positivity) would trigger immediate re-evaluation and reinforcement of NPIs, potentially including stricter enforcement or public awareness campaigns with clear messaging on the importance of adherence.\n",
       "4.  **Infection Fatality Rate (IFR) / Hospitalization Rate:** These fixed rates may vary by age or underlying conditions.\n",
       "    *   **Policy Update:** If surveillance data indicates a higher IFR, especially in younger populations, we would need to consider expanding vaccine eligibility to other vulnerable groups or essential workers beyond current allocations if more doses become available, and further emphasize NPIs across all age groups. If the hospitalization rate is higher, we would immediately activate surge capacity plans and consider emergency measures to expand healthcare infrastructure.\n",
       "5.  **New Variants:** The emergence of a more transmissible or virulent variant.\n",
       "    *   **Policy Update:** If a new variant significantly impacts R0 or vaccine effectiveness, immediate re-evaluation of all NPIs and vaccine strategies would be necessary. This could involve reinstating stricter lockdowns, adapting vaccine distribution, or accelerating development of new vaccines/treatments.\n",
       "\n",
       "---\n",
       "\n",
       "**4) Main Risks or Failure Modes of the Plan and Mitigations**\n",
       "\n",
       "1.  **Risk: Failure of Post-Lockdown Sustained Social Distancing.**\n",
       "    *   **Failure Mode:** After the 6-week strict lockdown, public fatigue or complacency leads to a rapid return to pre-outbreak contact levels (e.g., less than 40% reduction), causing R_eff to rise rapidly and overwhelm hospitals.\n",
       "    *   **Mitigation:**\n",
       "        *   **Intense Communication Campaign:** Launch an unprecedented public health campaign starting *during* the lockdown, clearly explaining the rationale for sustained social distancing, providing practical guidelines (masking, remote work, outdoor activities), and highlighting the collective benefit.\n",
       "        *   **Incentives and Support:** Implement programs to support remote work, provide free masks, and offer mental health services to combat fatigue.\n",
       "        *   **Gradual Reopening Plan:** A phased and data-driven reopening, tied to clear metrics (e.g., case numbers, hospital capacity), will allow for controlled relaxation of measures. If cases rebound, restrictions will be re-imposed.\n",
       "\n",
       "2.  **Risk: Insufficient Hospital Capacity in High R0 Scenario.**\n",
       "    *   **Failure Mode:** If the true R0 is at the higher end (3.2), our plan is predicted to exceed hospital capacity, leading to increased deaths due to lack of care.\n",
       "    *   **Mitigation:**\n",
       "        *   **Immediate Surge Capacity Activation:** Initiate plans for expanding hospital bed capacity (e.g., converting non-clinical spaces, establishing field hospitals) and staffing (e.g., recalling retired healthcare workers, cross-training staff, requesting external aid).\n",
       "        *   **Prioritized Care Protocols:** Develop and communicate clear ethical guidelines for rationing critical care resources in severe overload situations.\n",
       "        *   **Rapid Resource Acquisition:** Proactively secure additional ventilators, oxygen supplies, and personal protective equipment.\n",
       "\n",
       "3.  **Risk: Inequity or Access Issues in Vaccine/Antiviral Rollout.**\n",
       "    *   **Failure Mode:** Despite prioritization, vulnerable groups (e.g., elderly, essential workers) face barriers to accessing vaccines or antivirals due to logistics, digital divide, language barriers, or transportation issues.\n",
       "    *   **Mitigation:**\n",
       "        *   **Community-Based Rollout:** Establish mobile vaccination clinics and accessible treatment centers in neighborhoods with high concentrations of prioritized populations, leveraging community leaders and trusted organizations.\n",
       "        *   **Multi-Lingual Communication:** Ensure all public health information, registration, and consent forms are available in multiple languages and accessible formats.\n",
       "        *   **Dedicated Support Hotlines:** Set up phone hotlines to assist with appointments, provide information, and arrange transportation for those facing barriers.\n",
       "\n",
       "---\n",
       "\n",
       "**5) Public Summary**\n",
       "\n",
       "\"Island City, we face a critical challenge with this new virus. To protect our community, especially our elders and healthcare heroes, we are implementing a crucial 6-week strict lockdown starting today. This tough but necessary step will rapidly slow the virus, giving us time to vaccinate our frontline workers and most vulnerable residents, and to prepare our hospitals. After this initial period, we will ask for your continued vigilance with sustained social distancing. Your cooperation is vital to minimizing illness, saving lives, and ensuring our healthcare system can care for everyone who needs it.\""
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "gemini = OpenAI(api_key=google_api_key, base_url=\"https://generativelanguage.googleapis.com/v1beta/openai/\")\n",
    "model_name = \"gemini-2.5-flash\"\n",
    "\n",
    "response = gemini.chat.completions.create(model=model_name, messages=messages)\n",
    "answer = response.choices[0].message.content\n",
    "\n",
    "display(Markdown(answer))\n",
    "competitors.append(model_name)\n",
    "answers.append(answer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "ename": "APIStatusError",
     "evalue": "Error code: 402 - {'error': {'message': 'Insufficient Balance', 'type': 'unknown_error', 'param': None, 'code': 'invalid_request_error'}}",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mAPIStatusError\u001b[39m                            Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[11]\u001b[39m\u001b[32m, line 4\u001b[39m\n\u001b[32m      1\u001b[39m deepseek = OpenAI(api_key=deepseek_api_key, base_url=\u001b[33m\"\u001b[39m\u001b[33mhttps://api.deepseek.com/v1\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m      2\u001b[39m model_name = \u001b[33m\"\u001b[39m\u001b[33mdeepseek-chat\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m----> \u001b[39m\u001b[32m4\u001b[39m response = \u001b[43mdeepseek\u001b[49m\u001b[43m.\u001b[49m\u001b[43mchat\u001b[49m\u001b[43m.\u001b[49m\u001b[43mcompletions\u001b[49m\u001b[43m.\u001b[49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmodel_name\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m      5\u001b[39m answer = response.choices[\u001b[32m0\u001b[39m].message.content\n\u001b[32m      7\u001b[39m display(Markdown(answer))\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Admin\\projects\\agents\\.venv\\Lib\\site-packages\\openai\\_utils\\_utils.py:286\u001b[39m, in \u001b[36mrequired_args.<locals>.inner.<locals>.wrapper\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m    284\u001b[39m             msg = \u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[33mMissing required argument: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mquote(missing[\u001b[32m0\u001b[39m])\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m\"\u001b[39m\n\u001b[32m    285\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mTypeError\u001b[39;00m(msg)\n\u001b[32m--> \u001b[39m\u001b[32m286\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfunc\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Admin\\projects\\agents\\.venv\\Lib\\site-packages\\openai\\resources\\chat\\completions\\completions.py:1147\u001b[39m, in \u001b[36mCompletions.create\u001b[39m\u001b[34m(self, messages, model, audio, frequency_penalty, function_call, functions, logit_bias, logprobs, max_completion_tokens, max_tokens, metadata, modalities, n, parallel_tool_calls, prediction, presence_penalty, prompt_cache_key, reasoning_effort, response_format, safety_identifier, seed, service_tier, stop, store, stream, stream_options, temperature, tool_choice, tools, top_logprobs, top_p, user, verbosity, web_search_options, extra_headers, extra_query, extra_body, timeout)\u001b[39m\n\u001b[32m   1101\u001b[39m \u001b[38;5;129m@required_args\u001b[39m([\u001b[33m\"\u001b[39m\u001b[33mmessages\u001b[39m\u001b[33m\"\u001b[39m, \u001b[33m\"\u001b[39m\u001b[33mmodel\u001b[39m\u001b[33m\"\u001b[39m], [\u001b[33m\"\u001b[39m\u001b[33mmessages\u001b[39m\u001b[33m\"\u001b[39m, \u001b[33m\"\u001b[39m\u001b[33mmodel\u001b[39m\u001b[33m\"\u001b[39m, \u001b[33m\"\u001b[39m\u001b[33mstream\u001b[39m\u001b[33m\"\u001b[39m])\n\u001b[32m   1102\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mcreate\u001b[39m(\n\u001b[32m   1103\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   (...)\u001b[39m\u001b[32m   1144\u001b[39m     timeout: \u001b[38;5;28mfloat\u001b[39m | httpx.Timeout | \u001b[38;5;28;01mNone\u001b[39;00m | NotGiven = not_given,\n\u001b[32m   1145\u001b[39m ) -> ChatCompletion | Stream[ChatCompletionChunk]:\n\u001b[32m   1146\u001b[39m     validate_response_format(response_format)\n\u001b[32m-> \u001b[39m\u001b[32m1147\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_post\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1148\u001b[39m \u001b[43m        \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43m/chat/completions\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m   1149\u001b[39m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmaybe_transform\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1150\u001b[39m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\n\u001b[32m   1151\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmessages\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1152\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmodel\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1153\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43maudio\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43maudio\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1154\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mfrequency_penalty\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfrequency_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1155\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mfunction_call\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunction_call\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1156\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mfunctions\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunctions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1157\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mlogit_bias\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogit_bias\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1158\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mlogprobs\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1159\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmax_completion_tokens\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_completion_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1160\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmax_tokens\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1161\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmetadata\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1162\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmodalities\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodalities\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1163\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mn\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mn\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1164\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mparallel_tool_calls\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mparallel_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1165\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mprediction\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprediction\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1166\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mpresence_penalty\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mpresence_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1167\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mprompt_cache_key\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_key\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1168\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mreasoning_effort\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mreasoning_effort\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1169\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mresponse_format\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1170\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43msafety_identifier\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43msafety_identifier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1171\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mseed\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mseed\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1172\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mservice_tier\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mservice_tier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1173\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mstop\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstop\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1174\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mstore\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstore\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1175\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mstream\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1176\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mstream_options\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1177\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtemperature\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1178\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtool_choice\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtool_choice\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1179\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtools\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1180\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtop_logprobs\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_logprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1181\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtop_p\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_p\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1182\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43muser\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43muser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1183\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mverbosity\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mverbosity\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1184\u001b[39m \u001b[43m                \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mweb_search_options\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mweb_search_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1185\u001b[39m \u001b[43m            \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1186\u001b[39m \u001b[43m            \u001b[49m\u001b[43mcompletion_create_params\u001b[49m\u001b[43m.\u001b[49m\u001b[43mCompletionCreateParamsStreaming\u001b[49m\n\u001b[32m   1187\u001b[39m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\n\u001b[32m   1188\u001b[39m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01melse\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mcompletion_create_params\u001b[49m\u001b[43m.\u001b[49m\u001b[43mCompletionCreateParamsNonStreaming\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1189\u001b[39m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1190\u001b[39m \u001b[43m        \u001b[49m\u001b[43moptions\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmake_request_options\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1191\u001b[39m \u001b[43m            \u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[43m=\u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_query\u001b[49m\u001b[43m=\u001b[49m\u001b[43mextra_query\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_body\u001b[49m\u001b[43m=\u001b[49m\u001b[43mextra_body\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtimeout\u001b[49m\n\u001b[32m   1192\u001b[39m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1193\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m=\u001b[49m\u001b[43mChatCompletion\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1194\u001b[39m \u001b[43m        \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstream\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[32m   1195\u001b[39m \u001b[43m        \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[43m=\u001b[49m\u001b[43mStream\u001b[49m\u001b[43m[\u001b[49m\u001b[43mChatCompletionChunk\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1196\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Admin\\projects\\agents\\.venv\\Lib\\site-packages\\openai\\_base_client.py:1259\u001b[39m, in \u001b[36mSyncAPIClient.post\u001b[39m\u001b[34m(self, path, cast_to, body, options, files, stream, stream_cls)\u001b[39m\n\u001b[32m   1245\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mpost\u001b[39m(\n\u001b[32m   1246\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   1247\u001b[39m     path: \u001b[38;5;28mstr\u001b[39m,\n\u001b[32m   (...)\u001b[39m\u001b[32m   1254\u001b[39m     stream_cls: \u001b[38;5;28mtype\u001b[39m[_StreamT] | \u001b[38;5;28;01mNone\u001b[39;00m = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m   1255\u001b[39m ) -> ResponseT | _StreamT:\n\u001b[32m   1256\u001b[39m     opts = FinalRequestOptions.construct(\n\u001b[32m   1257\u001b[39m         method=\u001b[33m\"\u001b[39m\u001b[33mpost\u001b[39m\u001b[33m\"\u001b[39m, url=path, json_data=body, files=to_httpx_files(files), **options\n\u001b[32m   1258\u001b[39m     )\n\u001b[32m-> \u001b[39m\u001b[32m1259\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m cast(ResponseT, \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mopts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[43m)\u001b[49m)\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Admin\\projects\\agents\\.venv\\Lib\\site-packages\\openai\\_base_client.py:1047\u001b[39m, in \u001b[36mSyncAPIClient.request\u001b[39m\u001b[34m(self, cast_to, options, stream, stream_cls)\u001b[39m\n\u001b[32m   1044\u001b[39m             err.response.read()\n\u001b[32m   1046\u001b[39m         log.debug(\u001b[33m\"\u001b[39m\u001b[33mRe-raising status error\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m-> \u001b[39m\u001b[32m1047\u001b[39m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m._make_status_error_from_response(err.response) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[32m   1049\u001b[39m     \u001b[38;5;28;01mbreak\u001b[39;00m\n\u001b[32m   1051\u001b[39m \u001b[38;5;28;01massert\u001b[39;00m response \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m, \u001b[33m\"\u001b[39m\u001b[33mcould not resolve response (should never happen)\u001b[39m\u001b[33m\"\u001b[39m\n",
      "\u001b[31mAPIStatusError\u001b[39m: Error code: 402 - {'error': {'message': 'Insufficient Balance', 'type': 'unknown_error', 'param': None, 'code': 'invalid_request_error'}}"
     ]
    }
   ],
   "source": [
    "deepseek = OpenAI(api_key=deepseek_api_key, base_url=\"https://api.deepseek.com/v1\")\n",
    "model_name = \"deepseek-chat\"\n",
    "\n",
    "response = deepseek.chat.completions.create(model=model_name, messages=messages)\n",
    "answer = response.choices[0].message.content\n",
    "\n",
    "display(Markdown(answer))\n",
    "competitors.append(model_name)\n",
    "answers.append(answer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "**Island‑City COVID‑19 Response Plan (6‑month horizon)**  \n",
       "\n",
       "---\n",
       "\n",
       "### 1. Allocation & Prioritisation  \n",
       "\n",
       "| Resource | Who receives it first | Rationale | Roll‑out timing & logistics |\n",
       "|----------|----------------------|-----------|------------------------------|\n",
       "| **Vaccine (150 000 doses, 2‑dose schedule)** | 1️⃣ All **65 + year‑olds** (100 000 people) – 1 dose each, second dose 4 weeks later.  <br>2️⃣ **Healthcare workers** (50 000) – 1 dose each, second dose 4 weeks later.  <br>3️⃣ Remaining **essential workers** (up to 40 000 of the 200 000) – 1 dose each, second dose 4 weeks later.  <br>4️⃣ The last 10 000 doses go to **high‑risk adults (45‑64 y) with comorbidities** identified via primary‑care registries. | • 65 + have the highest infection‑fatality ratio (IFR ≈ 5 %). <br>• Health‑care workers must stay healthy to keep the system functional. <br>• Essential workers have twice the contact rate, so vaccinating a subset reduces onward transmission disproportionately. <br>• Remaining doses protect the next most vulnerable group. | • Day 0–30: Vaccinate 65 + and health‑care workers (first dose). <br>• Day 31–60: Give second doses to those groups; simultaneously start first doses for selected essential workers. <br>• Day 61–90: Complete second doses for essential workers and high‑risk adults. <br>• Cold‑chain, mobile teams, and employer‑based sites ensure >90 % coverage of each priority group within the 3‑month window. |\n",
       "| **Antiviral treatment (10 000 courses)** | **Any symptomatic case** meeting **all** of the following: <br>• Age ≥ 65 or has a known high‑risk comorbidity, **or** <br>• Is an essential/health‑care worker, **or** <br>• Presents ≤ 5 days after symptom onset. | The drug cuts the probability of severe disease by 60 % and is most valuable where the risk of hospitalization is highest. Prioritising the groups above maximises deaths averted per course. | • Test‑and‑treat clinics open city‑wide from Day 0. <br>• Rapid‑test kits distributed to primary‑care and occupational health services to guarantee ≤ 5‑day window. <br>• Real‑time allocation dashboard monitors usage; unused courses are re‑allocated to the next priority tier each week. |\n",
       "| **Non‑pharmaceutical Intervention (single choice)** | **6‑week strict lockdown** (70 % contact reduction). | • The virus’ basic reproduction number is uncertain but could be as high as 3.2; a short, intense reduction is the only realistic way to guarantee that the health system never exceeds 2 500 beds. <br>• Economic loss is confined to 6 weeks; a 3‑month moderate campaign would keep contacts higher for longer, increasing the chance of overwhelming hospitals and requiring an even longer, more disruptive lockdown later. | • Day 0‑42: All non‑essential businesses close; schools shift to remote learning; public transport limited to 30 % capacity; mask‑mandate enforced. <br>• Essential workers (including the 200 000) continue on‑site with PPE and physical‑distancing. <br>• After Day 42: Gradual step‑down (10 % contact restoration per week) while monitoring Rt; if Rt > 1.1, re‑impose targeted micro‑lockdowns. |\n",
       "\n",
       "---\n",
       "\n",
       "### 2. Quantitative Justification  \n",
       "\n",
       "**Model set‑up (simplified deterministic SEIR, 6‑month horizon, population = 1 000 000).**  \n",
       "\n",
       "*Basic parameters*  \n",
       "- Incubation = 5 d, infectious period = 7 d → generation time ≈ 5 d.  \n",
       "- Proportion symptomatic = 70 % (consistent with many respiratory viruses).  \n",
       "- Infection‑hospitalisation ratio (IHR) = 5 % (given).  \n",
       "- Infection‑fatality ratio (IFR) = 0.5 % overall; 5 % for 65 + , 1 % for 45‑64 y with comorbidities, 0.2 % for younger adults.  \n",
       "\n",
       "*Vaccine effects*  \n",
       "- 60 % efficacy against symptomatic disease (VEsym).  \n",
       "- 50 % efficacy against infection (VEinf).  \n",
       "- For the groups that receive two doses we assume the full efficacy after the second dose (effective from week 5 for each cohort).  \n",
       "\n",
       "*Antiviral effect*  \n",
       "- 60 % reduction in progression to severe disease among treated cases → reduces hospitalisation risk from 5 % to 2 % for those receiving the drug.  \n",
       "\n",
       "*Contact reductions*  \n",
       "- Strict lockdown: overall β reduced by 70 % → effective reproduction number **Re = R0 × 0.30** for the 6‑week period.  \n",
       "\n",
       "**Scenario A – **Plan above (Lockdown + vaccine allocation + antivirals).**  \n",
       "\n",
       "Assumptions:  \n",
       "- Best‑estimate R0 = **2.4**.  \n",
       "- During lockdown (weeks 0‑6): Re = 0.72 → epidemic contracts (≈ ‑5 % growth per week).  \n",
       "- After step‑down, contacts rise to 50 % of baseline → Re ≈ 1.2 (still > 1 but far slower).  \n",
       "- Vaccine‑derived immunity starts protecting the 65 + by week 5 and health‑care workers by week 7; essential‑worker sub‑cohort by week 9.  \n",
       "\n",
       "**Projected outcomes (6 months)**  \n",
       "\n",
       "| Outcome | Estimate (best‑case R0 = 2.4) | Estimate (high‑R0 = 3.0) |\n",
       "|---------|------------------------------|--------------------------|\n",
       "| Cumulative infections (including asymptomatic) | **≈ 120 000** (12 % of population) | **≈ 210 000** (21 %) |\n",
       "| Symptomatic cases | ≈ 84 000 | ≈ 147 000 |\n",
       "| Hospitalisations (5 % of symptomatic) | **≈ 2 200** (within 2 500‑bed capacity) | **≈ 3 650** (exceeds capacity by ~15 %) |\n",
       "| Deaths (using age‑specific IFR, vaccine & antiviral impact) | **≈ 350** (≈ 85 % averted vs no‑intervention) | **≈ 620** |\n",
       "| Antiviral courses used | 9 800 (≈ 98 % of stock) | 9 200 (slightly fewer cases early) |\n",
       "| Economic disruption (lockdown weeks) | 6 weeks full shutdown + 4 weeks phased reopening | Same (lockdown is identical) |\n",
       "\n",
       "**Scenario B – Moderate 3‑month social‑distancing (35 % contact cut, 80 % compliance) + same vaccine prioritisation.**  \n",
       "\n",
       "- Effective Re during SD = R0 × 0.65.  \n",
       "- With R0 = 2.4 → Re ≈ 1.56 (still expanding).  \n",
       "- No sharp contraction; cases rise steadily; hospitals exceed capacity around week 10.  \n",
       "\n",
       "| Outcome | Best‑estimate R0 = 2.4 | High‑R0 = 3.0 |\n",
       "|---------|------------------------|--------------|\n",
       "| Infections | ≈ 260 000 (26 %) | ≈ 380 000 (38 %) |\n",
       "| Hospitalisations | ≈ 6 500 (≈ 260 % capacity) | ≈ 9 500 |\n",
       "| Deaths | ≈ 1 300 | ≈ 2 000 |\n",
       "| Economic impact | 12 weeks of reduced activity (35 % loss) + prolonged absenteeism due to overload | Same length but higher indirect loss because of sick‑leave and excess mortality |\n",
       "\n",
       "**Scenario C – Same lockdown, but **vaccine allocated first to essential workers (200 000) and only later to the elderly**.**  \n",
       "\n",
       "- By vaccinating a larger share of high‑contact individuals we cut transmission more, but the elderly remain unprotected for longer.  \n",
       "\n",
       "| Outcome | Best‑estimate R0 = 2.4 | High‑R0 = 3.0 |\n",
       "|---------|------------------------|--------------|\n",
       "| Infections | ≈ 90 000 (9 %) | ≈ 150 000 (15 %) |\n",
       "| Hospitalisations | ≈ 2 900 (≈ 115 % capacity) | ≈ 4 800 |\n",
       "| Deaths | ≈ 480 (higher than Scenario A because 65 + are unvaccinated early) | ≈ 820 |\n",
       "| Antiviral use | similar (≈ 10 000) | similar |\n",
       "\n",
       "**Interpretation** – The **Plan (Scenario A)** gives the lowest death toll and keeps hospital demand at or below capacity while limiting the period of severe economic restriction to a single 6‑week lockdown. Scenario B protects the economy longer but at the cost of > 2 × more deaths and overwhelming hospitals. Scenario C reduces infections slightly more than A but raises deaths because the most vulnerable are exposed longer; it therefore fails the primary objective (minimise deaths).\n",
       "\n",
       "---\n",
       "\n",
       "### 3. Key Uncertainties & Adaptive Triggers  \n",
       "\n",
       "| Uncertainty | Potential impact on plan | Adaptive trigger & policy change |\n",
       "|-------------|--------------------------|----------------------------------|\n",
       "| **True R0 / transmissibility** (e.g., emergence of a more transmissible variant) | Higher R0 could push Re above 1 even during lockdown, risking overload. | *If early Rt (first 2 weeks) > 1.2 despite lockdown*, extend lockdown by 2 weeks and/or add targeted school closures. |\n",
       "| **Vaccine efficacy against infection** (VEinf) | If VEinf < 30 %, herd‑effect is weaker, more cases among unvaccinated groups. | *If post‑vaccination serosurveys show < 30 % reduction in infection incidence*, expand vaccination to an additional 30 000 essential workers (re‑allocate some doses from low‑risk adults). |\n",
       "| **Duration of immunity** (waning after 3‑4 months) | Could lead to resurgence after step‑down. | *If breakthrough infections rise > 5 % of vaccinated cohort after month 4*, plan for a booster campaign (use any leftover doses or procure additional). |\n",
       "| **Antiviral supply chain reliability** | Shortage reduces ability to prevent severe disease. | *If weekly antiviral dispensing falls < 80 % of target*, prioritize only 65 + and health‑care workers, and seek emergency imports. |\n",
       "| **Compliance to lockdown** (mobility data) | Lower compliance → less contact reduction → higher Rt. | *If mobility stays > 50 % of baseline after week 2*, add enforcement measures (fines, increased policing) and consider expanding lockdown to include selected low‑risk workplaces. |\n",
       "\n",
       "---\n",
       "\n",
       "### 4. Risks & Mitigations  \n",
       "\n",
       "| Risk / Failure mode | Why it matters | Specific mitigation |\n",
       "|---------------------|----------------|----------------------|\n",
       "| **Hospital capacity still breached** (e.g., sudden surge from a superspreading event). | Overload leads to excess mortality, breaking primary goal. | • Real‑time bed‑availability dashboard; trigger rapid “circuit‑breaker” micro‑lockdowns of affected neighbourhoods. <br>• Pre‑arranged overflow agreements with nearby islands/region for emergency ICU beds. |\n",
       "| **Vaccine hesitancy among priority groups** (especially health‑care workers). | Reduces effective coverage, undermines protection of the most vulnerable. | • Targeted communication campaign with respected clinicians, on‑site vaccination at hospitals, incentives (paid‑time‑off). <br>• Mobile units for home‑bound seniors. |\n",
       "| **Delayed antiviral treatment ( > 5 days after symptom onset)** → loss of efficacy. | Fewer severe cases averted, higher hospital demand. | • Rapid‑test distribution to workplaces and schools; same‑day courier of medication to positive cases; electronic triage line staffed 24 h. <br>• Public messaging: “If you feel unwell, get tested and call the treatment line within 48 h.” |\n",
       "\n",
       "---\n",
       "\n",
       "### 5. Public‑Facing Summary (for the community)\n",
       "\n",
       "> **Our city will protect the most vulnerable first.** Starting immediately, every senior citizen and health‑care worker will receive the COVID‑19 vaccine, followed by a portion of essential workers and high‑risk adults. We will also provide a limited antiviral medicine to those at greatest risk of severe illness. To keep hospitals from being overwhelmed, we will impose a **six‑week, city‑wide lockdown** that cuts contacts by 70 %, after which we will lift restrictions gradually while monitoring the virus. This approach saves the most lives, keeps our health system functional, and limits economic disruption to a short, well‑defined period. Please stay home, follow mask and distancing rules, and get tested quickly if you feel sick – together we will beat this outbreak."
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Updated with the latest Open Source model from OpenAI\n",
    "\n",
    "groq = OpenAI(api_key=groq_api_key, base_url=\"https://api.groq.com/openai/v1\")\n",
    "model_name = \"openai/gpt-oss-120b\"\n",
    "\n",
    "response = groq.chat.completions.create(model=model_name, messages=messages)\n",
    "answer = response.choices[0].message.content\n",
    "\n",
    "display(Markdown(answer))\n",
    "competitors.append(model_name)\n",
    "answers.append(answer)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## For the next cell, we will use Ollama\n",
    "\n",
    "Ollama runs a local web service that gives an OpenAI compatible endpoint,  \n",
    "and runs models locally using high performance C++ code.\n",
    "\n",
    "If you don't have Ollama, install it here by visiting https://ollama.com then pressing Download and following the instructions.\n",
    "\n",
    "After it's installed, you should be able to visit here: http://localhost:11434 and see the message \"Ollama is running\"\n",
    "\n",
    "You might need to restart Cursor (and maybe reboot). Then open a Terminal (control+\\`) and run `ollama serve`\n",
    "\n",
    "Useful Ollama commands (run these in the terminal, or with an exclamation mark in this notebook):\n",
    "\n",
    "`ollama pull <model_name>` downloads a model locally  \n",
    "`ollama ls` lists all the models you've downloaded  \n",
    "`ollama rm <model_name>` deletes the specified model from your downloads"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<table style=\"margin: 0; text-align: left; width:100%\">\n",
    "    <tr>\n",
    "        <td style=\"width: 150px; height: 150px; vertical-align: middle;\">\n",
    "            <img src=\"../assets/stop.png\" width=\"150\" height=\"150\" style=\"display: block;\" />\n",
    "        </td>\n",
    "        <td>\n",
    "            <h2 style=\"color:#ff7800;\">Super important - ignore me at your peril!</h2>\n",
    "            <span style=\"color:#ff7800;\">The model called <b>llama3.3</b> is FAR too large for home computers - it's not intended for personal computing and will consume all your resources! Stick with the nicely sized <b>llama3.2</b> or <b>llama3.2:1b</b> and if you want larger, try llama3.1 or smaller variants of Qwen, Gemma, Phi or DeepSeek. See the <A href=\"https://ollama.com/models\">the Ollama models page</a> for a full list of models and sizes.\n",
    "            </span>\n",
    "        </td>\n",
    "    </tr>\n",
    "</table>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "!ollama pull llama3.2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "ollama = OpenAI(base_url='http://localhost:11434/v1', api_key='ollama')\n",
    "model_name = \"llama3.2\"\n",
    "\n",
    "response = ollama.chat.completions.create(model=model_name, messages=messages)\n",
    "answer = response.choices[0].message.content\n",
    "\n",
    "display(Markdown(answer))\n",
    "competitors.append(model_name)\n",
    "answers.append(answer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['gpt-5-nano', 'gemini-2.5-flash', 'openai/gpt-oss-120b']\n",
      "['Below is a concise, action‑oriented advisory plan designed to minimize deaths, prevent hospital overload, and limit economic disruption. All numbers are approximate and based on a deliberately simple, transparent set of assumptions described inline.\\n\\n1) Concrete allocation and prioritization plan (vaccines, antivirals, NPIs)\\n\\nAssumptions used for this plan (consistently applied in all sections):\\n- Population: 1,000,000. Hospital capacity: 2,500 beds.\\n- Case severity: 5% of infections require hospitalization. Vaccination reduces infection risk by 50% and symptomatic disease by 60% in vaccinated people (i.e., 50% protection against infection; among breakthrough infections, a further 60% reduction in risk of developing symptomatic disease).\\n- Incubation: mean 5 days; infectious period: ~7 days; generation time ~5 days.\\n- Antivirals: up to 10,000 treatment courses total. They reduce progression to severe disease by 60% if given within 5 days of symptom onset; effect applies to those who would otherwise progress to severe disease.\\n- Non-pharmaceutical intervention (NPI) options (choose one):\\n  A) 6-week strict lockdown: 70% reduction in social contacts; assumed high compliance (consistent with the 70% contact reduction stated).\\n  B) 3-month moderate social distancing: 35% reduction in contacts with ~80% compliance (less effective per person, longer duration).\\n- Vaccine supply: 150,000 doses. For planning, assume one dose per person (single-dose deployment) with the stated efficacy values (50% infection protection; 60% protection against symptomatic disease). Priority is given to high-risk groups first.\\n- Time horizon: 6 months.\\n\\nSelected plan (priority: deaths > health system capacity > economy)\\n- Vaccination priority and rollout:\\n  - Phase 1 (Weeks 0–2): Vaccinate all people aged 65+ (100,000 individuals) and all healthcare workers (50,000). This uses all 150,000 doses in a front-loaded rollout, with the intent of protecting the most vulnerable for death and preserving hospital capacity.\\n  - Rationale: 65+ have the highest risk of death; healthcare workers are critical to maintaining hospital functionality and to reduce nosocomial transmission.\\n  - Rollout cadence: Target ~50,000 vaccinations per week for Weeks 0–3, achieving full Phase 1 coverage by end of Week 3.\\n  - Phase 2 (Weeks 3–24): If further vaccine stock arrives, continue vaccinating high‑risk adults (e.g., people with major comorbidities) and essential workers to blunt transmission and protect capacity; assume an additional ~50,000 doses through Weeks 4–6 if available.\\n- Antiviral allocation (up to 10,000 courses):\\n  - Criteria: Treat symptomatic adults who are 65+, or adults with high-risk comorbidities (e.g., cardiovascular disease, diabetes, chronic lung disease), and/or healthcare workers with symptomatic infection who present within 5 days of symptom onset.\\n  - Rollout cadence: Begin immediately; prioritize seniors and known high‑risk patients, then expand to other high‑risk groups as supply allows (roughly 2,000–3,000 courses per week over Weeks 0–6 if demand is steady).\\n  - Expected impact: Reduces progression to severe disease among treated individuals by 60%, which lowers hospitalization demand by up to roughly 0.03 per treated infected person (see quantitative justification). In practice this will shave a few thousand hospitalizations across the 6-month horizon, concentrated among high-risk cases.\\n- Non-pharmaceutical intervention (NP I):\\n  - Choice: 6-week strict lockdown (70% contact reduction).\\n  - Rationale: This maximally reduces transmission quickly, dramatically lowers peak demand on hospitals, and buys time for the vaccine to protect the most vulnerable. This option best aligns with the priority to minimize deaths and avoid health-system overload.\\n  - Timing: Start immediately (Day 0) and continue for 42 days. After 6 weeks, transition out of lockdown with maintenance of minimum necessary controls and the vaccination program continuing to scale up.\\n  - Compliance assumption: 70% contact reduction is achieved; if real-world compliance falls significantly, reassess with targeted containment or micro‑lockdowns in high-transmission locales.\\n\\nAssumptions about timing and rollout:\\n- Immediate deployment: Lockdown starts now; vaccine rollout begins Day 0 with Phase 1 completion by Day 21–Day 21 (end of Week 3).\\n- Masking, testing, and contact tracing remain in place at baseline; the pivotal change is the 70% contact reduction from the lockdown.\\n- Antivirals are deployed as soon as possible after symptom onset to eligible individuals throughout Weeks 0–6.\\n- After Week 6, lockdown constraints are relaxed in a staged fashion (subject to hospital occupancy and local transmission) while vaccines and antivirals continue to operate.\\n\\n2) Quantitative justification (best‑estimate R0 and one alternative R0)\\n\\nKey assumed constants used for the numbers below:\\n- Best-estimate R0: 2.6 (range 1.8–3.2 uncertainty; we use 2.6 as central).\\n- Alternative R0 for sensitivity: 3.0.\\n- Generation time: ~5 days.\\n- NPI effectiveness: lockdown reduces effective reproduction number to Rt = R0 × (1 − 0.70) = 0.78 during Weeks 0–6.\\n- Vaccine impact (on the population level): 7.5% effective reduction in susceptible population during the period (150,000 vaccinated × 50% efficacy against infection = 7.5% of population effectively protected against infection). This reduces the effective attack rate and the absolute number of infections accordingly.\\n- Antivirals: 10,000 courses reduce hospitalizations among treated infected people by 60% (i.e., if 10,000 treated would have progressed to hospitalization at 5%, their hospitalization rate among treated steps down to 2%).\\n\\nDerived rough quantities (6-month horizon, i.e., ~26 weeks):\\n- Without any interventions (for comparison): Under R0 ≈ 2.6, a substantial portion of the population would become infected with a sizable hospitalization burden. We do not rely on that as our baseline; instead, we compare interventions to expectations with the selected plan.\\n- With Plan (6-week lockdown + vaccination of 65+ and healthcare workers + antivirals):\\n  - Best estimate cumulative infections over 6 months: ~130,000 to ~170,000 (about 13–17% of the population).\\n  - Best estimate cumulative hospitalizations: 6,500 to 8,500.\\n    - Antiviral effect reduces hospitalizations by roughly 300–500 across the entire horizon (given 10,000 treated; 5% baseline hospitalization rate for infections; 60% reduction in progression to severe disease among treated), so adjust to ~6,200–8,200.\\n  - Deaths (illustrative range with broad IFR assumptions, acknowledging vaccination protects the elderly): ~500–900 deaths (most fatalities concentrated among unvaccinated strata before full vaccine protection and in high-risk patients who still become infected).\\n- Alternative Strategy A (Essential workers first vaccine priority, same lockdown):\\n  - Cumulative infections: ~140,000 to ~210,000.\\n  - Hospitalizations: ~7,000 to ~10,500 (antivirals yield modest reductions; total reductions similar in scale to the plan, but distribution shifts away from seniors; more hospitalizations in the non‑elderly group due to delayed vaccination).\\n  - Deaths: ~900–1,700 (higher than Plan due to more infections among non‑elderly, with fewer elderly protected early).\\n- Alternative Strategy B (Plan uses lockdown; but 3-month moderate distancing instead of lockdown; vaccine priority as in Plan):\\n  - Cumulative infections: ~180,000 to ~260,000 (moderate, longer duration distancing but lower per-day effectiveness leads to higher total infections than a short, strict lockdown).\\n  - Hospitalizations: ~9,000 to ~13,000.\\n  - Deaths: ~1,200–2,200.\\n\\nKey simplifications and formulas used (for transparency):\\n- Rt during lockdown: Rt_lockdown = R0 × (1 − 0.70) = 0.78 (best estimate; reduces growth phase to decay).\\n- Population-level infection protection from vaccination: overall susceptible reduction ≈ 150,000 vaccinated × 50% efficacy against infection = 75,000 people effectively less susceptible; relative population effect ≈ 75,000 / 1,000,000 = 7.5% fewer infections in the epidemic wave, applied to rough final size.\\n- Hospitalizations: H = 0.05 × I, where I is cumulative infections. Antiviral effect reduces hospitalizations among treated by 60%: for 10,000 treated, hospitalizations prevented ≈ 0.05 × 10,000 × 0.60 = 300 hospitalizations (as a rough cap, distributed across the horizon).\\n- IFR and age distribution are not modeled in detail here; the death estimates are intended to be proportional to infections with heavier weight on vaccines preventing infection in the elderly and reducing severe disease.\\n\\n3) Key uncertainties (critical unknowns and adaptive updates)\\n\\n- Vaccine effectiveness against infection (VE_inf) in the real population: If VE_inf is lower than 50% or wanes quickly, infection reductions will be smaller; if VE_inf is higher or longer-lasting, infections and hospitalizations drop further.\\n  - Update policy: If VE_inf proves higher, accelerate broader vaccination to more age/occupation groups earlier; if VE_inf is lower, rely more on NPIs and antivirals, and consider extending lockdown duration if hospital strain rises.\\n- R0 value and real-world contact patterns: The true R0 and the effectiveness of the 70% contact reduction are uncertain (especially with essential workers and healthcare settings).\\n  - Update policy: If R0 is closer to 3.0 or higher or if transmission among essential workers remains high, consider tighter or targeted lockdown segments, expand vaccination to essential workers sooner, or reimpose stricter NPIs in hotspots.\\n- Antiviral uptake and real-world effectiveness: Availability, speed of deployment, adherence within 5 days, and real efficacy may differ.\\n  - Update policy: If antivirals are less available or less effective than assumed, increase vaccination speed or consider shortening lockdown duration with increased testing and targeted quarantines; otherwise, expand antiviral allocation to household contacts of confirmed cases to widen indirect protection.\\n- Hospital capacity dynamics and surge risk: If hospital demand accelerates beyond 2,500 beds, you may need to reintroduce stricter NPIs or temporary surge capacity measures.\\n  - Update policy: Predefine trigger points (e.g., occupancy >2,000 beds for 7 consecutive days) to reimpose partial lockdown or to allocate more resources (temporary field hospitals, discharge planning to free beds).\\n- Compliance and inequality: 80% compliance assumption for the moderate strategy may not hold; 70% contact reduction may vary by district and by essential worker settings.\\n  - Update policy: Use data dashboards to identify and address pockets of noncompliance with targeted communications and localized restrictions if needed.\\n\\n4) Three main risks or failure modes and mitigations\\n\\n- Risk 1: Health-system overload if lockdown is delayed or vaccine impact is weaker than anticipated.\\n  Mitigation: Implement the 6-week lockdown immediately and strictly, with clear metrics for hospital occupancy and ICU utilization. Pre-plan surge capacity (temporary beds, staffing) and ensure antivirals are prioritized for high-risk patients to maximize the protective effect on hospitalizations.\\n- Risk 2: Inequitable access to vaccination and antivirals, leading to higher mortality in vulnerable subpopulations.\\n  Mitigation: Proactively map and target vaccination outreach to 65+ in all neighborhoods, with mobile clinics in high‑risk blocks; ensure antivirals are available through primary care networks and hospital systems; monitor coverage by age, race/ethnicity, and ZIP code and adjust outreach accordingly.\\n- Risk 3: Waning immunity or reduced VE, undermining the protection from vaccination over 6 months.\\n  Mitigation: Plan for booster or second-dose requirements if supply allows; maintain high vaccination coverage for high-risk groups; keep NPIs ready to scale if case trajectories re-emerge; maintain robust testing and tracing as a backstop.\\n\\n5) Public-facing summary (2–4 sentences)\\n\\nWe will implement a six-week citywide strict lockdown to quickly curb transmission, protect hospital capacity, and save lives, while rapidly vaccinating all residents aged 65+ and healthcare workers (150,000 doses). We will allocate antivirals to high-risk individuals who develop symptoms promptly to prevent hospitalizations. After the lockdown, vaccination will continue to expand to high-risk and essential workers, and we will monitor trends closely, ready to adjust NPIs if hospital usage or transmission rises. Use the expected decreases in risk from vaccination and antivirals to inform personal precautions (masking in crowded indoor spaces, hand hygiene, staying home when ill) and support community compliance.\\n\\nNotes for all readers:\\n- This plan prioritizes minimizing deaths and avoiding hospital overload as the first objectives, recognizing that some economic disruption is unavoidable. Personal actions (masking in high-risk settings, testing when symptomatic, staying away from work if ill) remain essential even after vaccination, as breakthrough infections and transmission can still occur in partially protected populations.', '**Advisory Plan for the Island City Outbreak**\\n\\nThis plan prioritizes minimizing deaths and preventing health system overload, recognizing that significant economic disruption is an unavoidable consequence of effective epidemic control. Our strategy leverages available resources (vaccines, antivirals) and decisive non-pharmaceutical interventions (NPIs) to flatten the curve and protect the most vulnerable.\\n\\n---\\n\\n**1) Allocation and Prioritization Plan**\\n\\n*   **Non-Pharmaceutical Intervention (NPI):**\\n    *   **Choice:** Implement a **6-week strict lockdown** immediately (reducing contacts by 70%). This will be followed by a robust, continuous public health campaign promoting voluntary, sustained social distancing behaviors, aiming for an average of 40% contact reduction for the subsequent 4.5 months.\\n    *   **Why:** The initial strict lockdown is crucial to rapidly reduce the effective reproduction number (R_eff) below 1, thereby suppressing the initial surge of infections. This buys invaluable time for vaccine rollout and allows the healthcare system to prepare. Given the high R0 uncertainty, a less stringent NPI like moderate social distancing alone would almost certainly lead to immediate and overwhelming health system overload. The subsequent sustained campaign aims to keep R_eff manageable and prevent a rapid rebound, balancing public health needs with economic feasibility.\\n    *   **Timing:** Strict lockdown begins immediately upon plan announcement. Public health campaign promoting sustained distancing will launch concurrently with the end of the strict lockdown and continue for the remainder of the 6-month period.\\n\\n*   **Vaccine Prioritization (150,000 doses total; 50% efficacy preventing infection, 60% preventing symptomatic disease):**\\n    *   **Phase 1 (First 2-3 weeks, 50,000 doses): Healthcare Workers (50,000 people).**\\n        *   **Why:** Protecting healthcare workers is paramount to maintaining the functional capacity of our hospitals and clinics. Vaccinating them reduces their risk of infection and symptomatic illness, thereby minimizing absenteeism and preventing in-hospital transmission to vulnerable patients. This directly supports the goal of preventing health system overload.\\n    *   **Phase 2 (Next 2-3 weeks, 100,000 doses): Individuals Aged 65+ (100,000 people).**\\n        *   **Why:** This demographic faces the highest risk of severe disease and death from respiratory viruses. Vaccinating all individuals in this group directly targets the primary goal of minimizing deaths.\\n    *   **Rollout Assumption:** We assume vaccine doses are distributed and administered rapidly within the first 4-6 weeks of the outbreak response. Protection is assumed to begin approximately 2 weeks post-vaccination.\\n\\n*   **Antiviral Allocation (10,000 treatments; reduces progression to severe disease by 60% if given within 5 days of symptom onset):**\\n    *   **Criteria:** Antiviral treatments will be reserved exclusively for individuals with confirmed infection who present with symptoms within 5 days of onset.\\n    *   **Prioritization:**\\n        1.  **Individuals Aged 65+:** This group is at highest risk of severe outcomes. All available antivirals will be directed here first.\\n        2.  **Individuals with significant comorbidities:** (e.g., chronic lung disease, heart disease, diabetes, immunosuppression). This priority group will be defined more specifically through clinical guidelines, to be treated if doses remain after the 65+ allocation is exhausted.\\n        *   **Why:** With limited supply, antivirals must be allocated to those most likely to benefit from reduced progression to severe disease, directly aiming to minimize deaths and hospitalizations. The 65+ population aligns with this goal.\\n\\n---\\n\\n**2) Quantitative Justification**\\n\\nOur epidemiological estimates are based on a simplified compartmental model (SIR-like) with key parameters: mean incubation 5 days, mean infectious period 7 days, 5% of infections require hospital care, and an Infection Fatality Rate (IFR) of 0.5% for individuals under 65 and 5% for individuals 65+. We assume an average hospital stay of 10 days. Hospital overload is estimated to double the IFR for those requiring hospitalization.\\n\\n**Key Assumptions for Modeling:**\\n*   **Best-estimate R0:** 2.5\\n*   **Alternative R0:** 3.2\\n*   **Vaccine Impact:** Reduces susceptibility by 50% (infection prevention). For those vaccinated 65+ who still get infected, the IFR is reduced by 60% from baseline (from 5% to 2%).\\n*   **Antiviral Impact:** Averts 60% of deaths for the 10,000 highest-risk treated individuals (primarily 65+).\\n*   **NPI Phases:** 6-week strict lockdown (70% contact reduction) followed by 4.5 months of 40% contact reduction due to sustained voluntary measures.\\n*   **Hospital Capacity:** 2,500 beds (equivalent to 250 new admissions per day for a 10-day average stay).\\n\\n**Estimated Outcomes Over 6 Months:**\\n\\n| Metric             | My Plan (R0=2.5)      | My Plan (R0=3.2)      | Alternative 1 (EW + Moderate NPI) (R0=2.5) | Alternative 2 (No NPI + General Pop Vaccine) (R0=2.5) |\\n| :----------------- | :-------------------- | :-------------------- | :------------------------------------------- | :---------------------------------------------------- |\\n| **Cumulative Infections** | **327,000**           | **511,000**           | **740,000**                                  | **601,250**                                           |\\n| **Hospitalizations**   | **16,350**            | **25,550**            | **37,000**                                   | **30,062**                                            |\\n| **Peak Beds Needed**   | **~3,000** (tight)    | **~3,900** (overload) | **~6,000+** (massive overload)               | **~5,000+** (massive overload)                        |\\n| **Deaths**             | **1,785**             | **5,000**             | **10,095**                                   | **8,446**                                             |\\n\\n**Reasoning for My Plan\\'s Superiority:**\\n*   **My Plan (R0=2.5):** The strict lockdown effectively suppresses the initial spread (limiting infections to ~5,000 in 6 weeks). The subsequent 40% contact reduction leads to an effective R (R_eff) of 1.5. Over the next 4.5 months, this results in approximately 322,000 new infections. Peak hospitalizations are estimated at around 3,000 beds, meaning the system operates at very tight capacity, but potentially avoids collapse. Deaths are minimized by prioritizing vaccination for the elderly and healthcare workers, and antiviral treatment for high-risk individuals.\\n*   **My Plan (R0=3.2):** Even with the same NPIs, a higher R0 of 3.2 makes control significantly harder. The R_eff post-lockdown becomes 1.92, leading to more infections (~506,000 in 4.5 months) and significantly increased hospital demand (~3,900 peak beds). This scenario leads to substantial hospital overload, which is factored into the higher death toll. While challenging, this still represents a substantial improvement over alternative strategies.\\n\\n**Comparison with Alternative Strategies (Modeled at R0=2.5):**\\n*   **Alternative 1 (Essential Workers + Moderate NPI):** Vaccinating essential workers may reduce some transmission, but the 3-month moderate NPI (effective 28% contact reduction, R_eff=1.8) and subsequent removal of NPIs leads to a massive wave of infections, overwhelming hospitals early on. Vaccinating essential workers does not directly protect the most vulnerable from death to the same extent as vaccinating the elderly. Deaths and hospitalizations are significantly higher.\\n*   **Alternative 2 (No NPI + General Pop Vaccine):** Without any NPIs, R_eff remains at R0 (2.5). Even with 15% of the population vaccinated (randomly), the epidemic explodes, leading to widespread infection and catastrophic hospital overload. Deaths are extremely high due to uncontrolled spread and lack of care.\\n\\n---\\n\\n**3) Key Uncertainties and Policy Updates**\\n\\n1.  **True R0 Value:** The range 1.8-3.2 is wide.\\n    *   **Policy Update:** If R0 is confirmed lower (e.g., closer to 1.8), we could potentially shorten the strict lockdown or implement a less stringent post-lockdown contact reduction (e.g., 30% instead of 40%) to reduce economic impact, provided hospital capacity is still maintained. If R0 is confirmed higher (e.g., closer to 3.2 or above), we would need to consider extending the strict lockdown or implementing stricter, longer-term NPIs (e.g., mandatory masking, stricter capacity limits) to prevent catastrophic hospital overload.\\n2.  **Vaccine Efficacy against Severe Disease/Death:** The current efficacy figures are for preventing infection (50%) and symptomatic disease (60%).\\n    *   **Policy Update:** If new data shows higher efficacy against severe disease/death, we could potentially ease NPIs slightly or prioritize further doses to other high-risk groups (e.g., those with comorbidities). If efficacy is lower, we would need to reinforce NPIs and potentially acquire more targeted antivirals.\\n3.  **Compliance with NPIs:** Our model assumes high compliance during lockdown and sustained 40% reduction post-lockdown.\\n    *   **Policy Update:** If compliance is lower than anticipated, real-time epidemiological data (e.g., rising case numbers, test positivity) would trigger immediate re-evaluation and reinforcement of NPIs, potentially including stricter enforcement or public awareness campaigns with clear messaging on the importance of adherence.\\n4.  **Infection Fatality Rate (IFR) / Hospitalization Rate:** These fixed rates may vary by age or underlying conditions.\\n    *   **Policy Update:** If surveillance data indicates a higher IFR, especially in younger populations, we would need to consider expanding vaccine eligibility to other vulnerable groups or essential workers beyond current allocations if more doses become available, and further emphasize NPIs across all age groups. If the hospitalization rate is higher, we would immediately activate surge capacity plans and consider emergency measures to expand healthcare infrastructure.\\n5.  **New Variants:** The emergence of a more transmissible or virulent variant.\\n    *   **Policy Update:** If a new variant significantly impacts R0 or vaccine effectiveness, immediate re-evaluation of all NPIs and vaccine strategies would be necessary. This could involve reinstating stricter lockdowns, adapting vaccine distribution, or accelerating development of new vaccines/treatments.\\n\\n---\\n\\n**4) Main Risks or Failure Modes of the Plan and Mitigations**\\n\\n1.  **Risk: Failure of Post-Lockdown Sustained Social Distancing.**\\n    *   **Failure Mode:** After the 6-week strict lockdown, public fatigue or complacency leads to a rapid return to pre-outbreak contact levels (e.g., less than 40% reduction), causing R_eff to rise rapidly and overwhelm hospitals.\\n    *   **Mitigation:**\\n        *   **Intense Communication Campaign:** Launch an unprecedented public health campaign starting *during* the lockdown, clearly explaining the rationale for sustained social distancing, providing practical guidelines (masking, remote work, outdoor activities), and highlighting the collective benefit.\\n        *   **Incentives and Support:** Implement programs to support remote work, provide free masks, and offer mental health services to combat fatigue.\\n        *   **Gradual Reopening Plan:** A phased and data-driven reopening, tied to clear metrics (e.g., case numbers, hospital capacity), will allow for controlled relaxation of measures. If cases rebound, restrictions will be re-imposed.\\n\\n2.  **Risk: Insufficient Hospital Capacity in High R0 Scenario.**\\n    *   **Failure Mode:** If the true R0 is at the higher end (3.2), our plan is predicted to exceed hospital capacity, leading to increased deaths due to lack of care.\\n    *   **Mitigation:**\\n        *   **Immediate Surge Capacity Activation:** Initiate plans for expanding hospital bed capacity (e.g., converting non-clinical spaces, establishing field hospitals) and staffing (e.g., recalling retired healthcare workers, cross-training staff, requesting external aid).\\n        *   **Prioritized Care Protocols:** Develop and communicate clear ethical guidelines for rationing critical care resources in severe overload situations.\\n        *   **Rapid Resource Acquisition:** Proactively secure additional ventilators, oxygen supplies, and personal protective equipment.\\n\\n3.  **Risk: Inequity or Access Issues in Vaccine/Antiviral Rollout.**\\n    *   **Failure Mode:** Despite prioritization, vulnerable groups (e.g., elderly, essential workers) face barriers to accessing vaccines or antivirals due to logistics, digital divide, language barriers, or transportation issues.\\n    *   **Mitigation:**\\n        *   **Community-Based Rollout:** Establish mobile vaccination clinics and accessible treatment centers in neighborhoods with high concentrations of prioritized populations, leveraging community leaders and trusted organizations.\\n        *   **Multi-Lingual Communication:** Ensure all public health information, registration, and consent forms are available in multiple languages and accessible formats.\\n        *   **Dedicated Support Hotlines:** Set up phone hotlines to assist with appointments, provide information, and arrange transportation for those facing barriers.\\n\\n---\\n\\n**5) Public Summary**\\n\\n\"Island City, we face a critical challenge with this new virus. To protect our community, especially our elders and healthcare heroes, we are implementing a crucial 6-week strict lockdown starting today. This tough but necessary step will rapidly slow the virus, giving us time to vaccinate our frontline workers and most vulnerable residents, and to prepare our hospitals. After this initial period, we will ask for your continued vigilance with sustained social distancing. Your cooperation is vital to minimizing illness, saving lives, and ensuring our healthcare system can care for everyone who needs it.\"', '**Island‑City COVID‑19 Response Plan (6‑month horizon)**  \\n\\n---\\n\\n### 1. Allocation & Prioritisation  \\n\\n| Resource | Who receives it first | Rationale | Roll‑out timing & logistics |\\n|----------|----------------------|-----------|------------------------------|\\n| **Vaccine (150\\u202f000 doses, 2‑dose schedule)** | 1️⃣ All **65\\u202f+\\u202fyear‑olds** (100\\u202f000 people) – 1 dose each, second dose 4\\u202fweeks later.  <br>2️⃣ **Healthcare workers** (50\\u202f000) – 1 dose each, second dose 4\\u202fweeks later.  <br>3️⃣ Remaining **essential workers** (up to 40\\u202f000 of the 200\\u202f000) – 1 dose each, second dose 4\\u202fweeks later.  <br>4️⃣ The last 10\\u202f000 doses go to **high‑risk adults (45‑64\\u202fy) with comorbidities** identified via primary‑care registries. | • 65\\u202f+\\u202fhave the highest infection‑fatality ratio (IFR ≈\\u202f5\\u202f%). <br>• Health‑care workers must stay healthy to keep the system functional. <br>• Essential workers have twice the contact rate, so vaccinating a subset reduces onward transmission disproportionately. <br>• Remaining doses protect the next most vulnerable group. | • Day\\u202f0–30: Vaccinate 65\\u202f+\\u202fand health‑care workers (first dose). <br>• Day\\u202f31–60: Give second doses to those groups; simultaneously start first doses for selected essential workers. <br>• Day\\u202f61–90: Complete second doses for essential workers and high‑risk adults. <br>• Cold‑chain, mobile teams, and employer‑based sites ensure >90\\u202f% coverage of each priority group within the 3‑month window. |\\n| **Antiviral treatment (10\\u202f000 courses)** | **Any symptomatic case** meeting **all** of the following: <br>• Age\\u202f≥\\u202f65\\u202for has a known high‑risk comorbidity, **or** <br>• Is an essential/health‑care worker, **or** <br>• Presents ≤\\u202f5\\u202fdays after symptom onset. | The drug cuts the probability of severe disease by 60\\u202f% and is most valuable where the risk of hospitalization is highest. Prioritising the groups above maximises deaths averted per course. | • Test‑and‑treat clinics open city‑wide from Day\\u202f0. <br>• Rapid‑test kits distributed to primary‑care and occupational health services to guarantee ≤\\u202f5‑day window. <br>• Real‑time allocation dashboard monitors usage; unused courses are re‑allocated to the next priority tier each week. |\\n| **Non‑pharmaceutical Intervention (single choice)** | **6‑week strict lockdown** (70\\u202f% contact reduction). | • The virus’ basic reproduction number is uncertain but could be as high as 3.2; a short, intense reduction is the only realistic way to guarantee that the health system never exceeds 2\\u202f500 beds. <br>• Economic loss is confined to 6\\u202fweeks; a 3‑month moderate campaign would keep contacts higher for longer, increasing the chance of overwhelming hospitals and requiring an even longer, more disruptive lockdown later. | • Day\\u202f0‑42: All non‑essential businesses close; schools shift to remote learning; public transport limited to 30\\u202f% capacity; mask‑mandate enforced. <br>• Essential workers (including the 200\\u202f000) continue on‑site with PPE and physical‑distancing. <br>• After Day\\u202f42: Gradual step‑down (10\\u202f% contact restoration per week) while monitoring Rt; if Rt\\u202f>\\u202f1.1, re‑impose targeted micro‑lockdowns. |\\n\\n---\\n\\n### 2. Quantitative Justification  \\n\\n**Model set‑up (simplified deterministic SEIR, 6‑month horizon, population = 1\\u202f000\\u202f000).**  \\n\\n*Basic parameters*  \\n- Incubation = 5\\u202fd, infectious period = 7\\u202fd → generation time ≈\\u202f5\\u202fd.  \\n- Proportion symptomatic = 70\\u202f% (consistent with many respiratory viruses).  \\n- Infection‑hospitalisation ratio (IHR) = 5\\u202f% (given).  \\n- Infection‑fatality ratio (IFR) = 0.5\\u202f% overall; 5\\u202f% for 65\\u202f+\\u202f, 1\\u202f% for 45‑64\\u202fy with comorbidities, 0.2\\u202f% for younger adults.  \\n\\n*Vaccine effects*  \\n- 60\\u202f% efficacy against symptomatic disease (VEsym).  \\n- 50\\u202f% efficacy against infection (VEinf).  \\n- For the groups that receive two doses we assume the full efficacy after the second dose (effective from week\\u202f5 for each cohort).  \\n\\n*Antiviral effect*  \\n- 60\\u202f% reduction in progression to severe disease among treated cases → reduces hospitalisation risk from 5\\u202f% to 2\\u202f% for those receiving the drug.  \\n\\n*Contact reductions*  \\n- Strict lockdown: overall β reduced by 70\\u202f% → effective reproduction number **Re = R0\\u202f×\\u202f0.30** for the 6‑week period.  \\n\\n**Scenario A – **Plan above (Lockdown + vaccine allocation + antivirals).**  \\n\\nAssumptions:  \\n- Best‑estimate R0 = **2.4**.  \\n- During lockdown (weeks\\u202f0‑6): Re = 0.72 → epidemic contracts (≈\\u202f‑5\\u202f% growth per week).  \\n- After step‑down, contacts rise to 50\\u202f% of baseline → Re ≈ 1.2 (still >\\u202f1 but far slower).  \\n- Vaccine‑derived immunity starts protecting the 65\\u202f+\\u202fby week\\u202f5 and health‑care workers by week\\u202f7; essential‑worker sub‑cohort by week\\u202f9.  \\n\\n**Projected outcomes (6\\u202fmonths)**  \\n\\n| Outcome | Estimate (best‑case R0\\u202f=\\u202f2.4) | Estimate (high‑R0\\u202f=\\u202f3.0) |\\n|---------|------------------------------|--------------------------|\\n| Cumulative infections (including asymptomatic) | **≈\\u202f120\\u202f000** (12\\u202f% of population) | **≈\\u202f210\\u202f000** (21\\u202f%) |\\n| Symptomatic cases | ≈\\u202f84\\u202f000 | ≈\\u202f147\\u202f000 |\\n| Hospitalisations (5\\u202f% of symptomatic) | **≈\\u202f2\\u202f200** (within 2\\u202f500‑bed capacity) | **≈\\u202f3\\u202f650** (exceeds capacity by ~15\\u202f%) |\\n| Deaths (using age‑specific IFR, vaccine & antiviral impact) | **≈\\u202f350** (≈\\u202f85\\u202f% averted vs no‑intervention) | **≈\\u202f620** |\\n| Antiviral courses used | 9\\u202f800 (≈\\u202f98\\u202f% of stock) | 9\\u202f200 (slightly fewer cases early) |\\n| Economic disruption (lockdown weeks) | 6\\u202fweeks full shutdown + 4\\u202fweeks phased reopening | Same (lockdown is identical) |\\n\\n**Scenario B – Moderate 3‑month social‑distancing (35\\u202f% contact cut, 80\\u202f% compliance) + same vaccine prioritisation.**  \\n\\n- Effective Re during SD = R0\\u202f×\\u202f0.65.  \\n- With R0\\u202f=\\u202f2.4 → Re\\u202f≈\\u202f1.56 (still expanding).  \\n- No sharp contraction; cases rise steadily; hospitals exceed capacity around week\\u202f10.  \\n\\n| Outcome | Best‑estimate R0\\u202f=\\u202f2.4 | High‑R0\\u202f=\\u202f3.0 |\\n|---------|------------------------|--------------|\\n| Infections | ≈\\u202f260\\u202f000 (26\\u202f%) | ≈\\u202f380\\u202f000 (38\\u202f%) |\\n| Hospitalisations | ≈\\u202f6\\u202f500 (≈\\u202f260\\u202f% capacity) | ≈\\u202f9\\u202f500 |\\n| Deaths | ≈\\u202f1\\u202f300 | ≈\\u202f2\\u202f000 |\\n| Economic impact | 12\\u202fweeks of reduced activity (35\\u202f% loss) + prolonged absenteeism due to overload | Same length but higher indirect loss because of sick‑leave and excess mortality |\\n\\n**Scenario C – Same lockdown, but **vaccine allocated first to essential workers (200\\u202f000) and only later to the elderly**.**  \\n\\n- By vaccinating a larger share of high‑contact individuals we cut transmission more, but the elderly remain unprotected for longer.  \\n\\n| Outcome | Best‑estimate R0\\u202f=\\u202f2.4 | High‑R0\\u202f=\\u202f3.0 |\\n|---------|------------------------|--------------|\\n| Infections | ≈\\u202f90\\u202f000 (9\\u202f%) | ≈\\u202f150\\u202f000 (15\\u202f%) |\\n| Hospitalisations | ≈\\u202f2\\u202f900 (≈\\u202f115\\u202f% capacity) | ≈\\u202f4\\u202f800 |\\n| Deaths | ≈\\u202f480 (higher than Scenario\\u202fA because 65\\u202f+\\u202fare unvaccinated early) | ≈\\u202f820 |\\n| Antiviral use | similar (≈\\u202f10\\u202f000) | similar |\\n\\n**Interpretation** – The **Plan (Scenario\\u202fA)** gives the lowest death toll and keeps hospital demand at or below capacity while limiting the period of severe economic restriction to a single 6‑week lockdown. Scenario\\u202fB protects the economy longer but at the cost of >\\u202f2\\u202f×\\u202fmore deaths and overwhelming hospitals. Scenario\\u202fC reduces infections slightly more than A but raises deaths because the most vulnerable are exposed longer; it therefore fails the primary objective (minimise deaths).\\n\\n---\\n\\n### 3. Key Uncertainties & Adaptive Triggers  \\n\\n| Uncertainty | Potential impact on plan | Adaptive trigger & policy change |\\n|-------------|--------------------------|----------------------------------|\\n| **True R0 / transmissibility** (e.g., emergence of a more transmissible variant) | Higher R0 could push Re above 1 even during lockdown, risking overload. | *If early Rt (first 2\\u202fweeks) >\\u202f1.2 despite lockdown*, extend lockdown by 2\\u202fweeks and/or add targeted school closures. |\\n| **Vaccine efficacy against infection** (VEinf) | If VEinf <\\u202f30\\u202f%, herd‑effect is weaker, more cases among unvaccinated groups. | *If post‑vaccination serosurveys show <\\u202f30\\u202f% reduction in infection incidence*, expand vaccination to an additional 30\\u202f000 essential workers (re‑allocate some doses from low‑risk adults). |\\n| **Duration of immunity** (waning after 3‑4\\u202fmonths) | Could lead to resurgence after step‑down. | *If breakthrough infections rise >\\u202f5\\u202f% of vaccinated cohort after month\\u202f4*, plan for a booster campaign (use any leftover doses or procure additional). |\\n| **Antiviral supply chain reliability** | Shortage reduces ability to prevent severe disease. | *If weekly antiviral dispensing falls <\\u202f80\\u202f% of target*, prioritize only 65\\u202f+\\u202fand health‑care workers, and seek emergency imports. |\\n| **Compliance to lockdown** (mobility data) | Lower compliance → less contact reduction → higher Rt. | *If mobility stays >\\u202f50\\u202f% of baseline after week\\u202f2*, add enforcement measures (fines, increased policing) and consider expanding lockdown to include selected low‑risk workplaces. |\\n\\n---\\n\\n### 4. Risks & Mitigations  \\n\\n| Risk / Failure mode | Why it matters | Specific mitigation |\\n|---------------------|----------------|----------------------|\\n| **Hospital capacity still breached** (e.g., sudden surge from a superspreading event). | Overload leads to excess mortality, breaking primary goal. | • Real‑time bed‑availability dashboard; trigger rapid “circuit‑breaker” micro‑lockdowns of affected neighbourhoods. <br>• Pre‑arranged overflow agreements with nearby islands/region for emergency ICU beds. |\\n| **Vaccine hesitancy among priority groups** (especially health‑care workers). | Reduces effective coverage, undermines protection of the most vulnerable. | • Targeted communication campaign with respected clinicians, on‑site vaccination at hospitals, incentives (paid‑time‑off). <br>• Mobile units for home‑bound seniors. |\\n| **Delayed antiviral treatment ( >\\u202f5\\u202fdays after symptom onset)** → loss of efficacy. | Fewer severe cases averted, higher hospital demand. | • Rapid‑test distribution to workplaces and schools; same‑day courier of medication to positive cases; electronic triage line staffed 24\\u202fh. <br>• Public messaging: “If you feel unwell, get tested and call the treatment line within 48\\u202fh.” |\\n\\n---\\n\\n### 5. Public‑Facing Summary (for the community)\\n\\n> **Our city will protect the most vulnerable first.** Starting immediately, every senior citizen and health‑care worker will receive the COVID‑19 vaccine, followed by a portion of essential workers and high‑risk adults. We will also provide a limited antiviral medicine to those at greatest risk of severe illness. To keep hospitals from being overwhelmed, we will impose a **six‑week, city‑wide lockdown** that cuts contacts by 70\\u202f%, after which we will lift restrictions gradually while monitoring the virus. This approach saves the most lives, keeps our health system functional, and limits economic disruption to a short, well‑defined period. Please stay home, follow mask and distancing rules, and get tested quickly if you feel sick – together we will beat this outbreak.']\n"
     ]
    }
   ],
   "source": [
    "# So where are we?\n",
    "\n",
    "print(competitors)\n",
    "print(answers)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Competitor: gpt-5-nano\n",
      "\n",
      "Below is a concise, action‑oriented advisory plan designed to minimize deaths, prevent hospital overload, and limit economic disruption. All numbers are approximate and based on a deliberately simple, transparent set of assumptions described inline.\n",
      "\n",
      "1) Concrete allocation and prioritization plan (vaccines, antivirals, NPIs)\n",
      "\n",
      "Assumptions used for this plan (consistently applied in all sections):\n",
      "- Population: 1,000,000. Hospital capacity: 2,500 beds.\n",
      "- Case severity: 5% of infections require hospitalization. Vaccination reduces infection risk by 50% and symptomatic disease by 60% in vaccinated people (i.e., 50% protection against infection; among breakthrough infections, a further 60% reduction in risk of developing symptomatic disease).\n",
      "- Incubation: mean 5 days; infectious period: ~7 days; generation time ~5 days.\n",
      "- Antivirals: up to 10,000 treatment courses total. They reduce progression to severe disease by 60% if given within 5 days of symptom onset; effect applies to those who would otherwise progress to severe disease.\n",
      "- Non-pharmaceutical intervention (NPI) options (choose one):\n",
      "  A) 6-week strict lockdown: 70% reduction in social contacts; assumed high compliance (consistent with the 70% contact reduction stated).\n",
      "  B) 3-month moderate social distancing: 35% reduction in contacts with ~80% compliance (less effective per person, longer duration).\n",
      "- Vaccine supply: 150,000 doses. For planning, assume one dose per person (single-dose deployment) with the stated efficacy values (50% infection protection; 60% protection against symptomatic disease). Priority is given to high-risk groups first.\n",
      "- Time horizon: 6 months.\n",
      "\n",
      "Selected plan (priority: deaths > health system capacity > economy)\n",
      "- Vaccination priority and rollout:\n",
      "  - Phase 1 (Weeks 0–2): Vaccinate all people aged 65+ (100,000 individuals) and all healthcare workers (50,000). This uses all 150,000 doses in a front-loaded rollout, with the intent of protecting the most vulnerable for death and preserving hospital capacity.\n",
      "  - Rationale: 65+ have the highest risk of death; healthcare workers are critical to maintaining hospital functionality and to reduce nosocomial transmission.\n",
      "  - Rollout cadence: Target ~50,000 vaccinations per week for Weeks 0–3, achieving full Phase 1 coverage by end of Week 3.\n",
      "  - Phase 2 (Weeks 3–24): If further vaccine stock arrives, continue vaccinating high‑risk adults (e.g., people with major comorbidities) and essential workers to blunt transmission and protect capacity; assume an additional ~50,000 doses through Weeks 4–6 if available.\n",
      "- Antiviral allocation (up to 10,000 courses):\n",
      "  - Criteria: Treat symptomatic adults who are 65+, or adults with high-risk comorbidities (e.g., cardiovascular disease, diabetes, chronic lung disease), and/or healthcare workers with symptomatic infection who present within 5 days of symptom onset.\n",
      "  - Rollout cadence: Begin immediately; prioritize seniors and known high‑risk patients, then expand to other high‑risk groups as supply allows (roughly 2,000–3,000 courses per week over Weeks 0–6 if demand is steady).\n",
      "  - Expected impact: Reduces progression to severe disease among treated individuals by 60%, which lowers hospitalization demand by up to roughly 0.03 per treated infected person (see quantitative justification). In practice this will shave a few thousand hospitalizations across the 6-month horizon, concentrated among high-risk cases.\n",
      "- Non-pharmaceutical intervention (NP I):\n",
      "  - Choice: 6-week strict lockdown (70% contact reduction).\n",
      "  - Rationale: This maximally reduces transmission quickly, dramatically lowers peak demand on hospitals, and buys time for the vaccine to protect the most vulnerable. This option best aligns with the priority to minimize deaths and avoid health-system overload.\n",
      "  - Timing: Start immediately (Day 0) and continue for 42 days. After 6 weeks, transition out of lockdown with maintenance of minimum necessary controls and the vaccination program continuing to scale up.\n",
      "  - Compliance assumption: 70% contact reduction is achieved; if real-world compliance falls significantly, reassess with targeted containment or micro‑lockdowns in high-transmission locales.\n",
      "\n",
      "Assumptions about timing and rollout:\n",
      "- Immediate deployment: Lockdown starts now; vaccine rollout begins Day 0 with Phase 1 completion by Day 21–Day 21 (end of Week 3).\n",
      "- Masking, testing, and contact tracing remain in place at baseline; the pivotal change is the 70% contact reduction from the lockdown.\n",
      "- Antivirals are deployed as soon as possible after symptom onset to eligible individuals throughout Weeks 0–6.\n",
      "- After Week 6, lockdown constraints are relaxed in a staged fashion (subject to hospital occupancy and local transmission) while vaccines and antivirals continue to operate.\n",
      "\n",
      "2) Quantitative justification (best‑estimate R0 and one alternative R0)\n",
      "\n",
      "Key assumed constants used for the numbers below:\n",
      "- Best-estimate R0: 2.6 (range 1.8–3.2 uncertainty; we use 2.6 as central).\n",
      "- Alternative R0 for sensitivity: 3.0.\n",
      "- Generation time: ~5 days.\n",
      "- NPI effectiveness: lockdown reduces effective reproduction number to Rt = R0 × (1 − 0.70) = 0.78 during Weeks 0–6.\n",
      "- Vaccine impact (on the population level): 7.5% effective reduction in susceptible population during the period (150,000 vaccinated × 50% efficacy against infection = 7.5% of population effectively protected against infection). This reduces the effective attack rate and the absolute number of infections accordingly.\n",
      "- Antivirals: 10,000 courses reduce hospitalizations among treated infected people by 60% (i.e., if 10,000 treated would have progressed to hospitalization at 5%, their hospitalization rate among treated steps down to 2%).\n",
      "\n",
      "Derived rough quantities (6-month horizon, i.e., ~26 weeks):\n",
      "- Without any interventions (for comparison): Under R0 ≈ 2.6, a substantial portion of the population would become infected with a sizable hospitalization burden. We do not rely on that as our baseline; instead, we compare interventions to expectations with the selected plan.\n",
      "- With Plan (6-week lockdown + vaccination of 65+ and healthcare workers + antivirals):\n",
      "  - Best estimate cumulative infections over 6 months: ~130,000 to ~170,000 (about 13–17% of the population).\n",
      "  - Best estimate cumulative hospitalizations: 6,500 to 8,500.\n",
      "    - Antiviral effect reduces hospitalizations by roughly 300–500 across the entire horizon (given 10,000 treated; 5% baseline hospitalization rate for infections; 60% reduction in progression to severe disease among treated), so adjust to ~6,200–8,200.\n",
      "  - Deaths (illustrative range with broad IFR assumptions, acknowledging vaccination protects the elderly): ~500–900 deaths (most fatalities concentrated among unvaccinated strata before full vaccine protection and in high-risk patients who still become infected).\n",
      "- Alternative Strategy A (Essential workers first vaccine priority, same lockdown):\n",
      "  - Cumulative infections: ~140,000 to ~210,000.\n",
      "  - Hospitalizations: ~7,000 to ~10,500 (antivirals yield modest reductions; total reductions similar in scale to the plan, but distribution shifts away from seniors; more hospitalizations in the non‑elderly group due to delayed vaccination).\n",
      "  - Deaths: ~900–1,700 (higher than Plan due to more infections among non‑elderly, with fewer elderly protected early).\n",
      "- Alternative Strategy B (Plan uses lockdown; but 3-month moderate distancing instead of lockdown; vaccine priority as in Plan):\n",
      "  - Cumulative infections: ~180,000 to ~260,000 (moderate, longer duration distancing but lower per-day effectiveness leads to higher total infections than a short, strict lockdown).\n",
      "  - Hospitalizations: ~9,000 to ~13,000.\n",
      "  - Deaths: ~1,200–2,200.\n",
      "\n",
      "Key simplifications and formulas used (for transparency):\n",
      "- Rt during lockdown: Rt_lockdown = R0 × (1 − 0.70) = 0.78 (best estimate; reduces growth phase to decay).\n",
      "- Population-level infection protection from vaccination: overall susceptible reduction ≈ 150,000 vaccinated × 50% efficacy against infection = 75,000 people effectively less susceptible; relative population effect ≈ 75,000 / 1,000,000 = 7.5% fewer infections in the epidemic wave, applied to rough final size.\n",
      "- Hospitalizations: H = 0.05 × I, where I is cumulative infections. Antiviral effect reduces hospitalizations among treated by 60%: for 10,000 treated, hospitalizations prevented ≈ 0.05 × 10,000 × 0.60 = 300 hospitalizations (as a rough cap, distributed across the horizon).\n",
      "- IFR and age distribution are not modeled in detail here; the death estimates are intended to be proportional to infections with heavier weight on vaccines preventing infection in the elderly and reducing severe disease.\n",
      "\n",
      "3) Key uncertainties (critical unknowns and adaptive updates)\n",
      "\n",
      "- Vaccine effectiveness against infection (VE_inf) in the real population: If VE_inf is lower than 50% or wanes quickly, infection reductions will be smaller; if VE_inf is higher or longer-lasting, infections and hospitalizations drop further.\n",
      "  - Update policy: If VE_inf proves higher, accelerate broader vaccination to more age/occupation groups earlier; if VE_inf is lower, rely more on NPIs and antivirals, and consider extending lockdown duration if hospital strain rises.\n",
      "- R0 value and real-world contact patterns: The true R0 and the effectiveness of the 70% contact reduction are uncertain (especially with essential workers and healthcare settings).\n",
      "  - Update policy: If R0 is closer to 3.0 or higher or if transmission among essential workers remains high, consider tighter or targeted lockdown segments, expand vaccination to essential workers sooner, or reimpose stricter NPIs in hotspots.\n",
      "- Antiviral uptake and real-world effectiveness: Availability, speed of deployment, adherence within 5 days, and real efficacy may differ.\n",
      "  - Update policy: If antivirals are less available or less effective than assumed, increase vaccination speed or consider shortening lockdown duration with increased testing and targeted quarantines; otherwise, expand antiviral allocation to household contacts of confirmed cases to widen indirect protection.\n",
      "- Hospital capacity dynamics and surge risk: If hospital demand accelerates beyond 2,500 beds, you may need to reintroduce stricter NPIs or temporary surge capacity measures.\n",
      "  - Update policy: Predefine trigger points (e.g., occupancy >2,000 beds for 7 consecutive days) to reimpose partial lockdown or to allocate more resources (temporary field hospitals, discharge planning to free beds).\n",
      "- Compliance and inequality: 80% compliance assumption for the moderate strategy may not hold; 70% contact reduction may vary by district and by essential worker settings.\n",
      "  - Update policy: Use data dashboards to identify and address pockets of noncompliance with targeted communications and localized restrictions if needed.\n",
      "\n",
      "4) Three main risks or failure modes and mitigations\n",
      "\n",
      "- Risk 1: Health-system overload if lockdown is delayed or vaccine impact is weaker than anticipated.\n",
      "  Mitigation: Implement the 6-week lockdown immediately and strictly, with clear metrics for hospital occupancy and ICU utilization. Pre-plan surge capacity (temporary beds, staffing) and ensure antivirals are prioritized for high-risk patients to maximize the protective effect on hospitalizations.\n",
      "- Risk 2: Inequitable access to vaccination and antivirals, leading to higher mortality in vulnerable subpopulations.\n",
      "  Mitigation: Proactively map and target vaccination outreach to 65+ in all neighborhoods, with mobile clinics in high‑risk blocks; ensure antivirals are available through primary care networks and hospital systems; monitor coverage by age, race/ethnicity, and ZIP code and adjust outreach accordingly.\n",
      "- Risk 3: Waning immunity or reduced VE, undermining the protection from vaccination over 6 months.\n",
      "  Mitigation: Plan for booster or second-dose requirements if supply allows; maintain high vaccination coverage for high-risk groups; keep NPIs ready to scale if case trajectories re-emerge; maintain robust testing and tracing as a backstop.\n",
      "\n",
      "5) Public-facing summary (2–4 sentences)\n",
      "\n",
      "We will implement a six-week citywide strict lockdown to quickly curb transmission, protect hospital capacity, and save lives, while rapidly vaccinating all residents aged 65+ and healthcare workers (150,000 doses). We will allocate antivirals to high-risk individuals who develop symptoms promptly to prevent hospitalizations. After the lockdown, vaccination will continue to expand to high-risk and essential workers, and we will monitor trends closely, ready to adjust NPIs if hospital usage or transmission rises. Use the expected decreases in risk from vaccination and antivirals to inform personal precautions (masking in crowded indoor spaces, hand hygiene, staying home when ill) and support community compliance.\n",
      "\n",
      "Notes for all readers:\n",
      "- This plan prioritizes minimizing deaths and avoiding hospital overload as the first objectives, recognizing that some economic disruption is unavoidable. Personal actions (masking in high-risk settings, testing when symptomatic, staying away from work if ill) remain essential even after vaccination, as breakthrough infections and transmission can still occur in partially protected populations.\n",
      "Competitor: gemini-2.5-flash\n",
      "\n",
      "**Advisory Plan for the Island City Outbreak**\n",
      "\n",
      "This plan prioritizes minimizing deaths and preventing health system overload, recognizing that significant economic disruption is an unavoidable consequence of effective epidemic control. Our strategy leverages available resources (vaccines, antivirals) and decisive non-pharmaceutical interventions (NPIs) to flatten the curve and protect the most vulnerable.\n",
      "\n",
      "---\n",
      "\n",
      "**1) Allocation and Prioritization Plan**\n",
      "\n",
      "*   **Non-Pharmaceutical Intervention (NPI):**\n",
      "    *   **Choice:** Implement a **6-week strict lockdown** immediately (reducing contacts by 70%). This will be followed by a robust, continuous public health campaign promoting voluntary, sustained social distancing behaviors, aiming for an average of 40% contact reduction for the subsequent 4.5 months.\n",
      "    *   **Why:** The initial strict lockdown is crucial to rapidly reduce the effective reproduction number (R_eff) below 1, thereby suppressing the initial surge of infections. This buys invaluable time for vaccine rollout and allows the healthcare system to prepare. Given the high R0 uncertainty, a less stringent NPI like moderate social distancing alone would almost certainly lead to immediate and overwhelming health system overload. The subsequent sustained campaign aims to keep R_eff manageable and prevent a rapid rebound, balancing public health needs with economic feasibility.\n",
      "    *   **Timing:** Strict lockdown begins immediately upon plan announcement. Public health campaign promoting sustained distancing will launch concurrently with the end of the strict lockdown and continue for the remainder of the 6-month period.\n",
      "\n",
      "*   **Vaccine Prioritization (150,000 doses total; 50% efficacy preventing infection, 60% preventing symptomatic disease):**\n",
      "    *   **Phase 1 (First 2-3 weeks, 50,000 doses): Healthcare Workers (50,000 people).**\n",
      "        *   **Why:** Protecting healthcare workers is paramount to maintaining the functional capacity of our hospitals and clinics. Vaccinating them reduces their risk of infection and symptomatic illness, thereby minimizing absenteeism and preventing in-hospital transmission to vulnerable patients. This directly supports the goal of preventing health system overload.\n",
      "    *   **Phase 2 (Next 2-3 weeks, 100,000 doses): Individuals Aged 65+ (100,000 people).**\n",
      "        *   **Why:** This demographic faces the highest risk of severe disease and death from respiratory viruses. Vaccinating all individuals in this group directly targets the primary goal of minimizing deaths.\n",
      "    *   **Rollout Assumption:** We assume vaccine doses are distributed and administered rapidly within the first 4-6 weeks of the outbreak response. Protection is assumed to begin approximately 2 weeks post-vaccination.\n",
      "\n",
      "*   **Antiviral Allocation (10,000 treatments; reduces progression to severe disease by 60% if given within 5 days of symptom onset):**\n",
      "    *   **Criteria:** Antiviral treatments will be reserved exclusively for individuals with confirmed infection who present with symptoms within 5 days of onset.\n",
      "    *   **Prioritization:**\n",
      "        1.  **Individuals Aged 65+:** This group is at highest risk of severe outcomes. All available antivirals will be directed here first.\n",
      "        2.  **Individuals with significant comorbidities:** (e.g., chronic lung disease, heart disease, diabetes, immunosuppression). This priority group will be defined more specifically through clinical guidelines, to be treated if doses remain after the 65+ allocation is exhausted.\n",
      "        *   **Why:** With limited supply, antivirals must be allocated to those most likely to benefit from reduced progression to severe disease, directly aiming to minimize deaths and hospitalizations. The 65+ population aligns with this goal.\n",
      "\n",
      "---\n",
      "\n",
      "**2) Quantitative Justification**\n",
      "\n",
      "Our epidemiological estimates are based on a simplified compartmental model (SIR-like) with key parameters: mean incubation 5 days, mean infectious period 7 days, 5% of infections require hospital care, and an Infection Fatality Rate (IFR) of 0.5% for individuals under 65 and 5% for individuals 65+. We assume an average hospital stay of 10 days. Hospital overload is estimated to double the IFR for those requiring hospitalization.\n",
      "\n",
      "**Key Assumptions for Modeling:**\n",
      "*   **Best-estimate R0:** 2.5\n",
      "*   **Alternative R0:** 3.2\n",
      "*   **Vaccine Impact:** Reduces susceptibility by 50% (infection prevention). For those vaccinated 65+ who still get infected, the IFR is reduced by 60% from baseline (from 5% to 2%).\n",
      "*   **Antiviral Impact:** Averts 60% of deaths for the 10,000 highest-risk treated individuals (primarily 65+).\n",
      "*   **NPI Phases:** 6-week strict lockdown (70% contact reduction) followed by 4.5 months of 40% contact reduction due to sustained voluntary measures.\n",
      "*   **Hospital Capacity:** 2,500 beds (equivalent to 250 new admissions per day for a 10-day average stay).\n",
      "\n",
      "**Estimated Outcomes Over 6 Months:**\n",
      "\n",
      "| Metric             | My Plan (R0=2.5)      | My Plan (R0=3.2)      | Alternative 1 (EW + Moderate NPI) (R0=2.5) | Alternative 2 (No NPI + General Pop Vaccine) (R0=2.5) |\n",
      "| :----------------- | :-------------------- | :-------------------- | :------------------------------------------- | :---------------------------------------------------- |\n",
      "| **Cumulative Infections** | **327,000**           | **511,000**           | **740,000**                                  | **601,250**                                           |\n",
      "| **Hospitalizations**   | **16,350**            | **25,550**            | **37,000**                                   | **30,062**                                            |\n",
      "| **Peak Beds Needed**   | **~3,000** (tight)    | **~3,900** (overload) | **~6,000+** (massive overload)               | **~5,000+** (massive overload)                        |\n",
      "| **Deaths**             | **1,785**             | **5,000**             | **10,095**                                   | **8,446**                                             |\n",
      "\n",
      "**Reasoning for My Plan's Superiority:**\n",
      "*   **My Plan (R0=2.5):** The strict lockdown effectively suppresses the initial spread (limiting infections to ~5,000 in 6 weeks). The subsequent 40% contact reduction leads to an effective R (R_eff) of 1.5. Over the next 4.5 months, this results in approximately 322,000 new infections. Peak hospitalizations are estimated at around 3,000 beds, meaning the system operates at very tight capacity, but potentially avoids collapse. Deaths are minimized by prioritizing vaccination for the elderly and healthcare workers, and antiviral treatment for high-risk individuals.\n",
      "*   **My Plan (R0=3.2):** Even with the same NPIs, a higher R0 of 3.2 makes control significantly harder. The R_eff post-lockdown becomes 1.92, leading to more infections (~506,000 in 4.5 months) and significantly increased hospital demand (~3,900 peak beds). This scenario leads to substantial hospital overload, which is factored into the higher death toll. While challenging, this still represents a substantial improvement over alternative strategies.\n",
      "\n",
      "**Comparison with Alternative Strategies (Modeled at R0=2.5):**\n",
      "*   **Alternative 1 (Essential Workers + Moderate NPI):** Vaccinating essential workers may reduce some transmission, but the 3-month moderate NPI (effective 28% contact reduction, R_eff=1.8) and subsequent removal of NPIs leads to a massive wave of infections, overwhelming hospitals early on. Vaccinating essential workers does not directly protect the most vulnerable from death to the same extent as vaccinating the elderly. Deaths and hospitalizations are significantly higher.\n",
      "*   **Alternative 2 (No NPI + General Pop Vaccine):** Without any NPIs, R_eff remains at R0 (2.5). Even with 15% of the population vaccinated (randomly), the epidemic explodes, leading to widespread infection and catastrophic hospital overload. Deaths are extremely high due to uncontrolled spread and lack of care.\n",
      "\n",
      "---\n",
      "\n",
      "**3) Key Uncertainties and Policy Updates**\n",
      "\n",
      "1.  **True R0 Value:** The range 1.8-3.2 is wide.\n",
      "    *   **Policy Update:** If R0 is confirmed lower (e.g., closer to 1.8), we could potentially shorten the strict lockdown or implement a less stringent post-lockdown contact reduction (e.g., 30% instead of 40%) to reduce economic impact, provided hospital capacity is still maintained. If R0 is confirmed higher (e.g., closer to 3.2 or above), we would need to consider extending the strict lockdown or implementing stricter, longer-term NPIs (e.g., mandatory masking, stricter capacity limits) to prevent catastrophic hospital overload.\n",
      "2.  **Vaccine Efficacy against Severe Disease/Death:** The current efficacy figures are for preventing infection (50%) and symptomatic disease (60%).\n",
      "    *   **Policy Update:** If new data shows higher efficacy against severe disease/death, we could potentially ease NPIs slightly or prioritize further doses to other high-risk groups (e.g., those with comorbidities). If efficacy is lower, we would need to reinforce NPIs and potentially acquire more targeted antivirals.\n",
      "3.  **Compliance with NPIs:** Our model assumes high compliance during lockdown and sustained 40% reduction post-lockdown.\n",
      "    *   **Policy Update:** If compliance is lower than anticipated, real-time epidemiological data (e.g., rising case numbers, test positivity) would trigger immediate re-evaluation and reinforcement of NPIs, potentially including stricter enforcement or public awareness campaigns with clear messaging on the importance of adherence.\n",
      "4.  **Infection Fatality Rate (IFR) / Hospitalization Rate:** These fixed rates may vary by age or underlying conditions.\n",
      "    *   **Policy Update:** If surveillance data indicates a higher IFR, especially in younger populations, we would need to consider expanding vaccine eligibility to other vulnerable groups or essential workers beyond current allocations if more doses become available, and further emphasize NPIs across all age groups. If the hospitalization rate is higher, we would immediately activate surge capacity plans and consider emergency measures to expand healthcare infrastructure.\n",
      "5.  **New Variants:** The emergence of a more transmissible or virulent variant.\n",
      "    *   **Policy Update:** If a new variant significantly impacts R0 or vaccine effectiveness, immediate re-evaluation of all NPIs and vaccine strategies would be necessary. This could involve reinstating stricter lockdowns, adapting vaccine distribution, or accelerating development of new vaccines/treatments.\n",
      "\n",
      "---\n",
      "\n",
      "**4) Main Risks or Failure Modes of the Plan and Mitigations**\n",
      "\n",
      "1.  **Risk: Failure of Post-Lockdown Sustained Social Distancing.**\n",
      "    *   **Failure Mode:** After the 6-week strict lockdown, public fatigue or complacency leads to a rapid return to pre-outbreak contact levels (e.g., less than 40% reduction), causing R_eff to rise rapidly and overwhelm hospitals.\n",
      "    *   **Mitigation:**\n",
      "        *   **Intense Communication Campaign:** Launch an unprecedented public health campaign starting *during* the lockdown, clearly explaining the rationale for sustained social distancing, providing practical guidelines (masking, remote work, outdoor activities), and highlighting the collective benefit.\n",
      "        *   **Incentives and Support:** Implement programs to support remote work, provide free masks, and offer mental health services to combat fatigue.\n",
      "        *   **Gradual Reopening Plan:** A phased and data-driven reopening, tied to clear metrics (e.g., case numbers, hospital capacity), will allow for controlled relaxation of measures. If cases rebound, restrictions will be re-imposed.\n",
      "\n",
      "2.  **Risk: Insufficient Hospital Capacity in High R0 Scenario.**\n",
      "    *   **Failure Mode:** If the true R0 is at the higher end (3.2), our plan is predicted to exceed hospital capacity, leading to increased deaths due to lack of care.\n",
      "    *   **Mitigation:**\n",
      "        *   **Immediate Surge Capacity Activation:** Initiate plans for expanding hospital bed capacity (e.g., converting non-clinical spaces, establishing field hospitals) and staffing (e.g., recalling retired healthcare workers, cross-training staff, requesting external aid).\n",
      "        *   **Prioritized Care Protocols:** Develop and communicate clear ethical guidelines for rationing critical care resources in severe overload situations.\n",
      "        *   **Rapid Resource Acquisition:** Proactively secure additional ventilators, oxygen supplies, and personal protective equipment.\n",
      "\n",
      "3.  **Risk: Inequity or Access Issues in Vaccine/Antiviral Rollout.**\n",
      "    *   **Failure Mode:** Despite prioritization, vulnerable groups (e.g., elderly, essential workers) face barriers to accessing vaccines or antivirals due to logistics, digital divide, language barriers, or transportation issues.\n",
      "    *   **Mitigation:**\n",
      "        *   **Community-Based Rollout:** Establish mobile vaccination clinics and accessible treatment centers in neighborhoods with high concentrations of prioritized populations, leveraging community leaders and trusted organizations.\n",
      "        *   **Multi-Lingual Communication:** Ensure all public health information, registration, and consent forms are available in multiple languages and accessible formats.\n",
      "        *   **Dedicated Support Hotlines:** Set up phone hotlines to assist with appointments, provide information, and arrange transportation for those facing barriers.\n",
      "\n",
      "---\n",
      "\n",
      "**5) Public Summary**\n",
      "\n",
      "\"Island City, we face a critical challenge with this new virus. To protect our community, especially our elders and healthcare heroes, we are implementing a crucial 6-week strict lockdown starting today. This tough but necessary step will rapidly slow the virus, giving us time to vaccinate our frontline workers and most vulnerable residents, and to prepare our hospitals. After this initial period, we will ask for your continued vigilance with sustained social distancing. Your cooperation is vital to minimizing illness, saving lives, and ensuring our healthcare system can care for everyone who needs it.\"\n",
      "Competitor: openai/gpt-oss-120b\n",
      "\n",
      "**Island‑City COVID‑19 Response Plan (6‑month horizon)**  \n",
      "\n",
      "---\n",
      "\n",
      "### 1. Allocation & Prioritisation  \n",
      "\n",
      "| Resource | Who receives it first | Rationale | Roll‑out timing & logistics |\n",
      "|----------|----------------------|-----------|------------------------------|\n",
      "| **Vaccine (150 000 doses, 2‑dose schedule)** | 1️⃣ All **65 + year‑olds** (100 000 people) – 1 dose each, second dose 4 weeks later.  <br>2️⃣ **Healthcare workers** (50 000) – 1 dose each, second dose 4 weeks later.  <br>3️⃣ Remaining **essential workers** (up to 40 000 of the 200 000) – 1 dose each, second dose 4 weeks later.  <br>4️⃣ The last 10 000 doses go to **high‑risk adults (45‑64 y) with comorbidities** identified via primary‑care registries. | • 65 + have the highest infection‑fatality ratio (IFR ≈ 5 %). <br>• Health‑care workers must stay healthy to keep the system functional. <br>• Essential workers have twice the contact rate, so vaccinating a subset reduces onward transmission disproportionately. <br>• Remaining doses protect the next most vulnerable group. | • Day 0–30: Vaccinate 65 + and health‑care workers (first dose). <br>• Day 31–60: Give second doses to those groups; simultaneously start first doses for selected essential workers. <br>• Day 61–90: Complete second doses for essential workers and high‑risk adults. <br>• Cold‑chain, mobile teams, and employer‑based sites ensure >90 % coverage of each priority group within the 3‑month window. |\n",
      "| **Antiviral treatment (10 000 courses)** | **Any symptomatic case** meeting **all** of the following: <br>• Age ≥ 65 or has a known high‑risk comorbidity, **or** <br>• Is an essential/health‑care worker, **or** <br>• Presents ≤ 5 days after symptom onset. | The drug cuts the probability of severe disease by 60 % and is most valuable where the risk of hospitalization is highest. Prioritising the groups above maximises deaths averted per course. | • Test‑and‑treat clinics open city‑wide from Day 0. <br>• Rapid‑test kits distributed to primary‑care and occupational health services to guarantee ≤ 5‑day window. <br>• Real‑time allocation dashboard monitors usage; unused courses are re‑allocated to the next priority tier each week. |\n",
      "| **Non‑pharmaceutical Intervention (single choice)** | **6‑week strict lockdown** (70 % contact reduction). | • The virus’ basic reproduction number is uncertain but could be as high as 3.2; a short, intense reduction is the only realistic way to guarantee that the health system never exceeds 2 500 beds. <br>• Economic loss is confined to 6 weeks; a 3‑month moderate campaign would keep contacts higher for longer, increasing the chance of overwhelming hospitals and requiring an even longer, more disruptive lockdown later. | • Day 0‑42: All non‑essential businesses close; schools shift to remote learning; public transport limited to 30 % capacity; mask‑mandate enforced. <br>• Essential workers (including the 200 000) continue on‑site with PPE and physical‑distancing. <br>• After Day 42: Gradual step‑down (10 % contact restoration per week) while monitoring Rt; if Rt > 1.1, re‑impose targeted micro‑lockdowns. |\n",
      "\n",
      "---\n",
      "\n",
      "### 2. Quantitative Justification  \n",
      "\n",
      "**Model set‑up (simplified deterministic SEIR, 6‑month horizon, population = 1 000 000).**  \n",
      "\n",
      "*Basic parameters*  \n",
      "- Incubation = 5 d, infectious period = 7 d → generation time ≈ 5 d.  \n",
      "- Proportion symptomatic = 70 % (consistent with many respiratory viruses).  \n",
      "- Infection‑hospitalisation ratio (IHR) = 5 % (given).  \n",
      "- Infection‑fatality ratio (IFR) = 0.5 % overall; 5 % for 65 + , 1 % for 45‑64 y with comorbidities, 0.2 % for younger adults.  \n",
      "\n",
      "*Vaccine effects*  \n",
      "- 60 % efficacy against symptomatic disease (VEsym).  \n",
      "- 50 % efficacy against infection (VEinf).  \n",
      "- For the groups that receive two doses we assume the full efficacy after the second dose (effective from week 5 for each cohort).  \n",
      "\n",
      "*Antiviral effect*  \n",
      "- 60 % reduction in progression to severe disease among treated cases → reduces hospitalisation risk from 5 % to 2 % for those receiving the drug.  \n",
      "\n",
      "*Contact reductions*  \n",
      "- Strict lockdown: overall β reduced by 70 % → effective reproduction number **Re = R0 × 0.30** for the 6‑week period.  \n",
      "\n",
      "**Scenario A – **Plan above (Lockdown + vaccine allocation + antivirals).**  \n",
      "\n",
      "Assumptions:  \n",
      "- Best‑estimate R0 = **2.4**.  \n",
      "- During lockdown (weeks 0‑6): Re = 0.72 → epidemic contracts (≈ ‑5 % growth per week).  \n",
      "- After step‑down, contacts rise to 50 % of baseline → Re ≈ 1.2 (still > 1 but far slower).  \n",
      "- Vaccine‑derived immunity starts protecting the 65 + by week 5 and health‑care workers by week 7; essential‑worker sub‑cohort by week 9.  \n",
      "\n",
      "**Projected outcomes (6 months)**  \n",
      "\n",
      "| Outcome | Estimate (best‑case R0 = 2.4) | Estimate (high‑R0 = 3.0) |\n",
      "|---------|------------------------------|--------------------------|\n",
      "| Cumulative infections (including asymptomatic) | **≈ 120 000** (12 % of population) | **≈ 210 000** (21 %) |\n",
      "| Symptomatic cases | ≈ 84 000 | ≈ 147 000 |\n",
      "| Hospitalisations (5 % of symptomatic) | **≈ 2 200** (within 2 500‑bed capacity) | **≈ 3 650** (exceeds capacity by ~15 %) |\n",
      "| Deaths (using age‑specific IFR, vaccine & antiviral impact) | **≈ 350** (≈ 85 % averted vs no‑intervention) | **≈ 620** |\n",
      "| Antiviral courses used | 9 800 (≈ 98 % of stock) | 9 200 (slightly fewer cases early) |\n",
      "| Economic disruption (lockdown weeks) | 6 weeks full shutdown + 4 weeks phased reopening | Same (lockdown is identical) |\n",
      "\n",
      "**Scenario B – Moderate 3‑month social‑distancing (35 % contact cut, 80 % compliance) + same vaccine prioritisation.**  \n",
      "\n",
      "- Effective Re during SD = R0 × 0.65.  \n",
      "- With R0 = 2.4 → Re ≈ 1.56 (still expanding).  \n",
      "- No sharp contraction; cases rise steadily; hospitals exceed capacity around week 10.  \n",
      "\n",
      "| Outcome | Best‑estimate R0 = 2.4 | High‑R0 = 3.0 |\n",
      "|---------|------------------------|--------------|\n",
      "| Infections | ≈ 260 000 (26 %) | ≈ 380 000 (38 %) |\n",
      "| Hospitalisations | ≈ 6 500 (≈ 260 % capacity) | ≈ 9 500 |\n",
      "| Deaths | ≈ 1 300 | ≈ 2 000 |\n",
      "| Economic impact | 12 weeks of reduced activity (35 % loss) + prolonged absenteeism due to overload | Same length but higher indirect loss because of sick‑leave and excess mortality |\n",
      "\n",
      "**Scenario C – Same lockdown, but **vaccine allocated first to essential workers (200 000) and only later to the elderly**.**  \n",
      "\n",
      "- By vaccinating a larger share of high‑contact individuals we cut transmission more, but the elderly remain unprotected for longer.  \n",
      "\n",
      "| Outcome | Best‑estimate R0 = 2.4 | High‑R0 = 3.0 |\n",
      "|---------|------------------------|--------------|\n",
      "| Infections | ≈ 90 000 (9 %) | ≈ 150 000 (15 %) |\n",
      "| Hospitalisations | ≈ 2 900 (≈ 115 % capacity) | ≈ 4 800 |\n",
      "| Deaths | ≈ 480 (higher than Scenario A because 65 + are unvaccinated early) | ≈ 820 |\n",
      "| Antiviral use | similar (≈ 10 000) | similar |\n",
      "\n",
      "**Interpretation** – The **Plan (Scenario A)** gives the lowest death toll and keeps hospital demand at or below capacity while limiting the period of severe economic restriction to a single 6‑week lockdown. Scenario B protects the economy longer but at the cost of > 2 × more deaths and overwhelming hospitals. Scenario C reduces infections slightly more than A but raises deaths because the most vulnerable are exposed longer; it therefore fails the primary objective (minimise deaths).\n",
      "\n",
      "---\n",
      "\n",
      "### 3. Key Uncertainties & Adaptive Triggers  \n",
      "\n",
      "| Uncertainty | Potential impact on plan | Adaptive trigger & policy change |\n",
      "|-------------|--------------------------|----------------------------------|\n",
      "| **True R0 / transmissibility** (e.g., emergence of a more transmissible variant) | Higher R0 could push Re above 1 even during lockdown, risking overload. | *If early Rt (first 2 weeks) > 1.2 despite lockdown*, extend lockdown by 2 weeks and/or add targeted school closures. |\n",
      "| **Vaccine efficacy against infection** (VEinf) | If VEinf < 30 %, herd‑effect is weaker, more cases among unvaccinated groups. | *If post‑vaccination serosurveys show < 30 % reduction in infection incidence*, expand vaccination to an additional 30 000 essential workers (re‑allocate some doses from low‑risk adults). |\n",
      "| **Duration of immunity** (waning after 3‑4 months) | Could lead to resurgence after step‑down. | *If breakthrough infections rise > 5 % of vaccinated cohort after month 4*, plan for a booster campaign (use any leftover doses or procure additional). |\n",
      "| **Antiviral supply chain reliability** | Shortage reduces ability to prevent severe disease. | *If weekly antiviral dispensing falls < 80 % of target*, prioritize only 65 + and health‑care workers, and seek emergency imports. |\n",
      "| **Compliance to lockdown** (mobility data) | Lower compliance → less contact reduction → higher Rt. | *If mobility stays > 50 % of baseline after week 2*, add enforcement measures (fines, increased policing) and consider expanding lockdown to include selected low‑risk workplaces. |\n",
      "\n",
      "---\n",
      "\n",
      "### 4. Risks & Mitigations  \n",
      "\n",
      "| Risk / Failure mode | Why it matters | Specific mitigation |\n",
      "|---------------------|----------------|----------------------|\n",
      "| **Hospital capacity still breached** (e.g., sudden surge from a superspreading event). | Overload leads to excess mortality, breaking primary goal. | • Real‑time bed‑availability dashboard; trigger rapid “circuit‑breaker” micro‑lockdowns of affected neighbourhoods. <br>• Pre‑arranged overflow agreements with nearby islands/region for emergency ICU beds. |\n",
      "| **Vaccine hesitancy among priority groups** (especially health‑care workers). | Reduces effective coverage, undermines protection of the most vulnerable. | • Targeted communication campaign with respected clinicians, on‑site vaccination at hospitals, incentives (paid‑time‑off). <br>• Mobile units for home‑bound seniors. |\n",
      "| **Delayed antiviral treatment ( > 5 days after symptom onset)** → loss of efficacy. | Fewer severe cases averted, higher hospital demand. | • Rapid‑test distribution to workplaces and schools; same‑day courier of medication to positive cases; electronic triage line staffed 24 h. <br>• Public messaging: “If you feel unwell, get tested and call the treatment line within 48 h.” |\n",
      "\n",
      "---\n",
      "\n",
      "### 5. Public‑Facing Summary (for the community)\n",
      "\n",
      "> **Our city will protect the most vulnerable first.** Starting immediately, every senior citizen and health‑care worker will receive the COVID‑19 vaccine, followed by a portion of essential workers and high‑risk adults. We will also provide a limited antiviral medicine to those at greatest risk of severe illness. To keep hospitals from being overwhelmed, we will impose a **six‑week, city‑wide lockdown** that cuts contacts by 70 %, after which we will lift restrictions gradually while monitoring the virus. This approach saves the most lives, keeps our health system functional, and limits economic disruption to a short, well‑defined period. Please stay home, follow mask and distancing rules, and get tested quickly if you feel sick – together we will beat this outbreak.\n"
     ]
    }
   ],
   "source": [
    "# It's nice to know how to use \"zip\"\n",
    "for competitor, answer in zip(competitors, answers):\n",
    "    print(f\"Competitor: {competitor}\\n\\n{answer}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Let's bring this together - note the use of \"enumerate\"\n",
    "\n",
    "together = \"\"\n",
    "for index, answer in enumerate(answers):\n",
    "    together += f\"# Response from competitor {index+1}\\n\\n\"\n",
    "    together += answer + \"\\n\\n\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# Response from competitor 1\n",
      "\n",
      "Below is a concise, action‑oriented advisory plan designed to minimize deaths, prevent hospital overload, and limit economic disruption. All numbers are approximate and based on a deliberately simple, transparent set of assumptions described inline.\n",
      "\n",
      "1) Concrete allocation and prioritization plan (vaccines, antivirals, NPIs)\n",
      "\n",
      "Assumptions used for this plan (consistently applied in all sections):\n",
      "- Population: 1,000,000. Hospital capacity: 2,500 beds.\n",
      "- Case severity: 5% of infections require hospitalization. Vaccination reduces infection risk by 50% and symptomatic disease by 60% in vaccinated people (i.e., 50% protection against infection; among breakthrough infections, a further 60% reduction in risk of developing symptomatic disease).\n",
      "- Incubation: mean 5 days; infectious period: ~7 days; generation time ~5 days.\n",
      "- Antivirals: up to 10,000 treatment courses total. They reduce progression to severe disease by 60% if given within 5 days of symptom onset; effect applies to those who would otherwise progress to severe disease.\n",
      "- Non-pharmaceutical intervention (NPI) options (choose one):\n",
      "  A) 6-week strict lockdown: 70% reduction in social contacts; assumed high compliance (consistent with the 70% contact reduction stated).\n",
      "  B) 3-month moderate social distancing: 35% reduction in contacts with ~80% compliance (less effective per person, longer duration).\n",
      "- Vaccine supply: 150,000 doses. For planning, assume one dose per person (single-dose deployment) with the stated efficacy values (50% infection protection; 60% protection against symptomatic disease). Priority is given to high-risk groups first.\n",
      "- Time horizon: 6 months.\n",
      "\n",
      "Selected plan (priority: deaths > health system capacity > economy)\n",
      "- Vaccination priority and rollout:\n",
      "  - Phase 1 (Weeks 0–2): Vaccinate all people aged 65+ (100,000 individuals) and all healthcare workers (50,000). This uses all 150,000 doses in a front-loaded rollout, with the intent of protecting the most vulnerable for death and preserving hospital capacity.\n",
      "  - Rationale: 65+ have the highest risk of death; healthcare workers are critical to maintaining hospital functionality and to reduce nosocomial transmission.\n",
      "  - Rollout cadence: Target ~50,000 vaccinations per week for Weeks 0–3, achieving full Phase 1 coverage by end of Week 3.\n",
      "  - Phase 2 (Weeks 3–24): If further vaccine stock arrives, continue vaccinating high‑risk adults (e.g., people with major comorbidities) and essential workers to blunt transmission and protect capacity; assume an additional ~50,000 doses through Weeks 4–6 if available.\n",
      "- Antiviral allocation (up to 10,000 courses):\n",
      "  - Criteria: Treat symptomatic adults who are 65+, or adults with high-risk comorbidities (e.g., cardiovascular disease, diabetes, chronic lung disease), and/or healthcare workers with symptomatic infection who present within 5 days of symptom onset.\n",
      "  - Rollout cadence: Begin immediately; prioritize seniors and known high‑risk patients, then expand to other high‑risk groups as supply allows (roughly 2,000–3,000 courses per week over Weeks 0–6 if demand is steady).\n",
      "  - Expected impact: Reduces progression to severe disease among treated individuals by 60%, which lowers hospitalization demand by up to roughly 0.03 per treated infected person (see quantitative justification). In practice this will shave a few thousand hospitalizations across the 6-month horizon, concentrated among high-risk cases.\n",
      "- Non-pharmaceutical intervention (NP I):\n",
      "  - Choice: 6-week strict lockdown (70% contact reduction).\n",
      "  - Rationale: This maximally reduces transmission quickly, dramatically lowers peak demand on hospitals, and buys time for the vaccine to protect the most vulnerable. This option best aligns with the priority to minimize deaths and avoid health-system overload.\n",
      "  - Timing: Start immediately (Day 0) and continue for 42 days. After 6 weeks, transition out of lockdown with maintenance of minimum necessary controls and the vaccination program continuing to scale up.\n",
      "  - Compliance assumption: 70% contact reduction is achieved; if real-world compliance falls significantly, reassess with targeted containment or micro‑lockdowns in high-transmission locales.\n",
      "\n",
      "Assumptions about timing and rollout:\n",
      "- Immediate deployment: Lockdown starts now; vaccine rollout begins Day 0 with Phase 1 completion by Day 21–Day 21 (end of Week 3).\n",
      "- Masking, testing, and contact tracing remain in place at baseline; the pivotal change is the 70% contact reduction from the lockdown.\n",
      "- Antivirals are deployed as soon as possible after symptom onset to eligible individuals throughout Weeks 0–6.\n",
      "- After Week 6, lockdown constraints are relaxed in a staged fashion (subject to hospital occupancy and local transmission) while vaccines and antivirals continue to operate.\n",
      "\n",
      "2) Quantitative justification (best‑estimate R0 and one alternative R0)\n",
      "\n",
      "Key assumed constants used for the numbers below:\n",
      "- Best-estimate R0: 2.6 (range 1.8–3.2 uncertainty; we use 2.6 as central).\n",
      "- Alternative R0 for sensitivity: 3.0.\n",
      "- Generation time: ~5 days.\n",
      "- NPI effectiveness: lockdown reduces effective reproduction number to Rt = R0 × (1 − 0.70) = 0.78 during Weeks 0–6.\n",
      "- Vaccine impact (on the population level): 7.5% effective reduction in susceptible population during the period (150,000 vaccinated × 50% efficacy against infection = 7.5% of population effectively protected against infection). This reduces the effective attack rate and the absolute number of infections accordingly.\n",
      "- Antivirals: 10,000 courses reduce hospitalizations among treated infected people by 60% (i.e., if 10,000 treated would have progressed to hospitalization at 5%, their hospitalization rate among treated steps down to 2%).\n",
      "\n",
      "Derived rough quantities (6-month horizon, i.e., ~26 weeks):\n",
      "- Without any interventions (for comparison): Under R0 ≈ 2.6, a substantial portion of the population would become infected with a sizable hospitalization burden. We do not rely on that as our baseline; instead, we compare interventions to expectations with the selected plan.\n",
      "- With Plan (6-week lockdown + vaccination of 65+ and healthcare workers + antivirals):\n",
      "  - Best estimate cumulative infections over 6 months: ~130,000 to ~170,000 (about 13–17% of the population).\n",
      "  - Best estimate cumulative hospitalizations: 6,500 to 8,500.\n",
      "    - Antiviral effect reduces hospitalizations by roughly 300–500 across the entire horizon (given 10,000 treated; 5% baseline hospitalization rate for infections; 60% reduction in progression to severe disease among treated), so adjust to ~6,200–8,200.\n",
      "  - Deaths (illustrative range with broad IFR assumptions, acknowledging vaccination protects the elderly): ~500–900 deaths (most fatalities concentrated among unvaccinated strata before full vaccine protection and in high-risk patients who still become infected).\n",
      "- Alternative Strategy A (Essential workers first vaccine priority, same lockdown):\n",
      "  - Cumulative infections: ~140,000 to ~210,000.\n",
      "  - Hospitalizations: ~7,000 to ~10,500 (antivirals yield modest reductions; total reductions similar in scale to the plan, but distribution shifts away from seniors; more hospitalizations in the non‑elderly group due to delayed vaccination).\n",
      "  - Deaths: ~900–1,700 (higher than Plan due to more infections among non‑elderly, with fewer elderly protected early).\n",
      "- Alternative Strategy B (Plan uses lockdown; but 3-month moderate distancing instead of lockdown; vaccine priority as in Plan):\n",
      "  - Cumulative infections: ~180,000 to ~260,000 (moderate, longer duration distancing but lower per-day effectiveness leads to higher total infections than a short, strict lockdown).\n",
      "  - Hospitalizations: ~9,000 to ~13,000.\n",
      "  - Deaths: ~1,200–2,200.\n",
      "\n",
      "Key simplifications and formulas used (for transparency):\n",
      "- Rt during lockdown: Rt_lockdown = R0 × (1 − 0.70) = 0.78 (best estimate; reduces growth phase to decay).\n",
      "- Population-level infection protection from vaccination: overall susceptible reduction ≈ 150,000 vaccinated × 50% efficacy against infection = 75,000 people effectively less susceptible; relative population effect ≈ 75,000 / 1,000,000 = 7.5% fewer infections in the epidemic wave, applied to rough final size.\n",
      "- Hospitalizations: H = 0.05 × I, where I is cumulative infections. Antiviral effect reduces hospitalizations among treated by 60%: for 10,000 treated, hospitalizations prevented ≈ 0.05 × 10,000 × 0.60 = 300 hospitalizations (as a rough cap, distributed across the horizon).\n",
      "- IFR and age distribution are not modeled in detail here; the death estimates are intended to be proportional to infections with heavier weight on vaccines preventing infection in the elderly and reducing severe disease.\n",
      "\n",
      "3) Key uncertainties (critical unknowns and adaptive updates)\n",
      "\n",
      "- Vaccine effectiveness against infection (VE_inf) in the real population: If VE_inf is lower than 50% or wanes quickly, infection reductions will be smaller; if VE_inf is higher or longer-lasting, infections and hospitalizations drop further.\n",
      "  - Update policy: If VE_inf proves higher, accelerate broader vaccination to more age/occupation groups earlier; if VE_inf is lower, rely more on NPIs and antivirals, and consider extending lockdown duration if hospital strain rises.\n",
      "- R0 value and real-world contact patterns: The true R0 and the effectiveness of the 70% contact reduction are uncertain (especially with essential workers and healthcare settings).\n",
      "  - Update policy: If R0 is closer to 3.0 or higher or if transmission among essential workers remains high, consider tighter or targeted lockdown segments, expand vaccination to essential workers sooner, or reimpose stricter NPIs in hotspots.\n",
      "- Antiviral uptake and real-world effectiveness: Availability, speed of deployment, adherence within 5 days, and real efficacy may differ.\n",
      "  - Update policy: If antivirals are less available or less effective than assumed, increase vaccination speed or consider shortening lockdown duration with increased testing and targeted quarantines; otherwise, expand antiviral allocation to household contacts of confirmed cases to widen indirect protection.\n",
      "- Hospital capacity dynamics and surge risk: If hospital demand accelerates beyond 2,500 beds, you may need to reintroduce stricter NPIs or temporary surge capacity measures.\n",
      "  - Update policy: Predefine trigger points (e.g., occupancy >2,000 beds for 7 consecutive days) to reimpose partial lockdown or to allocate more resources (temporary field hospitals, discharge planning to free beds).\n",
      "- Compliance and inequality: 80% compliance assumption for the moderate strategy may not hold; 70% contact reduction may vary by district and by essential worker settings.\n",
      "  - Update policy: Use data dashboards to identify and address pockets of noncompliance with targeted communications and localized restrictions if needed.\n",
      "\n",
      "4) Three main risks or failure modes and mitigations\n",
      "\n",
      "- Risk 1: Health-system overload if lockdown is delayed or vaccine impact is weaker than anticipated.\n",
      "  Mitigation: Implement the 6-week lockdown immediately and strictly, with clear metrics for hospital occupancy and ICU utilization. Pre-plan surge capacity (temporary beds, staffing) and ensure antivirals are prioritized for high-risk patients to maximize the protective effect on hospitalizations.\n",
      "- Risk 2: Inequitable access to vaccination and antivirals, leading to higher mortality in vulnerable subpopulations.\n",
      "  Mitigation: Proactively map and target vaccination outreach to 65+ in all neighborhoods, with mobile clinics in high‑risk blocks; ensure antivirals are available through primary care networks and hospital systems; monitor coverage by age, race/ethnicity, and ZIP code and adjust outreach accordingly.\n",
      "- Risk 3: Waning immunity or reduced VE, undermining the protection from vaccination over 6 months.\n",
      "  Mitigation: Plan for booster or second-dose requirements if supply allows; maintain high vaccination coverage for high-risk groups; keep NPIs ready to scale if case trajectories re-emerge; maintain robust testing and tracing as a backstop.\n",
      "\n",
      "5) Public-facing summary (2–4 sentences)\n",
      "\n",
      "We will implement a six-week citywide strict lockdown to quickly curb transmission, protect hospital capacity, and save lives, while rapidly vaccinating all residents aged 65+ and healthcare workers (150,000 doses). We will allocate antivirals to high-risk individuals who develop symptoms promptly to prevent hospitalizations. After the lockdown, vaccination will continue to expand to high-risk and essential workers, and we will monitor trends closely, ready to adjust NPIs if hospital usage or transmission rises. Use the expected decreases in risk from vaccination and antivirals to inform personal precautions (masking in crowded indoor spaces, hand hygiene, staying home when ill) and support community compliance.\n",
      "\n",
      "Notes for all readers:\n",
      "- This plan prioritizes minimizing deaths and avoiding hospital overload as the first objectives, recognizing that some economic disruption is unavoidable. Personal actions (masking in high-risk settings, testing when symptomatic, staying away from work if ill) remain essential even after vaccination, as breakthrough infections and transmission can still occur in partially protected populations.\n",
      "\n",
      "# Response from competitor 2\n",
      "\n",
      "**Advisory Plan for the Island City Outbreak**\n",
      "\n",
      "This plan prioritizes minimizing deaths and preventing health system overload, recognizing that significant economic disruption is an unavoidable consequence of effective epidemic control. Our strategy leverages available resources (vaccines, antivirals) and decisive non-pharmaceutical interventions (NPIs) to flatten the curve and protect the most vulnerable.\n",
      "\n",
      "---\n",
      "\n",
      "**1) Allocation and Prioritization Plan**\n",
      "\n",
      "*   **Non-Pharmaceutical Intervention (NPI):**\n",
      "    *   **Choice:** Implement a **6-week strict lockdown** immediately (reducing contacts by 70%). This will be followed by a robust, continuous public health campaign promoting voluntary, sustained social distancing behaviors, aiming for an average of 40% contact reduction for the subsequent 4.5 months.\n",
      "    *   **Why:** The initial strict lockdown is crucial to rapidly reduce the effective reproduction number (R_eff) below 1, thereby suppressing the initial surge of infections. This buys invaluable time for vaccine rollout and allows the healthcare system to prepare. Given the high R0 uncertainty, a less stringent NPI like moderate social distancing alone would almost certainly lead to immediate and overwhelming health system overload. The subsequent sustained campaign aims to keep R_eff manageable and prevent a rapid rebound, balancing public health needs with economic feasibility.\n",
      "    *   **Timing:** Strict lockdown begins immediately upon plan announcement. Public health campaign promoting sustained distancing will launch concurrently with the end of the strict lockdown and continue for the remainder of the 6-month period.\n",
      "\n",
      "*   **Vaccine Prioritization (150,000 doses total; 50% efficacy preventing infection, 60% preventing symptomatic disease):**\n",
      "    *   **Phase 1 (First 2-3 weeks, 50,000 doses): Healthcare Workers (50,000 people).**\n",
      "        *   **Why:** Protecting healthcare workers is paramount to maintaining the functional capacity of our hospitals and clinics. Vaccinating them reduces their risk of infection and symptomatic illness, thereby minimizing absenteeism and preventing in-hospital transmission to vulnerable patients. This directly supports the goal of preventing health system overload.\n",
      "    *   **Phase 2 (Next 2-3 weeks, 100,000 doses): Individuals Aged 65+ (100,000 people).**\n",
      "        *   **Why:** This demographic faces the highest risk of severe disease and death from respiratory viruses. Vaccinating all individuals in this group directly targets the primary goal of minimizing deaths.\n",
      "    *   **Rollout Assumption:** We assume vaccine doses are distributed and administered rapidly within the first 4-6 weeks of the outbreak response. Protection is assumed to begin approximately 2 weeks post-vaccination.\n",
      "\n",
      "*   **Antiviral Allocation (10,000 treatments; reduces progression to severe disease by 60% if given within 5 days of symptom onset):**\n",
      "    *   **Criteria:** Antiviral treatments will be reserved exclusively for individuals with confirmed infection who present with symptoms within 5 days of onset.\n",
      "    *   **Prioritization:**\n",
      "        1.  **Individuals Aged 65+:** This group is at highest risk of severe outcomes. All available antivirals will be directed here first.\n",
      "        2.  **Individuals with significant comorbidities:** (e.g., chronic lung disease, heart disease, diabetes, immunosuppression). This priority group will be defined more specifically through clinical guidelines, to be treated if doses remain after the 65+ allocation is exhausted.\n",
      "        *   **Why:** With limited supply, antivirals must be allocated to those most likely to benefit from reduced progression to severe disease, directly aiming to minimize deaths and hospitalizations. The 65+ population aligns with this goal.\n",
      "\n",
      "---\n",
      "\n",
      "**2) Quantitative Justification**\n",
      "\n",
      "Our epidemiological estimates are based on a simplified compartmental model (SIR-like) with key parameters: mean incubation 5 days, mean infectious period 7 days, 5% of infections require hospital care, and an Infection Fatality Rate (IFR) of 0.5% for individuals under 65 and 5% for individuals 65+. We assume an average hospital stay of 10 days. Hospital overload is estimated to double the IFR for those requiring hospitalization.\n",
      "\n",
      "**Key Assumptions for Modeling:**\n",
      "*   **Best-estimate R0:** 2.5\n",
      "*   **Alternative R0:** 3.2\n",
      "*   **Vaccine Impact:** Reduces susceptibility by 50% (infection prevention). For those vaccinated 65+ who still get infected, the IFR is reduced by 60% from baseline (from 5% to 2%).\n",
      "*   **Antiviral Impact:** Averts 60% of deaths for the 10,000 highest-risk treated individuals (primarily 65+).\n",
      "*   **NPI Phases:** 6-week strict lockdown (70% contact reduction) followed by 4.5 months of 40% contact reduction due to sustained voluntary measures.\n",
      "*   **Hospital Capacity:** 2,500 beds (equivalent to 250 new admissions per day for a 10-day average stay).\n",
      "\n",
      "**Estimated Outcomes Over 6 Months:**\n",
      "\n",
      "| Metric             | My Plan (R0=2.5)      | My Plan (R0=3.2)      | Alternative 1 (EW + Moderate NPI) (R0=2.5) | Alternative 2 (No NPI + General Pop Vaccine) (R0=2.5) |\n",
      "| :----------------- | :-------------------- | :-------------------- | :------------------------------------------- | :---------------------------------------------------- |\n",
      "| **Cumulative Infections** | **327,000**           | **511,000**           | **740,000**                                  | **601,250**                                           |\n",
      "| **Hospitalizations**   | **16,350**            | **25,550**            | **37,000**                                   | **30,062**                                            |\n",
      "| **Peak Beds Needed**   | **~3,000** (tight)    | **~3,900** (overload) | **~6,000+** (massive overload)               | **~5,000+** (massive overload)                        |\n",
      "| **Deaths**             | **1,785**             | **5,000**             | **10,095**                                   | **8,446**                                             |\n",
      "\n",
      "**Reasoning for My Plan's Superiority:**\n",
      "*   **My Plan (R0=2.5):** The strict lockdown effectively suppresses the initial spread (limiting infections to ~5,000 in 6 weeks). The subsequent 40% contact reduction leads to an effective R (R_eff) of 1.5. Over the next 4.5 months, this results in approximately 322,000 new infections. Peak hospitalizations are estimated at around 3,000 beds, meaning the system operates at very tight capacity, but potentially avoids collapse. Deaths are minimized by prioritizing vaccination for the elderly and healthcare workers, and antiviral treatment for high-risk individuals.\n",
      "*   **My Plan (R0=3.2):** Even with the same NPIs, a higher R0 of 3.2 makes control significantly harder. The R_eff post-lockdown becomes 1.92, leading to more infections (~506,000 in 4.5 months) and significantly increased hospital demand (~3,900 peak beds). This scenario leads to substantial hospital overload, which is factored into the higher death toll. While challenging, this still represents a substantial improvement over alternative strategies.\n",
      "\n",
      "**Comparison with Alternative Strategies (Modeled at R0=2.5):**\n",
      "*   **Alternative 1 (Essential Workers + Moderate NPI):** Vaccinating essential workers may reduce some transmission, but the 3-month moderate NPI (effective 28% contact reduction, R_eff=1.8) and subsequent removal of NPIs leads to a massive wave of infections, overwhelming hospitals early on. Vaccinating essential workers does not directly protect the most vulnerable from death to the same extent as vaccinating the elderly. Deaths and hospitalizations are significantly higher.\n",
      "*   **Alternative 2 (No NPI + General Pop Vaccine):** Without any NPIs, R_eff remains at R0 (2.5). Even with 15% of the population vaccinated (randomly), the epidemic explodes, leading to widespread infection and catastrophic hospital overload. Deaths are extremely high due to uncontrolled spread and lack of care.\n",
      "\n",
      "---\n",
      "\n",
      "**3) Key Uncertainties and Policy Updates**\n",
      "\n",
      "1.  **True R0 Value:** The range 1.8-3.2 is wide.\n",
      "    *   **Policy Update:** If R0 is confirmed lower (e.g., closer to 1.8), we could potentially shorten the strict lockdown or implement a less stringent post-lockdown contact reduction (e.g., 30% instead of 40%) to reduce economic impact, provided hospital capacity is still maintained. If R0 is confirmed higher (e.g., closer to 3.2 or above), we would need to consider extending the strict lockdown or implementing stricter, longer-term NPIs (e.g., mandatory masking, stricter capacity limits) to prevent catastrophic hospital overload.\n",
      "2.  **Vaccine Efficacy against Severe Disease/Death:** The current efficacy figures are for preventing infection (50%) and symptomatic disease (60%).\n",
      "    *   **Policy Update:** If new data shows higher efficacy against severe disease/death, we could potentially ease NPIs slightly or prioritize further doses to other high-risk groups (e.g., those with comorbidities). If efficacy is lower, we would need to reinforce NPIs and potentially acquire more targeted antivirals.\n",
      "3.  **Compliance with NPIs:** Our model assumes high compliance during lockdown and sustained 40% reduction post-lockdown.\n",
      "    *   **Policy Update:** If compliance is lower than anticipated, real-time epidemiological data (e.g., rising case numbers, test positivity) would trigger immediate re-evaluation and reinforcement of NPIs, potentially including stricter enforcement or public awareness campaigns with clear messaging on the importance of adherence.\n",
      "4.  **Infection Fatality Rate (IFR) / Hospitalization Rate:** These fixed rates may vary by age or underlying conditions.\n",
      "    *   **Policy Update:** If surveillance data indicates a higher IFR, especially in younger populations, we would need to consider expanding vaccine eligibility to other vulnerable groups or essential workers beyond current allocations if more doses become available, and further emphasize NPIs across all age groups. If the hospitalization rate is higher, we would immediately activate surge capacity plans and consider emergency measures to expand healthcare infrastructure.\n",
      "5.  **New Variants:** The emergence of a more transmissible or virulent variant.\n",
      "    *   **Policy Update:** If a new variant significantly impacts R0 or vaccine effectiveness, immediate re-evaluation of all NPIs and vaccine strategies would be necessary. This could involve reinstating stricter lockdowns, adapting vaccine distribution, or accelerating development of new vaccines/treatments.\n",
      "\n",
      "---\n",
      "\n",
      "**4) Main Risks or Failure Modes of the Plan and Mitigations**\n",
      "\n",
      "1.  **Risk: Failure of Post-Lockdown Sustained Social Distancing.**\n",
      "    *   **Failure Mode:** After the 6-week strict lockdown, public fatigue or complacency leads to a rapid return to pre-outbreak contact levels (e.g., less than 40% reduction), causing R_eff to rise rapidly and overwhelm hospitals.\n",
      "    *   **Mitigation:**\n",
      "        *   **Intense Communication Campaign:** Launch an unprecedented public health campaign starting *during* the lockdown, clearly explaining the rationale for sustained social distancing, providing practical guidelines (masking, remote work, outdoor activities), and highlighting the collective benefit.\n",
      "        *   **Incentives and Support:** Implement programs to support remote work, provide free masks, and offer mental health services to combat fatigue.\n",
      "        *   **Gradual Reopening Plan:** A phased and data-driven reopening, tied to clear metrics (e.g., case numbers, hospital capacity), will allow for controlled relaxation of measures. If cases rebound, restrictions will be re-imposed.\n",
      "\n",
      "2.  **Risk: Insufficient Hospital Capacity in High R0 Scenario.**\n",
      "    *   **Failure Mode:** If the true R0 is at the higher end (3.2), our plan is predicted to exceed hospital capacity, leading to increased deaths due to lack of care.\n",
      "    *   **Mitigation:**\n",
      "        *   **Immediate Surge Capacity Activation:** Initiate plans for expanding hospital bed capacity (e.g., converting non-clinical spaces, establishing field hospitals) and staffing (e.g., recalling retired healthcare workers, cross-training staff, requesting external aid).\n",
      "        *   **Prioritized Care Protocols:** Develop and communicate clear ethical guidelines for rationing critical care resources in severe overload situations.\n",
      "        *   **Rapid Resource Acquisition:** Proactively secure additional ventilators, oxygen supplies, and personal protective equipment.\n",
      "\n",
      "3.  **Risk: Inequity or Access Issues in Vaccine/Antiviral Rollout.**\n",
      "    *   **Failure Mode:** Despite prioritization, vulnerable groups (e.g., elderly, essential workers) face barriers to accessing vaccines or antivirals due to logistics, digital divide, language barriers, or transportation issues.\n",
      "    *   **Mitigation:**\n",
      "        *   **Community-Based Rollout:** Establish mobile vaccination clinics and accessible treatment centers in neighborhoods with high concentrations of prioritized populations, leveraging community leaders and trusted organizations.\n",
      "        *   **Multi-Lingual Communication:** Ensure all public health information, registration, and consent forms are available in multiple languages and accessible formats.\n",
      "        *   **Dedicated Support Hotlines:** Set up phone hotlines to assist with appointments, provide information, and arrange transportation for those facing barriers.\n",
      "\n",
      "---\n",
      "\n",
      "**5) Public Summary**\n",
      "\n",
      "\"Island City, we face a critical challenge with this new virus. To protect our community, especially our elders and healthcare heroes, we are implementing a crucial 6-week strict lockdown starting today. This tough but necessary step will rapidly slow the virus, giving us time to vaccinate our frontline workers and most vulnerable residents, and to prepare our hospitals. After this initial period, we will ask for your continued vigilance with sustained social distancing. Your cooperation is vital to minimizing illness, saving lives, and ensuring our healthcare system can care for everyone who needs it.\"\n",
      "\n",
      "# Response from competitor 3\n",
      "\n",
      "**Island‑City COVID‑19 Response Plan (6‑month horizon)**  \n",
      "\n",
      "---\n",
      "\n",
      "### 1. Allocation & Prioritisation  \n",
      "\n",
      "| Resource | Who receives it first | Rationale | Roll‑out timing & logistics |\n",
      "|----------|----------------------|-----------|------------------------------|\n",
      "| **Vaccine (150 000 doses, 2‑dose schedule)** | 1️⃣ All **65 + year‑olds** (100 000 people) – 1 dose each, second dose 4 weeks later.  <br>2️⃣ **Healthcare workers** (50 000) – 1 dose each, second dose 4 weeks later.  <br>3️⃣ Remaining **essential workers** (up to 40 000 of the 200 000) – 1 dose each, second dose 4 weeks later.  <br>4️⃣ The last 10 000 doses go to **high‑risk adults (45‑64 y) with comorbidities** identified via primary‑care registries. | • 65 + have the highest infection‑fatality ratio (IFR ≈ 5 %). <br>• Health‑care workers must stay healthy to keep the system functional. <br>• Essential workers have twice the contact rate, so vaccinating a subset reduces onward transmission disproportionately. <br>• Remaining doses protect the next most vulnerable group. | • Day 0–30: Vaccinate 65 + and health‑care workers (first dose). <br>• Day 31–60: Give second doses to those groups; simultaneously start first doses for selected essential workers. <br>• Day 61–90: Complete second doses for essential workers and high‑risk adults. <br>• Cold‑chain, mobile teams, and employer‑based sites ensure >90 % coverage of each priority group within the 3‑month window. |\n",
      "| **Antiviral treatment (10 000 courses)** | **Any symptomatic case** meeting **all** of the following: <br>• Age ≥ 65 or has a known high‑risk comorbidity, **or** <br>• Is an essential/health‑care worker, **or** <br>• Presents ≤ 5 days after symptom onset. | The drug cuts the probability of severe disease by 60 % and is most valuable where the risk of hospitalization is highest. Prioritising the groups above maximises deaths averted per course. | • Test‑and‑treat clinics open city‑wide from Day 0. <br>• Rapid‑test kits distributed to primary‑care and occupational health services to guarantee ≤ 5‑day window. <br>• Real‑time allocation dashboard monitors usage; unused courses are re‑allocated to the next priority tier each week. |\n",
      "| **Non‑pharmaceutical Intervention (single choice)** | **6‑week strict lockdown** (70 % contact reduction). | • The virus’ basic reproduction number is uncertain but could be as high as 3.2; a short, intense reduction is the only realistic way to guarantee that the health system never exceeds 2 500 beds. <br>• Economic loss is confined to 6 weeks; a 3‑month moderate campaign would keep contacts higher for longer, increasing the chance of overwhelming hospitals and requiring an even longer, more disruptive lockdown later. | • Day 0‑42: All non‑essential businesses close; schools shift to remote learning; public transport limited to 30 % capacity; mask‑mandate enforced. <br>• Essential workers (including the 200 000) continue on‑site with PPE and physical‑distancing. <br>• After Day 42: Gradual step‑down (10 % contact restoration per week) while monitoring Rt; if Rt > 1.1, re‑impose targeted micro‑lockdowns. |\n",
      "\n",
      "---\n",
      "\n",
      "### 2. Quantitative Justification  \n",
      "\n",
      "**Model set‑up (simplified deterministic SEIR, 6‑month horizon, population = 1 000 000).**  \n",
      "\n",
      "*Basic parameters*  \n",
      "- Incubation = 5 d, infectious period = 7 d → generation time ≈ 5 d.  \n",
      "- Proportion symptomatic = 70 % (consistent with many respiratory viruses).  \n",
      "- Infection‑hospitalisation ratio (IHR) = 5 % (given).  \n",
      "- Infection‑fatality ratio (IFR) = 0.5 % overall; 5 % for 65 + , 1 % for 45‑64 y with comorbidities, 0.2 % for younger adults.  \n",
      "\n",
      "*Vaccine effects*  \n",
      "- 60 % efficacy against symptomatic disease (VEsym).  \n",
      "- 50 % efficacy against infection (VEinf).  \n",
      "- For the groups that receive two doses we assume the full efficacy after the second dose (effective from week 5 for each cohort).  \n",
      "\n",
      "*Antiviral effect*  \n",
      "- 60 % reduction in progression to severe disease among treated cases → reduces hospitalisation risk from 5 % to 2 % for those receiving the drug.  \n",
      "\n",
      "*Contact reductions*  \n",
      "- Strict lockdown: overall β reduced by 70 % → effective reproduction number **Re = R0 × 0.30** for the 6‑week period.  \n",
      "\n",
      "**Scenario A – **Plan above (Lockdown + vaccine allocation + antivirals).**  \n",
      "\n",
      "Assumptions:  \n",
      "- Best‑estimate R0 = **2.4**.  \n",
      "- During lockdown (weeks 0‑6): Re = 0.72 → epidemic contracts (≈ ‑5 % growth per week).  \n",
      "- After step‑down, contacts rise to 50 % of baseline → Re ≈ 1.2 (still > 1 but far slower).  \n",
      "- Vaccine‑derived immunity starts protecting the 65 + by week 5 and health‑care workers by week 7; essential‑worker sub‑cohort by week 9.  \n",
      "\n",
      "**Projected outcomes (6 months)**  \n",
      "\n",
      "| Outcome | Estimate (best‑case R0 = 2.4) | Estimate (high‑R0 = 3.0) |\n",
      "|---------|------------------------------|--------------------------|\n",
      "| Cumulative infections (including asymptomatic) | **≈ 120 000** (12 % of population) | **≈ 210 000** (21 %) |\n",
      "| Symptomatic cases | ≈ 84 000 | ≈ 147 000 |\n",
      "| Hospitalisations (5 % of symptomatic) | **≈ 2 200** (within 2 500‑bed capacity) | **≈ 3 650** (exceeds capacity by ~15 %) |\n",
      "| Deaths (using age‑specific IFR, vaccine & antiviral impact) | **≈ 350** (≈ 85 % averted vs no‑intervention) | **≈ 620** |\n",
      "| Antiviral courses used | 9 800 (≈ 98 % of stock) | 9 200 (slightly fewer cases early) |\n",
      "| Economic disruption (lockdown weeks) | 6 weeks full shutdown + 4 weeks phased reopening | Same (lockdown is identical) |\n",
      "\n",
      "**Scenario B – Moderate 3‑month social‑distancing (35 % contact cut, 80 % compliance) + same vaccine prioritisation.**  \n",
      "\n",
      "- Effective Re during SD = R0 × 0.65.  \n",
      "- With R0 = 2.4 → Re ≈ 1.56 (still expanding).  \n",
      "- No sharp contraction; cases rise steadily; hospitals exceed capacity around week 10.  \n",
      "\n",
      "| Outcome | Best‑estimate R0 = 2.4 | High‑R0 = 3.0 |\n",
      "|---------|------------------------|--------------|\n",
      "| Infections | ≈ 260 000 (26 %) | ≈ 380 000 (38 %) |\n",
      "| Hospitalisations | ≈ 6 500 (≈ 260 % capacity) | ≈ 9 500 |\n",
      "| Deaths | ≈ 1 300 | ≈ 2 000 |\n",
      "| Economic impact | 12 weeks of reduced activity (35 % loss) + prolonged absenteeism due to overload | Same length but higher indirect loss because of sick‑leave and excess mortality |\n",
      "\n",
      "**Scenario C – Same lockdown, but **vaccine allocated first to essential workers (200 000) and only later to the elderly**.**  \n",
      "\n",
      "- By vaccinating a larger share of high‑contact individuals we cut transmission more, but the elderly remain unprotected for longer.  \n",
      "\n",
      "| Outcome | Best‑estimate R0 = 2.4 | High‑R0 = 3.0 |\n",
      "|---------|------------------------|--------------|\n",
      "| Infections | ≈ 90 000 (9 %) | ≈ 150 000 (15 %) |\n",
      "| Hospitalisations | ≈ 2 900 (≈ 115 % capacity) | ≈ 4 800 |\n",
      "| Deaths | ≈ 480 (higher than Scenario A because 65 + are unvaccinated early) | ≈ 820 |\n",
      "| Antiviral use | similar (≈ 10 000) | similar |\n",
      "\n",
      "**Interpretation** – The **Plan (Scenario A)** gives the lowest death toll and keeps hospital demand at or below capacity while limiting the period of severe economic restriction to a single 6‑week lockdown. Scenario B protects the economy longer but at the cost of > 2 × more deaths and overwhelming hospitals. Scenario C reduces infections slightly more than A but raises deaths because the most vulnerable are exposed longer; it therefore fails the primary objective (minimise deaths).\n",
      "\n",
      "---\n",
      "\n",
      "### 3. Key Uncertainties & Adaptive Triggers  \n",
      "\n",
      "| Uncertainty | Potential impact on plan | Adaptive trigger & policy change |\n",
      "|-------------|--------------------------|----------------------------------|\n",
      "| **True R0 / transmissibility** (e.g., emergence of a more transmissible variant) | Higher R0 could push Re above 1 even during lockdown, risking overload. | *If early Rt (first 2 weeks) > 1.2 despite lockdown*, extend lockdown by 2 weeks and/or add targeted school closures. |\n",
      "| **Vaccine efficacy against infection** (VEinf) | If VEinf < 30 %, herd‑effect is weaker, more cases among unvaccinated groups. | *If post‑vaccination serosurveys show < 30 % reduction in infection incidence*, expand vaccination to an additional 30 000 essential workers (re‑allocate some doses from low‑risk adults). |\n",
      "| **Duration of immunity** (waning after 3‑4 months) | Could lead to resurgence after step‑down. | *If breakthrough infections rise > 5 % of vaccinated cohort after month 4*, plan for a booster campaign (use any leftover doses or procure additional). |\n",
      "| **Antiviral supply chain reliability** | Shortage reduces ability to prevent severe disease. | *If weekly antiviral dispensing falls < 80 % of target*, prioritize only 65 + and health‑care workers, and seek emergency imports. |\n",
      "| **Compliance to lockdown** (mobility data) | Lower compliance → less contact reduction → higher Rt. | *If mobility stays > 50 % of baseline after week 2*, add enforcement measures (fines, increased policing) and consider expanding lockdown to include selected low‑risk workplaces. |\n",
      "\n",
      "---\n",
      "\n",
      "### 4. Risks & Mitigations  \n",
      "\n",
      "| Risk / Failure mode | Why it matters | Specific mitigation |\n",
      "|---------------------|----------------|----------------------|\n",
      "| **Hospital capacity still breached** (e.g., sudden surge from a superspreading event). | Overload leads to excess mortality, breaking primary goal. | • Real‑time bed‑availability dashboard; trigger rapid “circuit‑breaker” micro‑lockdowns of affected neighbourhoods. <br>• Pre‑arranged overflow agreements with nearby islands/region for emergency ICU beds. |\n",
      "| **Vaccine hesitancy among priority groups** (especially health‑care workers). | Reduces effective coverage, undermines protection of the most vulnerable. | • Targeted communication campaign with respected clinicians, on‑site vaccination at hospitals, incentives (paid‑time‑off). <br>• Mobile units for home‑bound seniors. |\n",
      "| **Delayed antiviral treatment ( > 5 days after symptom onset)** → loss of efficacy. | Fewer severe cases averted, higher hospital demand. | • Rapid‑test distribution to workplaces and schools; same‑day courier of medication to positive cases; electronic triage line staffed 24 h. <br>• Public messaging: “If you feel unwell, get tested and call the treatment line within 48 h.” |\n",
      "\n",
      "---\n",
      "\n",
      "### 5. Public‑Facing Summary (for the community)\n",
      "\n",
      "> **Our city will protect the most vulnerable first.** Starting immediately, every senior citizen and health‑care worker will receive the COVID‑19 vaccine, followed by a portion of essential workers and high‑risk adults. We will also provide a limited antiviral medicine to those at greatest risk of severe illness. To keep hospitals from being overwhelmed, we will impose a **six‑week, city‑wide lockdown** that cuts contacts by 70 %, after which we will lift restrictions gradually while monitoring the virus. This approach saves the most lives, keeps our health system functional, and limits economic disruption to a short, well‑defined period. Please stay home, follow mask and distancing rules, and get tested quickly if you feel sick – together we will beat this outbreak.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(together)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "judge = f\"\"\"You are judging a competition between {len(competitors)} competitors.\n",
    "Each model has been given this question:\n",
    "\n",
    "{question}\n",
    "\n",
    "Your job is to evaluate each response for clarity and strength of argument, and rank them in order of best to worst.\n",
    "Respond with JSON, and only JSON, with the following format:\n",
    "{{\"results\": [\"best competitor number\", \"second best competitor number\", \"third best competitor number\", ...]}}\n",
    "\n",
    "Here are the responses from each competitor:\n",
    "\n",
    "{together}\n",
    "\n",
    "Now respond with the JSON with the ranked order of the competitors, nothing else. Do not include markdown formatting or code blocks.\"\"\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "You are judging a competition between 3 competitors.\n",
      "Each model has been given this question:\n",
      "\n",
      "Imagine you are advising the mayor of an island city of 1,000,000 people facing an outbreak of a novel respiratory virus. You have 150,000 doses of a partially effective vaccine (60% efficacy at preventing symptomatic disease, 50% efficacy at preventing infection), antiviral treatment sufficient for 10,000 people (reduces progression to severe disease by 60% if given within 5 days of symptom onset), and the ability to implement one citywide non‑pharmaceutical intervention (choose either a 6‑week strict lockdown that reduces contacts by 70% or a 3‑month moderate social‑distancing campaign that reduces contacts by 35% with 80% compliance). Current epidemiological estimates: R0 between 1.8 and 3.2 (uncertain), mean incubation 5 days, mean infectious period 7 days, 5% of infections require hospital care, and hospital capacity is 2,500 beds. The population includes 100,000 people aged 65+, 200,000 essential workers with roughly double the contact rate of average residents, and 50,000 healthcare workers.\n",
      "\n",
      "Your goals (in order of priority) are: 1) minimize deaths, 2) prevent health‑system overload (hospitalizations > capacity), and 3) minimize economic disruption.\n",
      "\n",
      "Produce a single, final advisory plan that includes the following (do not reveal chain‑of‑thought; present only the final plan, numbers, and reasoning):\n",
      "\n",
      "1) A concrete allocation and prioritization plan: who receives the vaccine first and why, how to allocate antivirals (including criteria for treatment), and which NPI you choose and why. Specify timing and rollout assumptions.\n",
      "\n",
      "2) Quantitative justification: under clearly stated assumptions (including a best‑estimate R0 and one alternative R0), estimate approximate cumulative infections, hospitalizations, and deaths over the next 6 months under your plan, and compare those outcomes to two clearly defined alternative plausible strategies (each alternative should differ meaningfully in vaccine prioritization and/or choice of NPI). Give numbers or ranges and state key model simplifications or formulas used (no internal chain‑of‑thought; only final assumptions and calculations).\n",
      "\n",
      "3) Key uncertainties: list the critical unknowns that could change your decision, and for each, specify how you would update policy if new data reduced uncertainty (e.g., new estimate of vaccine effectiveness, faster spread, waning immunity).\n",
      "\n",
      "4) Three main risks or failure modes of your plan and specific mitigations for each.\n",
      "\n",
      "5) A one‑paragraph summary (2–4 sentences) of the plan written for the general public that explains what you will do, why, and what the community should expect and do.\n",
      "\n",
      "Be explicit about assumptions and tradeoffs; use approximate numerical estimates where asked.\n",
      "\n",
      "Your job is to evaluate each response for clarity and strength of argument, and rank them in order of best to worst.\n",
      "Respond with JSON, and only JSON, with the following format:\n",
      "{\"results\": [\"best competitor number\", \"second best competitor number\", \"third best competitor number\", ...]}\n",
      "\n",
      "Here are the responses from each competitor:\n",
      "\n",
      "# Response from competitor 1\n",
      "\n",
      "Below is a concise, action‑oriented advisory plan designed to minimize deaths, prevent hospital overload, and limit economic disruption. All numbers are approximate and based on a deliberately simple, transparent set of assumptions described inline.\n",
      "\n",
      "1) Concrete allocation and prioritization plan (vaccines, antivirals, NPIs)\n",
      "\n",
      "Assumptions used for this plan (consistently applied in all sections):\n",
      "- Population: 1,000,000. Hospital capacity: 2,500 beds.\n",
      "- Case severity: 5% of infections require hospitalization. Vaccination reduces infection risk by 50% and symptomatic disease by 60% in vaccinated people (i.e., 50% protection against infection; among breakthrough infections, a further 60% reduction in risk of developing symptomatic disease).\n",
      "- Incubation: mean 5 days; infectious period: ~7 days; generation time ~5 days.\n",
      "- Antivirals: up to 10,000 treatment courses total. They reduce progression to severe disease by 60% if given within 5 days of symptom onset; effect applies to those who would otherwise progress to severe disease.\n",
      "- Non-pharmaceutical intervention (NPI) options (choose one):\n",
      "  A) 6-week strict lockdown: 70% reduction in social contacts; assumed high compliance (consistent with the 70% contact reduction stated).\n",
      "  B) 3-month moderate social distancing: 35% reduction in contacts with ~80% compliance (less effective per person, longer duration).\n",
      "- Vaccine supply: 150,000 doses. For planning, assume one dose per person (single-dose deployment) with the stated efficacy values (50% infection protection; 60% protection against symptomatic disease). Priority is given to high-risk groups first.\n",
      "- Time horizon: 6 months.\n",
      "\n",
      "Selected plan (priority: deaths > health system capacity > economy)\n",
      "- Vaccination priority and rollout:\n",
      "  - Phase 1 (Weeks 0–2): Vaccinate all people aged 65+ (100,000 individuals) and all healthcare workers (50,000). This uses all 150,000 doses in a front-loaded rollout, with the intent of protecting the most vulnerable for death and preserving hospital capacity.\n",
      "  - Rationale: 65+ have the highest risk of death; healthcare workers are critical to maintaining hospital functionality and to reduce nosocomial transmission.\n",
      "  - Rollout cadence: Target ~50,000 vaccinations per week for Weeks 0–3, achieving full Phase 1 coverage by end of Week 3.\n",
      "  - Phase 2 (Weeks 3–24): If further vaccine stock arrives, continue vaccinating high‑risk adults (e.g., people with major comorbidities) and essential workers to blunt transmission and protect capacity; assume an additional ~50,000 doses through Weeks 4–6 if available.\n",
      "- Antiviral allocation (up to 10,000 courses):\n",
      "  - Criteria: Treat symptomatic adults who are 65+, or adults with high-risk comorbidities (e.g., cardiovascular disease, diabetes, chronic lung disease), and/or healthcare workers with symptomatic infection who present within 5 days of symptom onset.\n",
      "  - Rollout cadence: Begin immediately; prioritize seniors and known high‑risk patients, then expand to other high‑risk groups as supply allows (roughly 2,000–3,000 courses per week over Weeks 0–6 if demand is steady).\n",
      "  - Expected impact: Reduces progression to severe disease among treated individuals by 60%, which lowers hospitalization demand by up to roughly 0.03 per treated infected person (see quantitative justification). In practice this will shave a few thousand hospitalizations across the 6-month horizon, concentrated among high-risk cases.\n",
      "- Non-pharmaceutical intervention (NP I):\n",
      "  - Choice: 6-week strict lockdown (70% contact reduction).\n",
      "  - Rationale: This maximally reduces transmission quickly, dramatically lowers peak demand on hospitals, and buys time for the vaccine to protect the most vulnerable. This option best aligns with the priority to minimize deaths and avoid health-system overload.\n",
      "  - Timing: Start immediately (Day 0) and continue for 42 days. After 6 weeks, transition out of lockdown with maintenance of minimum necessary controls and the vaccination program continuing to scale up.\n",
      "  - Compliance assumption: 70% contact reduction is achieved; if real-world compliance falls significantly, reassess with targeted containment or micro‑lockdowns in high-transmission locales.\n",
      "\n",
      "Assumptions about timing and rollout:\n",
      "- Immediate deployment: Lockdown starts now; vaccine rollout begins Day 0 with Phase 1 completion by Day 21–Day 21 (end of Week 3).\n",
      "- Masking, testing, and contact tracing remain in place at baseline; the pivotal change is the 70% contact reduction from the lockdown.\n",
      "- Antivirals are deployed as soon as possible after symptom onset to eligible individuals throughout Weeks 0–6.\n",
      "- After Week 6, lockdown constraints are relaxed in a staged fashion (subject to hospital occupancy and local transmission) while vaccines and antivirals continue to operate.\n",
      "\n",
      "2) Quantitative justification (best‑estimate R0 and one alternative R0)\n",
      "\n",
      "Key assumed constants used for the numbers below:\n",
      "- Best-estimate R0: 2.6 (range 1.8–3.2 uncertainty; we use 2.6 as central).\n",
      "- Alternative R0 for sensitivity: 3.0.\n",
      "- Generation time: ~5 days.\n",
      "- NPI effectiveness: lockdown reduces effective reproduction number to Rt = R0 × (1 − 0.70) = 0.78 during Weeks 0–6.\n",
      "- Vaccine impact (on the population level): 7.5% effective reduction in susceptible population during the period (150,000 vaccinated × 50% efficacy against infection = 7.5% of population effectively protected against infection). This reduces the effective attack rate and the absolute number of infections accordingly.\n",
      "- Antivirals: 10,000 courses reduce hospitalizations among treated infected people by 60% (i.e., if 10,000 treated would have progressed to hospitalization at 5%, their hospitalization rate among treated steps down to 2%).\n",
      "\n",
      "Derived rough quantities (6-month horizon, i.e., ~26 weeks):\n",
      "- Without any interventions (for comparison): Under R0 ≈ 2.6, a substantial portion of the population would become infected with a sizable hospitalization burden. We do not rely on that as our baseline; instead, we compare interventions to expectations with the selected plan.\n",
      "- With Plan (6-week lockdown + vaccination of 65+ and healthcare workers + antivirals):\n",
      "  - Best estimate cumulative infections over 6 months: ~130,000 to ~170,000 (about 13–17% of the population).\n",
      "  - Best estimate cumulative hospitalizations: 6,500 to 8,500.\n",
      "    - Antiviral effect reduces hospitalizations by roughly 300–500 across the entire horizon (given 10,000 treated; 5% baseline hospitalization rate for infections; 60% reduction in progression to severe disease among treated), so adjust to ~6,200–8,200.\n",
      "  - Deaths (illustrative range with broad IFR assumptions, acknowledging vaccination protects the elderly): ~500–900 deaths (most fatalities concentrated among unvaccinated strata before full vaccine protection and in high-risk patients who still become infected).\n",
      "- Alternative Strategy A (Essential workers first vaccine priority, same lockdown):\n",
      "  - Cumulative infections: ~140,000 to ~210,000.\n",
      "  - Hospitalizations: ~7,000 to ~10,500 (antivirals yield modest reductions; total reductions similar in scale to the plan, but distribution shifts away from seniors; more hospitalizations in the non‑elderly group due to delayed vaccination).\n",
      "  - Deaths: ~900–1,700 (higher than Plan due to more infections among non‑elderly, with fewer elderly protected early).\n",
      "- Alternative Strategy B (Plan uses lockdown; but 3-month moderate distancing instead of lockdown; vaccine priority as in Plan):\n",
      "  - Cumulative infections: ~180,000 to ~260,000 (moderate, longer duration distancing but lower per-day effectiveness leads to higher total infections than a short, strict lockdown).\n",
      "  - Hospitalizations: ~9,000 to ~13,000.\n",
      "  - Deaths: ~1,200–2,200.\n",
      "\n",
      "Key simplifications and formulas used (for transparency):\n",
      "- Rt during lockdown: Rt_lockdown = R0 × (1 − 0.70) = 0.78 (best estimate; reduces growth phase to decay).\n",
      "- Population-level infection protection from vaccination: overall susceptible reduction ≈ 150,000 vaccinated × 50% efficacy against infection = 75,000 people effectively less susceptible; relative population effect ≈ 75,000 / 1,000,000 = 7.5% fewer infections in the epidemic wave, applied to rough final size.\n",
      "- Hospitalizations: H = 0.05 × I, where I is cumulative infections. Antiviral effect reduces hospitalizations among treated by 60%: for 10,000 treated, hospitalizations prevented ≈ 0.05 × 10,000 × 0.60 = 300 hospitalizations (as a rough cap, distributed across the horizon).\n",
      "- IFR and age distribution are not modeled in detail here; the death estimates are intended to be proportional to infections with heavier weight on vaccines preventing infection in the elderly and reducing severe disease.\n",
      "\n",
      "3) Key uncertainties (critical unknowns and adaptive updates)\n",
      "\n",
      "- Vaccine effectiveness against infection (VE_inf) in the real population: If VE_inf is lower than 50% or wanes quickly, infection reductions will be smaller; if VE_inf is higher or longer-lasting, infections and hospitalizations drop further.\n",
      "  - Update policy: If VE_inf proves higher, accelerate broader vaccination to more age/occupation groups earlier; if VE_inf is lower, rely more on NPIs and antivirals, and consider extending lockdown duration if hospital strain rises.\n",
      "- R0 value and real-world contact patterns: The true R0 and the effectiveness of the 70% contact reduction are uncertain (especially with essential workers and healthcare settings).\n",
      "  - Update policy: If R0 is closer to 3.0 or higher or if transmission among essential workers remains high, consider tighter or targeted lockdown segments, expand vaccination to essential workers sooner, or reimpose stricter NPIs in hotspots.\n",
      "- Antiviral uptake and real-world effectiveness: Availability, speed of deployment, adherence within 5 days, and real efficacy may differ.\n",
      "  - Update policy: If antivirals are less available or less effective than assumed, increase vaccination speed or consider shortening lockdown duration with increased testing and targeted quarantines; otherwise, expand antiviral allocation to household contacts of confirmed cases to widen indirect protection.\n",
      "- Hospital capacity dynamics and surge risk: If hospital demand accelerates beyond 2,500 beds, you may need to reintroduce stricter NPIs or temporary surge capacity measures.\n",
      "  - Update policy: Predefine trigger points (e.g., occupancy >2,000 beds for 7 consecutive days) to reimpose partial lockdown or to allocate more resources (temporary field hospitals, discharge planning to free beds).\n",
      "- Compliance and inequality: 80% compliance assumption for the moderate strategy may not hold; 70% contact reduction may vary by district and by essential worker settings.\n",
      "  - Update policy: Use data dashboards to identify and address pockets of noncompliance with targeted communications and localized restrictions if needed.\n",
      "\n",
      "4) Three main risks or failure modes and mitigations\n",
      "\n",
      "- Risk 1: Health-system overload if lockdown is delayed or vaccine impact is weaker than anticipated.\n",
      "  Mitigation: Implement the 6-week lockdown immediately and strictly, with clear metrics for hospital occupancy and ICU utilization. Pre-plan surge capacity (temporary beds, staffing) and ensure antivirals are prioritized for high-risk patients to maximize the protective effect on hospitalizations.\n",
      "- Risk 2: Inequitable access to vaccination and antivirals, leading to higher mortality in vulnerable subpopulations.\n",
      "  Mitigation: Proactively map and target vaccination outreach to 65+ in all neighborhoods, with mobile clinics in high‑risk blocks; ensure antivirals are available through primary care networks and hospital systems; monitor coverage by age, race/ethnicity, and ZIP code and adjust outreach accordingly.\n",
      "- Risk 3: Waning immunity or reduced VE, undermining the protection from vaccination over 6 months.\n",
      "  Mitigation: Plan for booster or second-dose requirements if supply allows; maintain high vaccination coverage for high-risk groups; keep NPIs ready to scale if case trajectories re-emerge; maintain robust testing and tracing as a backstop.\n",
      "\n",
      "5) Public-facing summary (2–4 sentences)\n",
      "\n",
      "We will implement a six-week citywide strict lockdown to quickly curb transmission, protect hospital capacity, and save lives, while rapidly vaccinating all residents aged 65+ and healthcare workers (150,000 doses). We will allocate antivirals to high-risk individuals who develop symptoms promptly to prevent hospitalizations. After the lockdown, vaccination will continue to expand to high-risk and essential workers, and we will monitor trends closely, ready to adjust NPIs if hospital usage or transmission rises. Use the expected decreases in risk from vaccination and antivirals to inform personal precautions (masking in crowded indoor spaces, hand hygiene, staying home when ill) and support community compliance.\n",
      "\n",
      "Notes for all readers:\n",
      "- This plan prioritizes minimizing deaths and avoiding hospital overload as the first objectives, recognizing that some economic disruption is unavoidable. Personal actions (masking in high-risk settings, testing when symptomatic, staying away from work if ill) remain essential even after vaccination, as breakthrough infections and transmission can still occur in partially protected populations.\n",
      "\n",
      "# Response from competitor 2\n",
      "\n",
      "**Advisory Plan for the Island City Outbreak**\n",
      "\n",
      "This plan prioritizes minimizing deaths and preventing health system overload, recognizing that significant economic disruption is an unavoidable consequence of effective epidemic control. Our strategy leverages available resources (vaccines, antivirals) and decisive non-pharmaceutical interventions (NPIs) to flatten the curve and protect the most vulnerable.\n",
      "\n",
      "---\n",
      "\n",
      "**1) Allocation and Prioritization Plan**\n",
      "\n",
      "*   **Non-Pharmaceutical Intervention (NPI):**\n",
      "    *   **Choice:** Implement a **6-week strict lockdown** immediately (reducing contacts by 70%). This will be followed by a robust, continuous public health campaign promoting voluntary, sustained social distancing behaviors, aiming for an average of 40% contact reduction for the subsequent 4.5 months.\n",
      "    *   **Why:** The initial strict lockdown is crucial to rapidly reduce the effective reproduction number (R_eff) below 1, thereby suppressing the initial surge of infections. This buys invaluable time for vaccine rollout and allows the healthcare system to prepare. Given the high R0 uncertainty, a less stringent NPI like moderate social distancing alone would almost certainly lead to immediate and overwhelming health system overload. The subsequent sustained campaign aims to keep R_eff manageable and prevent a rapid rebound, balancing public health needs with economic feasibility.\n",
      "    *   **Timing:** Strict lockdown begins immediately upon plan announcement. Public health campaign promoting sustained distancing will launch concurrently with the end of the strict lockdown and continue for the remainder of the 6-month period.\n",
      "\n",
      "*   **Vaccine Prioritization (150,000 doses total; 50% efficacy preventing infection, 60% preventing symptomatic disease):**\n",
      "    *   **Phase 1 (First 2-3 weeks, 50,000 doses): Healthcare Workers (50,000 people).**\n",
      "        *   **Why:** Protecting healthcare workers is paramount to maintaining the functional capacity of our hospitals and clinics. Vaccinating them reduces their risk of infection and symptomatic illness, thereby minimizing absenteeism and preventing in-hospital transmission to vulnerable patients. This directly supports the goal of preventing health system overload.\n",
      "    *   **Phase 2 (Next 2-3 weeks, 100,000 doses): Individuals Aged 65+ (100,000 people).**\n",
      "        *   **Why:** This demographic faces the highest risk of severe disease and death from respiratory viruses. Vaccinating all individuals in this group directly targets the primary goal of minimizing deaths.\n",
      "    *   **Rollout Assumption:** We assume vaccine doses are distributed and administered rapidly within the first 4-6 weeks of the outbreak response. Protection is assumed to begin approximately 2 weeks post-vaccination.\n",
      "\n",
      "*   **Antiviral Allocation (10,000 treatments; reduces progression to severe disease by 60% if given within 5 days of symptom onset):**\n",
      "    *   **Criteria:** Antiviral treatments will be reserved exclusively for individuals with confirmed infection who present with symptoms within 5 days of onset.\n",
      "    *   **Prioritization:**\n",
      "        1.  **Individuals Aged 65+:** This group is at highest risk of severe outcomes. All available antivirals will be directed here first.\n",
      "        2.  **Individuals with significant comorbidities:** (e.g., chronic lung disease, heart disease, diabetes, immunosuppression). This priority group will be defined more specifically through clinical guidelines, to be treated if doses remain after the 65+ allocation is exhausted.\n",
      "        *   **Why:** With limited supply, antivirals must be allocated to those most likely to benefit from reduced progression to severe disease, directly aiming to minimize deaths and hospitalizations. The 65+ population aligns with this goal.\n",
      "\n",
      "---\n",
      "\n",
      "**2) Quantitative Justification**\n",
      "\n",
      "Our epidemiological estimates are based on a simplified compartmental model (SIR-like) with key parameters: mean incubation 5 days, mean infectious period 7 days, 5% of infections require hospital care, and an Infection Fatality Rate (IFR) of 0.5% for individuals under 65 and 5% for individuals 65+. We assume an average hospital stay of 10 days. Hospital overload is estimated to double the IFR for those requiring hospitalization.\n",
      "\n",
      "**Key Assumptions for Modeling:**\n",
      "*   **Best-estimate R0:** 2.5\n",
      "*   **Alternative R0:** 3.2\n",
      "*   **Vaccine Impact:** Reduces susceptibility by 50% (infection prevention). For those vaccinated 65+ who still get infected, the IFR is reduced by 60% from baseline (from 5% to 2%).\n",
      "*   **Antiviral Impact:** Averts 60% of deaths for the 10,000 highest-risk treated individuals (primarily 65+).\n",
      "*   **NPI Phases:** 6-week strict lockdown (70% contact reduction) followed by 4.5 months of 40% contact reduction due to sustained voluntary measures.\n",
      "*   **Hospital Capacity:** 2,500 beds (equivalent to 250 new admissions per day for a 10-day average stay).\n",
      "\n",
      "**Estimated Outcomes Over 6 Months:**\n",
      "\n",
      "| Metric             | My Plan (R0=2.5)      | My Plan (R0=3.2)      | Alternative 1 (EW + Moderate NPI) (R0=2.5) | Alternative 2 (No NPI + General Pop Vaccine) (R0=2.5) |\n",
      "| :----------------- | :-------------------- | :-------------------- | :------------------------------------------- | :---------------------------------------------------- |\n",
      "| **Cumulative Infections** | **327,000**           | **511,000**           | **740,000**                                  | **601,250**                                           |\n",
      "| **Hospitalizations**   | **16,350**            | **25,550**            | **37,000**                                   | **30,062**                                            |\n",
      "| **Peak Beds Needed**   | **~3,000** (tight)    | **~3,900** (overload) | **~6,000+** (massive overload)               | **~5,000+** (massive overload)                        |\n",
      "| **Deaths**             | **1,785**             | **5,000**             | **10,095**                                   | **8,446**                                             |\n",
      "\n",
      "**Reasoning for My Plan's Superiority:**\n",
      "*   **My Plan (R0=2.5):** The strict lockdown effectively suppresses the initial spread (limiting infections to ~5,000 in 6 weeks). The subsequent 40% contact reduction leads to an effective R (R_eff) of 1.5. Over the next 4.5 months, this results in approximately 322,000 new infections. Peak hospitalizations are estimated at around 3,000 beds, meaning the system operates at very tight capacity, but potentially avoids collapse. Deaths are minimized by prioritizing vaccination for the elderly and healthcare workers, and antiviral treatment for high-risk individuals.\n",
      "*   **My Plan (R0=3.2):** Even with the same NPIs, a higher R0 of 3.2 makes control significantly harder. The R_eff post-lockdown becomes 1.92, leading to more infections (~506,000 in 4.5 months) and significantly increased hospital demand (~3,900 peak beds). This scenario leads to substantial hospital overload, which is factored into the higher death toll. While challenging, this still represents a substantial improvement over alternative strategies.\n",
      "\n",
      "**Comparison with Alternative Strategies (Modeled at R0=2.5):**\n",
      "*   **Alternative 1 (Essential Workers + Moderate NPI):** Vaccinating essential workers may reduce some transmission, but the 3-month moderate NPI (effective 28% contact reduction, R_eff=1.8) and subsequent removal of NPIs leads to a massive wave of infections, overwhelming hospitals early on. Vaccinating essential workers does not directly protect the most vulnerable from death to the same extent as vaccinating the elderly. Deaths and hospitalizations are significantly higher.\n",
      "*   **Alternative 2 (No NPI + General Pop Vaccine):** Without any NPIs, R_eff remains at R0 (2.5). Even with 15% of the population vaccinated (randomly), the epidemic explodes, leading to widespread infection and catastrophic hospital overload. Deaths are extremely high due to uncontrolled spread and lack of care.\n",
      "\n",
      "---\n",
      "\n",
      "**3) Key Uncertainties and Policy Updates**\n",
      "\n",
      "1.  **True R0 Value:** The range 1.8-3.2 is wide.\n",
      "    *   **Policy Update:** If R0 is confirmed lower (e.g., closer to 1.8), we could potentially shorten the strict lockdown or implement a less stringent post-lockdown contact reduction (e.g., 30% instead of 40%) to reduce economic impact, provided hospital capacity is still maintained. If R0 is confirmed higher (e.g., closer to 3.2 or above), we would need to consider extending the strict lockdown or implementing stricter, longer-term NPIs (e.g., mandatory masking, stricter capacity limits) to prevent catastrophic hospital overload.\n",
      "2.  **Vaccine Efficacy against Severe Disease/Death:** The current efficacy figures are for preventing infection (50%) and symptomatic disease (60%).\n",
      "    *   **Policy Update:** If new data shows higher efficacy against severe disease/death, we could potentially ease NPIs slightly or prioritize further doses to other high-risk groups (e.g., those with comorbidities). If efficacy is lower, we would need to reinforce NPIs and potentially acquire more targeted antivirals.\n",
      "3.  **Compliance with NPIs:** Our model assumes high compliance during lockdown and sustained 40% reduction post-lockdown.\n",
      "    *   **Policy Update:** If compliance is lower than anticipated, real-time epidemiological data (e.g., rising case numbers, test positivity) would trigger immediate re-evaluation and reinforcement of NPIs, potentially including stricter enforcement or public awareness campaigns with clear messaging on the importance of adherence.\n",
      "4.  **Infection Fatality Rate (IFR) / Hospitalization Rate:** These fixed rates may vary by age or underlying conditions.\n",
      "    *   **Policy Update:** If surveillance data indicates a higher IFR, especially in younger populations, we would need to consider expanding vaccine eligibility to other vulnerable groups or essential workers beyond current allocations if more doses become available, and further emphasize NPIs across all age groups. If the hospitalization rate is higher, we would immediately activate surge capacity plans and consider emergency measures to expand healthcare infrastructure.\n",
      "5.  **New Variants:** The emergence of a more transmissible or virulent variant.\n",
      "    *   **Policy Update:** If a new variant significantly impacts R0 or vaccine effectiveness, immediate re-evaluation of all NPIs and vaccine strategies would be necessary. This could involve reinstating stricter lockdowns, adapting vaccine distribution, or accelerating development of new vaccines/treatments.\n",
      "\n",
      "---\n",
      "\n",
      "**4) Main Risks or Failure Modes of the Plan and Mitigations**\n",
      "\n",
      "1.  **Risk: Failure of Post-Lockdown Sustained Social Distancing.**\n",
      "    *   **Failure Mode:** After the 6-week strict lockdown, public fatigue or complacency leads to a rapid return to pre-outbreak contact levels (e.g., less than 40% reduction), causing R_eff to rise rapidly and overwhelm hospitals.\n",
      "    *   **Mitigation:**\n",
      "        *   **Intense Communication Campaign:** Launch an unprecedented public health campaign starting *during* the lockdown, clearly explaining the rationale for sustained social distancing, providing practical guidelines (masking, remote work, outdoor activities), and highlighting the collective benefit.\n",
      "        *   **Incentives and Support:** Implement programs to support remote work, provide free masks, and offer mental health services to combat fatigue.\n",
      "        *   **Gradual Reopening Plan:** A phased and data-driven reopening, tied to clear metrics (e.g., case numbers, hospital capacity), will allow for controlled relaxation of measures. If cases rebound, restrictions will be re-imposed.\n",
      "\n",
      "2.  **Risk: Insufficient Hospital Capacity in High R0 Scenario.**\n",
      "    *   **Failure Mode:** If the true R0 is at the higher end (3.2), our plan is predicted to exceed hospital capacity, leading to increased deaths due to lack of care.\n",
      "    *   **Mitigation:**\n",
      "        *   **Immediate Surge Capacity Activation:** Initiate plans for expanding hospital bed capacity (e.g., converting non-clinical spaces, establishing field hospitals) and staffing (e.g., recalling retired healthcare workers, cross-training staff, requesting external aid).\n",
      "        *   **Prioritized Care Protocols:** Develop and communicate clear ethical guidelines for rationing critical care resources in severe overload situations.\n",
      "        *   **Rapid Resource Acquisition:** Proactively secure additional ventilators, oxygen supplies, and personal protective equipment.\n",
      "\n",
      "3.  **Risk: Inequity or Access Issues in Vaccine/Antiviral Rollout.**\n",
      "    *   **Failure Mode:** Despite prioritization, vulnerable groups (e.g., elderly, essential workers) face barriers to accessing vaccines or antivirals due to logistics, digital divide, language barriers, or transportation issues.\n",
      "    *   **Mitigation:**\n",
      "        *   **Community-Based Rollout:** Establish mobile vaccination clinics and accessible treatment centers in neighborhoods with high concentrations of prioritized populations, leveraging community leaders and trusted organizations.\n",
      "        *   **Multi-Lingual Communication:** Ensure all public health information, registration, and consent forms are available in multiple languages and accessible formats.\n",
      "        *   **Dedicated Support Hotlines:** Set up phone hotlines to assist with appointments, provide information, and arrange transportation for those facing barriers.\n",
      "\n",
      "---\n",
      "\n",
      "**5) Public Summary**\n",
      "\n",
      "\"Island City, we face a critical challenge with this new virus. To protect our community, especially our elders and healthcare heroes, we are implementing a crucial 6-week strict lockdown starting today. This tough but necessary step will rapidly slow the virus, giving us time to vaccinate our frontline workers and most vulnerable residents, and to prepare our hospitals. After this initial period, we will ask for your continued vigilance with sustained social distancing. Your cooperation is vital to minimizing illness, saving lives, and ensuring our healthcare system can care for everyone who needs it.\"\n",
      "\n",
      "# Response from competitor 3\n",
      "\n",
      "**Island‑City COVID‑19 Response Plan (6‑month horizon)**  \n",
      "\n",
      "---\n",
      "\n",
      "### 1. Allocation & Prioritisation  \n",
      "\n",
      "| Resource | Who receives it first | Rationale | Roll‑out timing & logistics |\n",
      "|----------|----------------------|-----------|------------------------------|\n",
      "| **Vaccine (150 000 doses, 2‑dose schedule)** | 1️⃣ All **65 + year‑olds** (100 000 people) – 1 dose each, second dose 4 weeks later.  <br>2️⃣ **Healthcare workers** (50 000) – 1 dose each, second dose 4 weeks later.  <br>3️⃣ Remaining **essential workers** (up to 40 000 of the 200 000) – 1 dose each, second dose 4 weeks later.  <br>4️⃣ The last 10 000 doses go to **high‑risk adults (45‑64 y) with comorbidities** identified via primary‑care registries. | • 65 + have the highest infection‑fatality ratio (IFR ≈ 5 %). <br>• Health‑care workers must stay healthy to keep the system functional. <br>• Essential workers have twice the contact rate, so vaccinating a subset reduces onward transmission disproportionately. <br>• Remaining doses protect the next most vulnerable group. | • Day 0–30: Vaccinate 65 + and health‑care workers (first dose). <br>• Day 31–60: Give second doses to those groups; simultaneously start first doses for selected essential workers. <br>• Day 61–90: Complete second doses for essential workers and high‑risk adults. <br>• Cold‑chain, mobile teams, and employer‑based sites ensure >90 % coverage of each priority group within the 3‑month window. |\n",
      "| **Antiviral treatment (10 000 courses)** | **Any symptomatic case** meeting **all** of the following: <br>• Age ≥ 65 or has a known high‑risk comorbidity, **or** <br>• Is an essential/health‑care worker, **or** <br>• Presents ≤ 5 days after symptom onset. | The drug cuts the probability of severe disease by 60 % and is most valuable where the risk of hospitalization is highest. Prioritising the groups above maximises deaths averted per course. | • Test‑and‑treat clinics open city‑wide from Day 0. <br>• Rapid‑test kits distributed to primary‑care and occupational health services to guarantee ≤ 5‑day window. <br>• Real‑time allocation dashboard monitors usage; unused courses are re‑allocated to the next priority tier each week. |\n",
      "| **Non‑pharmaceutical Intervention (single choice)** | **6‑week strict lockdown** (70 % contact reduction). | • The virus’ basic reproduction number is uncertain but could be as high as 3.2; a short, intense reduction is the only realistic way to guarantee that the health system never exceeds 2 500 beds. <br>• Economic loss is confined to 6 weeks; a 3‑month moderate campaign would keep contacts higher for longer, increasing the chance of overwhelming hospitals and requiring an even longer, more disruptive lockdown later. | • Day 0‑42: All non‑essential businesses close; schools shift to remote learning; public transport limited to 30 % capacity; mask‑mandate enforced. <br>• Essential workers (including the 200 000) continue on‑site with PPE and physical‑distancing. <br>• After Day 42: Gradual step‑down (10 % contact restoration per week) while monitoring Rt; if Rt > 1.1, re‑impose targeted micro‑lockdowns. |\n",
      "\n",
      "---\n",
      "\n",
      "### 2. Quantitative Justification  \n",
      "\n",
      "**Model set‑up (simplified deterministic SEIR, 6‑month horizon, population = 1 000 000).**  \n",
      "\n",
      "*Basic parameters*  \n",
      "- Incubation = 5 d, infectious period = 7 d → generation time ≈ 5 d.  \n",
      "- Proportion symptomatic = 70 % (consistent with many respiratory viruses).  \n",
      "- Infection‑hospitalisation ratio (IHR) = 5 % (given).  \n",
      "- Infection‑fatality ratio (IFR) = 0.5 % overall; 5 % for 65 + , 1 % for 45‑64 y with comorbidities, 0.2 % for younger adults.  \n",
      "\n",
      "*Vaccine effects*  \n",
      "- 60 % efficacy against symptomatic disease (VEsym).  \n",
      "- 50 % efficacy against infection (VEinf).  \n",
      "- For the groups that receive two doses we assume the full efficacy after the second dose (effective from week 5 for each cohort).  \n",
      "\n",
      "*Antiviral effect*  \n",
      "- 60 % reduction in progression to severe disease among treated cases → reduces hospitalisation risk from 5 % to 2 % for those receiving the drug.  \n",
      "\n",
      "*Contact reductions*  \n",
      "- Strict lockdown: overall β reduced by 70 % → effective reproduction number **Re = R0 × 0.30** for the 6‑week period.  \n",
      "\n",
      "**Scenario A – **Plan above (Lockdown + vaccine allocation + antivirals).**  \n",
      "\n",
      "Assumptions:  \n",
      "- Best‑estimate R0 = **2.4**.  \n",
      "- During lockdown (weeks 0‑6): Re = 0.72 → epidemic contracts (≈ ‑5 % growth per week).  \n",
      "- After step‑down, contacts rise to 50 % of baseline → Re ≈ 1.2 (still > 1 but far slower).  \n",
      "- Vaccine‑derived immunity starts protecting the 65 + by week 5 and health‑care workers by week 7; essential‑worker sub‑cohort by week 9.  \n",
      "\n",
      "**Projected outcomes (6 months)**  \n",
      "\n",
      "| Outcome | Estimate (best‑case R0 = 2.4) | Estimate (high‑R0 = 3.0) |\n",
      "|---------|------------------------------|--------------------------|\n",
      "| Cumulative infections (including asymptomatic) | **≈ 120 000** (12 % of population) | **≈ 210 000** (21 %) |\n",
      "| Symptomatic cases | ≈ 84 000 | ≈ 147 000 |\n",
      "| Hospitalisations (5 % of symptomatic) | **≈ 2 200** (within 2 500‑bed capacity) | **≈ 3 650** (exceeds capacity by ~15 %) |\n",
      "| Deaths (using age‑specific IFR, vaccine & antiviral impact) | **≈ 350** (≈ 85 % averted vs no‑intervention) | **≈ 620** |\n",
      "| Antiviral courses used | 9 800 (≈ 98 % of stock) | 9 200 (slightly fewer cases early) |\n",
      "| Economic disruption (lockdown weeks) | 6 weeks full shutdown + 4 weeks phased reopening | Same (lockdown is identical) |\n",
      "\n",
      "**Scenario B – Moderate 3‑month social‑distancing (35 % contact cut, 80 % compliance) + same vaccine prioritisation.**  \n",
      "\n",
      "- Effective Re during SD = R0 × 0.65.  \n",
      "- With R0 = 2.4 → Re ≈ 1.56 (still expanding).  \n",
      "- No sharp contraction; cases rise steadily; hospitals exceed capacity around week 10.  \n",
      "\n",
      "| Outcome | Best‑estimate R0 = 2.4 | High‑R0 = 3.0 |\n",
      "|---------|------------------------|--------------|\n",
      "| Infections | ≈ 260 000 (26 %) | ≈ 380 000 (38 %) |\n",
      "| Hospitalisations | ≈ 6 500 (≈ 260 % capacity) | ≈ 9 500 |\n",
      "| Deaths | ≈ 1 300 | ≈ 2 000 |\n",
      "| Economic impact | 12 weeks of reduced activity (35 % loss) + prolonged absenteeism due to overload | Same length but higher indirect loss because of sick‑leave and excess mortality |\n",
      "\n",
      "**Scenario C – Same lockdown, but **vaccine allocated first to essential workers (200 000) and only later to the elderly**.**  \n",
      "\n",
      "- By vaccinating a larger share of high‑contact individuals we cut transmission more, but the elderly remain unprotected for longer.  \n",
      "\n",
      "| Outcome | Best‑estimate R0 = 2.4 | High‑R0 = 3.0 |\n",
      "|---------|------------------------|--------------|\n",
      "| Infections | ≈ 90 000 (9 %) | ≈ 150 000 (15 %) |\n",
      "| Hospitalisations | ≈ 2 900 (≈ 115 % capacity) | ≈ 4 800 |\n",
      "| Deaths | ≈ 480 (higher than Scenario A because 65 + are unvaccinated early) | ≈ 820 |\n",
      "| Antiviral use | similar (≈ 10 000) | similar |\n",
      "\n",
      "**Interpretation** – The **Plan (Scenario A)** gives the lowest death toll and keeps hospital demand at or below capacity while limiting the period of severe economic restriction to a single 6‑week lockdown. Scenario B protects the economy longer but at the cost of > 2 × more deaths and overwhelming hospitals. Scenario C reduces infections slightly more than A but raises deaths because the most vulnerable are exposed longer; it therefore fails the primary objective (minimise deaths).\n",
      "\n",
      "---\n",
      "\n",
      "### 3. Key Uncertainties & Adaptive Triggers  \n",
      "\n",
      "| Uncertainty | Potential impact on plan | Adaptive trigger & policy change |\n",
      "|-------------|--------------------------|----------------------------------|\n",
      "| **True R0 / transmissibility** (e.g., emergence of a more transmissible variant) | Higher R0 could push Re above 1 even during lockdown, risking overload. | *If early Rt (first 2 weeks) > 1.2 despite lockdown*, extend lockdown by 2 weeks and/or add targeted school closures. |\n",
      "| **Vaccine efficacy against infection** (VEinf) | If VEinf < 30 %, herd‑effect is weaker, more cases among unvaccinated groups. | *If post‑vaccination serosurveys show < 30 % reduction in infection incidence*, expand vaccination to an additional 30 000 essential workers (re‑allocate some doses from low‑risk adults). |\n",
      "| **Duration of immunity** (waning after 3‑4 months) | Could lead to resurgence after step‑down. | *If breakthrough infections rise > 5 % of vaccinated cohort after month 4*, plan for a booster campaign (use any leftover doses or procure additional). |\n",
      "| **Antiviral supply chain reliability** | Shortage reduces ability to prevent severe disease. | *If weekly antiviral dispensing falls < 80 % of target*, prioritize only 65 + and health‑care workers, and seek emergency imports. |\n",
      "| **Compliance to lockdown** (mobility data) | Lower compliance → less contact reduction → higher Rt. | *If mobility stays > 50 % of baseline after week 2*, add enforcement measures (fines, increased policing) and consider expanding lockdown to include selected low‑risk workplaces. |\n",
      "\n",
      "---\n",
      "\n",
      "### 4. Risks & Mitigations  \n",
      "\n",
      "| Risk / Failure mode | Why it matters | Specific mitigation |\n",
      "|---------------------|----------------|----------------------|\n",
      "| **Hospital capacity still breached** (e.g., sudden surge from a superspreading event). | Overload leads to excess mortality, breaking primary goal. | • Real‑time bed‑availability dashboard; trigger rapid “circuit‑breaker” micro‑lockdowns of affected neighbourhoods. <br>• Pre‑arranged overflow agreements with nearby islands/region for emergency ICU beds. |\n",
      "| **Vaccine hesitancy among priority groups** (especially health‑care workers). | Reduces effective coverage, undermines protection of the most vulnerable. | • Targeted communication campaign with respected clinicians, on‑site vaccination at hospitals, incentives (paid‑time‑off). <br>• Mobile units for home‑bound seniors. |\n",
      "| **Delayed antiviral treatment ( > 5 days after symptom onset)** → loss of efficacy. | Fewer severe cases averted, higher hospital demand. | • Rapid‑test distribution to workplaces and schools; same‑day courier of medication to positive cases; electronic triage line staffed 24 h. <br>• Public messaging: “If you feel unwell, get tested and call the treatment line within 48 h.” |\n",
      "\n",
      "---\n",
      "\n",
      "### 5. Public‑Facing Summary (for the community)\n",
      "\n",
      "> **Our city will protect the most vulnerable first.** Starting immediately, every senior citizen and health‑care worker will receive the COVID‑19 vaccine, followed by a portion of essential workers and high‑risk adults. We will also provide a limited antiviral medicine to those at greatest risk of severe illness. To keep hospitals from being overwhelmed, we will impose a **six‑week, city‑wide lockdown** that cuts contacts by 70 %, after which we will lift restrictions gradually while monitoring the virus. This approach saves the most lives, keeps our health system functional, and limits economic disruption to a short, well‑defined period. Please stay home, follow mask and distancing rules, and get tested quickly if you feel sick – together we will beat this outbreak.\n",
      "\n",
      "\n",
      "\n",
      "Now respond with the JSON with the ranked order of the competitors, nothing else. Do not include markdown formatting or code blocks.\n"
     ]
    }
   ],
   "source": [
    "print(judge)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "judge_messages = [{\"role\": \"user\", \"content\": judge}]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\"results\": [\"2\", \"1\", \"3\"]}\n"
     ]
    }
   ],
   "source": [
    "# Judgement time!\n",
    "\n",
    "openai = OpenAI()\n",
    "response = openai.chat.completions.create(\n",
    "    model=\"gpt-5-mini\",\n",
    "    messages=judge_messages,\n",
    ")\n",
    "results = response.choices[0].message.content\n",
    "print(results)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Rank 1: gemini-2.5-flash\n",
      "Rank 2: gpt-5-nano\n",
      "Rank 3: openai/gpt-oss-120b\n"
     ]
    }
   ],
   "source": [
    "# OK let's turn this into results!\n",
    "\n",
    "results_dict = json.loads(results)\n",
    "ranks = results_dict[\"results\"]\n",
    "for index, result in enumerate(ranks):\n",
    "    competitor = competitors[int(result)-1]\n",
    "    print(f\"Rank {index+1}: {competitor}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<table style=\"margin: 0; text-align: left; width:100%\">\n",
    "    <tr>\n",
    "        <td style=\"width: 150px; height: 150px; vertical-align: middle;\">\n",
    "            <img src=\"../assets/exercise.png\" width=\"150\" height=\"150\" style=\"display: block;\" />\n",
    "        </td>\n",
    "        <td>\n",
    "            <h2 style=\"color:#ff7800;\">Exercise</h2>\n",
    "            <span style=\"color:#ff7800;\">Which pattern(s) did this use? Try updating this to add another Agentic design pattern.\n",
    "            </span>\n",
    "        </td>\n",
    "    </tr>\n",
    "</table>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<table style=\"margin: 0; text-align: left; width:100%\">\n",
    "    <tr>\n",
    "        <td style=\"width: 150px; height: 150px; vertical-align: middle;\">\n",
    "            <img src=\"../assets/business.png\" width=\"150\" height=\"150\" style=\"display: block;\" />\n",
    "        </td>\n",
    "        <td>\n",
    "            <h2 style=\"color:#00bfff;\">Commercial implications</h2>\n",
    "            <span style=\"color:#00bfff;\">These kinds of patterns - to send a task to multiple models, and evaluate results,\n",
    "            are common where you need to improve the quality of your LLM response. This approach can be universally applied\n",
    "            to business projects where accuracy is critical.\n",
    "            </span>\n",
    "        </td>\n",
    "    </tr>\n",
    "</table>"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
